Antibody composition for disrupting biofilm

By specifically binding to DNABII protein antibody fragments to destroy biofilms, the barrier problem of bacterial biofilms against antibiotics and immune systems is solved, and the efficiency of infection treatment and equipment maintenance is improved.

CN114401986BActive Publication Date: 2024-11-08RES INST AT NATIONWIDE CHILDRENS HOSPITAL
View PDF 44 Cites 0 Cited by

Patent Information

Application Number
CN202080061193.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-06-01
Filing Date
2020-07-07
Publication Date
2024-11-08
Estimated Expiration
2040-07-07

AI Technical Summary

Technical Problem

The presence of bacterial biofilms makes it difficult for the host immune system and antibiotics to access protected bacteria, making infections difficult to deal with and causing equipment clogging and corrosion problems in industrial and water treatment.

Method used

Develop antibody or antigen binding fragments, including heavy and light chain immunoglobulin variable region sequences, specifically bind DNABII proteins, interfere with their binding to DNA, thereby destroying biofilms.

Benefits of technology

Effectively destroy biofilms, promote antibiotics and immune system attacks on bacteria, reduce equipment blockage and corrosion, and improve water quality and equipment performance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114401986B_ABST
    Figure CN114401986B_ABST
Patent Text Reader

Abstract

Provided herein are methods and compositions for disrupting biofilms in vitro and in vivo. Also disclosed herein are antibodies comprising specific heavy chain (HC) immunoglobulin variable domain sequences and / or specific light chain (LC) immunoglobulin variable domain sequences.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-reference to related applications

[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 033,109, filed June 1, 2020, and U.S. Provisional Application No. 62 / 871,457, filed July 8, 2019, filed under 35 U.S. SC §119(e), the contents of each of which are incorporated herein by reference in their entirety.

[0003] Government funding statement

[0004] This invention was made with government funding (grant number R01 DC011818) from the National Institute for Deafness and Other Communication Disorders (NIDCD) of the National Institutes of Health (NIH). The government holds certain rights in this invention.

[0005] open field

[0006] This disclosure generally relates to methods and compositions for mitigating and / or eradicating bacterial biofilms.

[0007] background

[0008] The DNABII protein family is naturally present on the external surface of bacterial cells and promotes biofilm formation. At least one protein from the DNABII family is present in all known eubacteria. While these proteins elicit strong innate and adaptive immune responses, the host cannot naturally produce protective antibodies against family members due to infection. A major problem associated with bacterial biofilms is the inability of the host immune system and / or antibiotics and other antimicrobial agents to access the bacteria protected within the biofilm.

[0009] Biofilms are also present in industrial equipment. For example, biofilms are involved in various petroleum process problems, from oilfield extraction to gas station storage tanks. In this field, sulfate-reducing biofilm bacteria produce hydrogen sulfide (acidic oil). In process pipelines, biofilm activity gradually forms sludge, clogging filters and orifices. Biofilms and biofilm organisms also cause corrosion of pipelines and petroleum process equipment. These problems can manifest throughout oil or gas production facilities, to the point that sludge and corrosive biofilm organisms have been found on the surfaces of end-product storage tanks.

[0010] Biofilms are also involved in various water treatment processes, both domestic and industrial. They can grow on the surfaces of process equipment, hindering its performance, such as degrading heat transfer or clogging filters and membranes. Biofilms growing on cooling tower packing can add enough weight to cause the packing to collapse. Biofilms can even cause corrosion of highly specialized stainless steel. Biofilms in water treatment can reduce the value of end products, such as biofilm contamination in papermaking or even the attachment of a single cell to silicon chips. Biofilms growing in drinking water distribution systems can harbor potentially pathogenic, corrosive, or bacterial organisms, reducing the sensory quality of the water. In the home, biofilms can be found in or on any surface that supports microbial growth, such as in sewers, on food preparation utensils, in toilets, and in swimming pools and bathtubs.

[0011] Therefore, it is necessary to disrupt the protective barrier of biofilms in order to treat or kill the associated bacterial infections and remove them from various surfaces and water systems.

[0012] Overview

[0013] In bacterial cells, the DNABII protein is a DNA-binding protein that, upon binding, is required to bend the DNA substrate. Similarly, an exemplary substrate is DNA already in a bent conformation, since no energy is needed for bending at this point.

[0014] The DNABII family is a member of a class of proteins known as nucleoid-associated proteins (NAPs), which are bacterial proteins that partially shape the intracellular bacterial nucleoid (Browning et al. (2010) Curr. Opin. Microbiol. 13:773-780). Furthermore, this family is ubiquitous and expressed by almost all eubacteria. To date, all characterized family members function as homodimers or heterodimers of subunits. The family is divided into two types, HU (histone-like proteins) and IHF (integrative host factors), with *B. cenocepacia* expressing both types (strain J2315 genes: BCAL3530, hupA; BCAL1585, hupB; BCAL1487, ihfA; and BCAL2949, ihfb), while many other bacteria also express HU and IHF. The main difference between these family members is that HU binds to DNA in a sequence-independent manner, while IHF binds to a conserved sequence across genera (WATCAANNNNTTR, where W is A or T and R is a purine, SEQ ID NO: 28) (Swinger et al. (2004) Curr. Opin. Struct. Biol. 14:28-35). All DNABII proteins bind to DNA and significantly bend it; for example, E. coli IHF can bend DNA into an almost U-shaped loop (Rice et al. (1996) Cell 87:1295-1306). Furthermore, all family members favor pre-bent or coiled DNA structures, such as the Holliday linker, a cross-shaped structure that is the center of DNA recombination. In fact, DNABII proteins function as cofactors, promoting all intracellular DNA functions, including gene expression, recombination, repair, and replication (Swinger et al. (2004) Curr. Opin. Struct. Biol. 14:28-35).

[0015] The DNABII protein family is located on the exterior of bacterial cells in a biofilm state. The applicant has demonstrated that these proteins actually bind to extracellular DNA at critical branched junctions.

[0016] Therefore, this document provides an antibody or an antigen-binding fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable region sequence and / or a light chain (LC) immunoglobulin variable region sequence, wherein the HC immunoglobulin variable region comprises, or substantially comprises, the sequence of amino acids (aa) 25 to aa 144 of SEQ ID NO:13 or equivalents thereof, and the LC immunoglobulin variable region comprises, or substantially comprises, the sequence of aa 21 to aa 132 of SEQ ID NO:14 or equivalents thereof, and the LC immunoglobulin variable region comprises, or substantially comprises, the sequence of aa 21 to aa 132 of SEQ ID NO:14. This document further provides an antibody or an antigen-binding fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable region sequence and / or a light chain (LC) immunoglobulin variable region sequence, wherein the HC immunoglobulin variable region comprises, or substantially comprises, aa25 to aa144 selected from SEQ ID NO:13, 24 or 26, or equivalents thereof, wherein the LC immunoglobulin variable region comprises, or substantially comprises, aa21 to aa132 selected from SEQ ID NO:14 or 25, aa21 to aa126 selected from SEQ ID NO:27, or equivalents thereof, wherein the antibody or fragment thereof binds to a DNABII peptide (e.g., the tip region of a DNABII peptide, including but not limited to: the tip region of IHF or HU, the tip region of IHFA or IHFB and / or the tip chimeric peptide IhfA5-mIhfB4). NTHI ; and / or the tail region of the DNABII peptide, including but not limited to the tail region of IHF or HU, the tail region of IHFA or IHFB, and / or the tail chimeric peptide IhfA3-IhfB2. NTHI In one embodiment, the antibody or a fragment thereof binds to the head chimeric peptide IhfA5-mIhfB4. NTHI Or tail-based chimeric peptide IhfA3-IhfB2 NTHI .

[0017] This document also provides an antibody or an antigen-binding fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable region sequence and / or a light chain (LC) immunoglobulin variable region sequence, wherein the HC immunoglobulin variable region comprises, or substantially comprises, a sequence selected from aa 25 to aa 144 of SEQ ID NO: 13 or 24, or an equivalent thereof, wherein the LC immunoglobulin variable region comprises, or substantially comprises, a sequence selected from aa 21 to aa 132 of SEQ ID NO: 14 or 25, or an equivalent thereof, wherein the antibody or fragment thereof binds to a DNABII peptide (e.g., the head region of a DNABII peptide, including but not limited to: the head region of IHF or HU, the head region of IHFA or IHFB, and / or the head chimeric peptide IhfA5-mIhfB4). NTHI In one embodiment, the antibody or a fragment thereof binds to the head chimeric peptide IhfA5-mIhfB4. NTHI .

[0018] This document further provides an antibody or an antigen-binding fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable region sequence and / or a light chain (LC) immunoglobulin variable region sequence, wherein the HC immunoglobulin variable region comprises, or substantially comprises, aa 25 to aa 144 sequences selected from SEQ ID NO:1-6, 24 or 26, or equivalents thereof, and the LC immunoglobulin variable region comprises, or substantially comprises, aa 21 to aa 132 sequences selected from SEQ ID NO:7-9 or 25, aa 21 to aa 126 sequences selected from SEQ ID NO:10-12 or 27, or equivalents thereof, or substantially comprises, or substantially comprises, aa 21 to aa 126 sequences, or equivalents thereof. In some embodiments, the antibody or a fragment thereof binds to a DNABII peptide (e.g., the head region of a DNABII peptide, including but not limited to: the head region of IHF or HU, the head region of IHFA or IHFB, and / or the head chimeric peptide IhfA5-mIhfB4). NTHI ; and / or the tail region of the DNABII peptide, including but not limited to: the tail region of IHF or HU, the tail region of IHFA or IHFB and / or the tail chimeric peptide IhfA3-IhfB2. NTHI In one embodiment, the antibody or a fragment thereof binds to the head chimeric peptide IhfA5-mIhfB4. NTHI Or tail-based chimeric peptide IhfA3-IhfB2 NTHI .

[0019] This document further provides an antibody or an antigen-binding fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable region sequence and / or a light chain (LC) immunoglobulin variable region sequence, wherein the HC immunoglobulin variable region comprises, or substantially comprises, aa 25 to aa 473 selected from SEQ ID NO: 1-6, 13, 24 or 26, or equivalents thereof, wherein the LC immunoglobulin variable region comprises, or substantially comprises, aa 21 to aa 239 selected from SEQ ID NO: 7-9, 14 or 25, aa 21 to aa 233 selected from SEQ ID NO: 10-12 or 27, or equivalents thereof, either or substantially comprises, or consists thereof. In some embodiments, the antibody or a fragment thereof binds to a DNABII peptide (e.g., the head region of a DNABII peptide, including but not limited to: the head region of IHF or HU, the head region of IHFA or IHFB, and / or the head chimeric peptide IhfA5-mIhfB4). NTHI ; and / or the tail region of the DNABII peptide, including but not limited to: the tail region of IHF or HU, the tail region of IHFA or IHFB and / or the tail chimeric peptide IhfA3-IhfB2. NTHI In one embodiment, the antibody or a fragment thereof binds to the head chimeric peptide IhfA5-mIhfB4. NTHI Or tail-based chimeric peptide IhfA3-IhfB2 NTHI .

[0020] This document also provides an antibody or antigen-binding fragment thereof comprising, substantially comprising, or comprising: any one, any two, or all three CDRs selected from sequences of SEQ ID NO: 1-6, 13, 24, or 26 or equivalents thereof; and / or any one, any two, or all three CDRs selected from sequences of SEQ ID NO: 7-12, 14, 25, or 27 or equivalents thereof. In some embodiments, the antibody or fragment thereof binds to a DNABII peptide (e.g., the head region of a DNABII peptide, including but not limited to: the head region of IHF or HU, the head region of IHFA or IHFB, and / or the head chimeric peptide IhfA5-mIhfB4). NTHI ; and / or the tail region of the DNABII peptide, including but not limited to: the tail region of IHF or HU, the tail region of IHFA or IHFB and / or the tail chimeric peptide IhfA3-IhfB2. NTHI In one embodiment, the antibody or a fragment thereof binds to the head chimeric peptide IhfA5-mIhfB4. NTHI Or tail-based chimeric peptide IhfA3-IhfB2 NTHI .

[0021] Non-restricted examples of antigen-binding fragments are selected from Fab, F(ab')2, Fab', scFv, or Fv.

[0022] In another aspect, this document provides a Fab fragment of the antibody, wherein the antibody specifically binds to the head region of the DNABII peptide (including, but not limited to, the head region of IHF or HU, the head region of IHFA or IHFB, and / or the head chimeric peptide IhfA5-mIhfB4). NTHI This document also provides fragments of the antibodies disclosed herein. In one embodiment, the fragment is an antigen-binding fragment selected from Fab, F(ab')2, Fab', scFv, or Fv. In another embodiment, the fragment specifically binds to the head region of the DNABII peptide.

[0023] This article also provides formulations containing the Fab fragment.

[0024] In another aspect, the antibody or a fragment thereof is modified. Non-limiting examples of modification include PEGylation, PEG mimetic, polysialylation, HES-ization, or glycosylation.

[0025] The antibody and antigen-binding fragment may be detectably labeled, or may include detectable markers and / or purified markers.

[0026] This document also provides peptides that comprise, are substantially composed of, or consist of the antibody or antigen-binding fragments or regions disclosed above. The CDR may be selected from CDR1, CDR2, or CDR3. The CDR may be detectably labeled, or include detectable markers and / or purified markers.

[0027] This document further provides isolated polypeptides comprising, or substantially comprising, an amino acid sequence selected from, or substantially comprising: SEQ ID NO: 1-14 or 24-27; amino acids (aa) 25 to aa 144 of SEQ ID NO: 1-6, 13, 24 or 26; aa 21 to aa 132 of SEQ ID NO: 7-9, 14 or 25; aa 21 to aa 126 of SEQ ID NO: 10-12 or 27; or equivalents thereof. This document also provides isolated polypeptides comprising, or substantially comprising, an amino acid sequence of one or more antibodies or fragments thereof disclosed herein. The polypeptides may be detectably labeled and / or include detectable markers and / or purification markers. In a further embodiment, the polypeptide further comprises a signal peptide.

[0028] This document further provides isolated polynucleotides encoding antibodies or antigen-binding fragments thereof, CDRs of said antigen-binding fragments or antibodies, said polypeptides, or equivalents thereof, optionally operably linked to promoter and / or enhancer elements. The polynucleotides may be detectably labeled and / or include detectable markers and / or purification markers. The polynucleotides may further comprise a signal peptide polynucleotide sequence located upstream of the immunoglobulin variable region of the antibody. They may be contained in vectors and / or host cells. Therefore, this document further provides a vector comprising, or substantially consisting of, the isolated polynucleotides disclosed herein. Such vectors may be plasmids or viral vectors, optionally selected from retroviral vectors, lentiviral vectors, adenoviral vectors, and adeno-associated virus vectors. This document also provides host cells comprising one or more of the polynucleotides and / or vectors disclosed herein.

[0029] This document further provides compositions comprising a carrier and one or more of the following: an antibody or a fragment thereof, a CDR, a polypeptide, an isolated polynucleotide, a carrier or a host cell, or substantially composed of, or composed of, thereof. In one embodiment, the carrier is a pharmaceutically acceptable carrier. Alternatively or additionally, the carrier is a solid-phase carrier or solid-phase support. In another embodiment, the carrier is suitable for an industrial environment. This document also provides non-physiological surfaces coated with antibodies or fragments thereof as disclosed herein. In one embodiment, the surface is in an industrial environment. In some embodiments, the fragment is an antigen-binding fragment.

[0030] This document also provides a method for producing the said antibody, fragment, CDR, or peptide, the method comprising, or substantially comprising, the following steps: culturing a host cell containing a polynucleotide encoding the said antibody, antigen-binding fragment, peptide, or CDR under conditions for expressing a polynucleotide; and optionally isolating the said antibody, fragment, CDR, and / or peptide from the cell and / or culture. In one embodiment, the host cell is a mammalian cell.

[0031] In one aspect, this document provides a method for inhibiting or competing the binding of a DNABII peptide or protein to microbial DNA. The method includes, or substantially comprises, the steps of contacting the DNABII peptide or protein with one or more antibodies, fragments thereof, peptides, or CDRs disclosed herein. In one embodiment, the antibody, fragment thereof, or CDR binds to the head region of the DNABII peptide (including, but not limited to, the head region of IHF or HU, the head region of IHFA or IHFB, and / or the head chimeric peptide IhfA5-mIhfB4). NTHIIn a further embodiment, the antibody, its fragment, peptide, or CDR binds to the head chimeric peptide IhfA5-mIhfB4. NTHI In a further embodiment, the contact may be performed in vivo or in vitro.

[0032] In another aspect, this document provides a method for disrupting biofilms. The method includes, or substantially comprises, the steps of contacting the biofilm with one or more antibodies, fragments thereof, peptides, or CDRs disclosed herein. In one embodiment, the antibody, fragment thereof, or CDR binds to the head region of a DNABII peptide (including, but not limited to, the head region of IHF or HU, the head region of IHFA or IHFB, and / or the head chimeric peptide IhfA5-mIhfB4). NTHI In a further embodiment, the antibody, its fragment, peptide, or CDR binds to the head chimeric peptide IhfA5-mIhfB4. NTHI In a further embodiment, the contact may be performed in vivo or in vitro.

[0033] This document also provides methods for preventing biofilm formation on surfaces or for disrupting biofilms on surfaces, methods comprising, substantially comprising, or comprising the following steps: treating a biofilm-sensitive or biofilm-containing surface with one or more antibodies, antigen-binding fragments, peptides, or CDRs disclosed herein, wherein said antibody, fragment thereof, peptide, or CDR binds to the head region of a DNABII peptide (including, but not limited to, the head region of IHF or HU, the head region of IHFA or IHFB, and / or the head chimeric peptide IhfA5-mIhfB4). NTHI In a further embodiment, the antibody, its fragment, peptide, or CDR binds to the head chimeric peptide IhfA5-mIhfB4. NTHI In a further embodiment, the treatment is performed in vivo or in vitro.

[0034] This document also provides a method for detecting biofilms on a surface, the method comprising, or substantially comprising, the following steps: contacting the surface (in one aspect, the surface being biofilm-sensitive or containing a biofilm) with one or more antibodies, antigen-binding fragments, peptides, or CDRs disclosed herein, wherein the antibody, fragment thereof, peptide, or CDR binds to the head region of a DNABII peptide (including, but not limited to, the head region of IHF or HU, the head region of IHFA or IHFB, and / or the head chimeric peptide IhfA5-mIhfB4). NTHI In a further embodiment, the antibody, its fragment, peptide, or CDR binds to the head chimeric peptide IhfA5-mIhfB4. NTHI In a further embodiment, the contact may be performed in vivo or in vitro.

[0035] In one aspect, this document provides a method for detecting microbial infections that generate biofilms in an object. The method includes, or substantially comprises, the steps of: contacting a biological sample suspected of containing a biofilm, isolated from the object, with one or more antibodies, antigen-binding fragments, peptides, or CDRs disclosed herein, and detecting the binding of the antibody, antigen-binding fragment, peptide, or CDR to any biofilm in the sample. The dosage may be determined by a treating physician or veterinarian, for example, an amount effective for the object. In one embodiment, the antibody, fragment thereof, peptide, or CDR binds to the tail or head region of a DNABII peptide (including, but not limited to, the head region of IHF or HU, the head region of IHFA or IHFB, and the head chimeric peptide IhfA5-mIhfB4). NTHI The tail region of IHF or HU, the tail region of IHFA or IHFB, and / or the tail chimeric peptide IhfA3-IhfB2 NTHI In a further embodiment, the contact may be performed in vivo or in vitro.

[0036] In another aspect, this document provides a method for screening objects with biomembranes, the method comprising, or substantially comprising, the steps of: contacting a biomembrane-containing biological sample isolated from said object with one or more antibodies, fragments thereof, peptides, or CDRs disclosed herein, and detecting the binding of said antibody, fragment thereof, peptide, or CDR to any biomembrane in the sample. In one embodiment, said antibody, fragment thereof, peptide, or CDR binds to the tail region or head region of a DNABII peptide (including, but not limited to, the head region of IHF or HU, the head region of IHFA or IHFB, and the head chimeric peptide IhfA5-mIhfB4). NTHI The tail region of IHF or HU, the tail region of IHFA or IHFB, and / or the tail chimeric peptide IhfA3-IhfB2 NTHI In a further embodiment, the object detected as having the binding is selected to administer one or more antibodies, fragments thereof, peptides, or CDRs disclosed herein, and / or one or more polynucleotides or vectors encoding said antibody, fragment thereof, peptide, or CDR, wherein said antibody, fragment thereof, peptide, or CDR binds to the head region of a DNABII peptide (including, but not limited to, the head region of IHF or HU, the head region of IHFA or IHFB, and / or the head chimeric peptide IhfA5-mIhfB4). NTHI The dosage can be determined by the treating physician or veterinarian, for example, the amount effective for the subject. In a further embodiment, the contact may be made in vivo or in vitro.

[0037] This document provides a method for detecting biofilms in a subject by administering one or more antibodies or fragments thereof disclosed herein to the subject and detecting any binding of the disclosed antibodies, fragments thereof, peptides, or CDRs to the biofilm. In one aspect, the antibodies, fragments thereof, peptides, or CDRs bind to the tail or head region of the DNABII peptide (including, but not limited to, the head region of IHF or HU, the head region of IHFA or IHFB, and the head chimeric peptide IhfA5-mIhfB4). NTHI The tail region of IHF or HU, the tail region of IHFA or IHFB, and / or the tail chimeric peptide IhfA3-IhfB2 NTHI In another embodiment, the method further includes detecting the binding of the antibody, its fragment, peptide, or CDR to the biological membrane.

[0038] In one aspect, this document provides a method for preventing or disrupting biofilms in a subject, the method comprising, or substantially comprising, the steps of: administering to the subject one or more antibodies, fragments thereof, peptides or CDRs disclosed herein, and / or one or more polynucleotides or carriers encoding said antibody, fragment thereof, peptide or CDR, wherein these bind to the head region of a DNABII peptide (including, but not limited to, the head region of IHF or HU, the head region of IHFA or IHFB and / or the head chimeric peptide IhfA5-mIhfB4). NTHI The dosage can be determined by the treating physician or veterinarian, for example, the amount effective for the subject. In one embodiment, the method further includes detecting biofilms: contacting one or more antibodies, fragments thereof, peptides or CDRs disclosed herein with a sample suspected of containing biofilms and detecting the binding of the biofilm to the antibody, fragment thereof, peptide or CDR, wherein the antibody, fragment thereof, peptide or CDR binds to the tail region or head region of a DNABII peptide (including, but not limited to, the head region of IHF or HU, the head region of IHFA or IHFB, the head chimeric peptide IhfA5-mIhfB4). NTHI The tail region of IHF or HU, the tail region of IHFA or IHFB, and / or the tail chimeric peptide IhfA3-IhfB2 NTHI ).

[0039] In another aspect, this document provides methods for inhibiting, preventing, or treating microbial infections that produce biofilms in a subject, the methods comprising, or substantially comprising, the steps of: administering to the subject one or more antibodies, fragments thereof, peptides, or CDRs disclosed herein, and / or one or more polynucleotides or carriers encoding said antibodies, fragments thereof, peptides, or CDRs, wherein these bind to the head region of a DNABII peptide (including, but not limited to, the head region of IHF or HU, the head region of IHFA or IHFB, and / or the head chimeric peptide IhfA5-mIhfB4). NTHI The dosage can be determined by the treating physician or veterinarian, for example, the amount effective for the subject. In one embodiment, the method further includes detecting biofilms: contacting one or more antibodies, fragments thereof, peptides or CDRs disclosed herein with a sample suspected of containing biofilms and detecting the binding of the biofilm to the antibody, fragment thereof, peptide or CDR, wherein the antibody, fragment thereof, peptide or CDR binds to the tail region or head region of a DNABII peptide (including, but not limited to, the head region of IHF or HU, the head region of IHFA or IHFB, the head chimeric peptide IhfA5-mIhfB4). NTHI The tail region of IHF or HU, the tail region of IHFA or IHFB, and / or the tail chimeric peptide IhfA3-IhfB2 NTHI ).

[0040] In another aspect, this document provides prevention or treatment of a condition in a subject characterized by biofilm formation, achieved by administering to the subject one or more antibodies, fragments thereof, peptides, or CDRs disclosed herein, and / or one or more polynucleotides or carriers encoding said antibodies, fragments thereof, peptides, or CDRs, wherein these bind to the head region of a DNABII peptide (including, but not limited to, the head region of IHF or HU, the head region of IHFA or IHFB, and / or the head chimeric peptide IhfA5-mIhfB4). NTHIDosage may be determined by the treating physician or veterinarian, for example, the amount effective for the individual. Non-limiting examples of conditions include chronic non-healing wounds, lung infections caused by Burkholderia sp., venous ulcers, diabetic foot ulcers, ear infections, sinus infections, urinary tract infections, gastrointestinal diseases, hospital-acquired pneumonia, ventilator-associated pneumonia, surgical implant-related infections, lung infections, respiratory tract infections, cystic fibrosis, chronic obstructive pulmonary disease, catheter-related infections, indwelling device-related infections, implant-related prostheses, osteomyelitis, cellulitis, abscesses, and periodontal disease. In one embodiment, the method further includes detecting biofilms: contacting one or more antibodies, fragments thereof, peptides, or CDRs disclosed herein with a sample suspected of containing biofilms and detecting the binding of the biofilm to the antibody, fragment thereof, peptide, or CDR, wherein the antibody, fragment thereof, peptide, or CDR binds to the tail region or head region of a DNABII peptide (including, but not limited to, the head region of IHF or HU, the head region of IHFA or IHFB, and the head chimeric peptide IhfA5-mIhfB4). NTHI The tail region of IHF or HU, the tail region of IHFA or IHFB, and / or the tail chimeric peptide IhfA3-IhfB2 NTHI ).

[0041] In some embodiments of the methods disclosed herein, one or more of the antibodies, fragments thereof, peptides, or CDR-reducing agents are administered to reduce one or more pro-inflammatory cytokines in the target. Non-limiting examples of pro-inflammatory cytokines include IL-1β, IL6, IL8, IL12p70, IL17A, interferon (IFN), and tumor necrosis factor (TFN). Additionally or alternatively, one or more of the antibodies, fragments thereof, peptides, or CDR-increasing agents are administered to increase one or more anti-inflammatory cytokines in the target. In one embodiment, anti-inflammatory cytokines include, but are not limited to, IL10, IL13, IL-1ra, IL-4, IL-11, and transforming growth factor-β (TGF-β).

[0042] This document also provides a method for conferring passive immunity on a subject, the method comprising, or substantially comprising, the following steps: administering to the subject one or more antibodies, fragments thereof, peptides or CDRs disclosed herein, and / or one or more polynucleotides or vectors encoding said antibody, fragment thereof, peptide or CDR, wherein said antibody, fragment thereof, peptide or CDR binds to the head region of a DNABII peptide (including, but not limited to, the head region of IHF or HU, the head region of IHFA or IHFB and / or the head chimeric peptide IhfA5-mIhfB4). NTHI Dosage can be determined by the treating physician or veterinarian, for example, the amount effective for the individual.

[0043] In one aspect, the antibodies, fragments thereof, peptides or CDRs disclosed herein are used to combine therapeutic and diagnostic methods to detect and / or monitor biofilm formation and disruption.

[0044] In some embodiments, the biofilm is derived from (i.e., produced from) Gram-negative or Gram-positive biofilm-producing bacteria. In some embodiments, the biofilm contains a DNABII protein. In a further embodiment, the biofilm contains a histone-like protein (HU) or an integration host factor (IHF) binding protein from *Escherichia coli* U93. In some embodiments, the DNABII peptide is an IHF peptide. Alternatively or additionally, the DNABII peptide is a HU peptide. In some embodiments, the head region of the DNABII peptide is the head region of an IHFA and / or the head region of an IHFB. In a further embodiment, the head region of the DNABII peptide is an IHFA head region directly or indirectly (e.g., via a linker) coupled to the IHFB head region. In a further embodiment, the head region of the DNABII peptide is IhfA5-mIhfB4. NTHI Head-connected chimeric peptide. In some embodiments, the tail region of the DNABII peptide is the tail region of an IHFA and / or an IHFB. In further embodiments, the tail region of the DNABII peptide is an IHFA tail region directly or indirectly (e.g., via a linker) coupled to the IHFB tail region. In further embodiments, the tail region of the DNABII peptide is IhfA3-IhfB2. NTHI Tail-end chimeric peptide.

[0045] This document further provides a method for preparing interfering nucleic acids, which includes, or substantially consists of, the following steps: preparing a nucleic acid consisting of about 10-20 nucleotides that specifically binds to a binding partner of an antibody or fragment thereof disclosed herein, and optionally isolating the interfering nucleic acid prepared by the method.

[0046] In another aspect, this document provides a non-physiological surface covered with one or more antibodies, fragments thereof, peptides or CDRs disclosed herein, and optionally, in one aspect, the surface is in an industrial environment.

[0047] This article also provides methods for obtaining antiserum that effectively disrupts biological membranes, including immunizing the subject with a small molecule and recovering the antiserum from the subject, and optionally isolating polyclonal antiserum or monoclonal antibody from the subject.

[0048] This document also provides a kit. The kit contains one or more antibodies, fragments thereof, peptides, CDRs, polynucleotides, vectors, host cells or compositions disclosed herein, and optionally, instructions for use. Brief description of the attached diagram

[0050] Figure 1 Provides a diagram showing how DNABII proteins (such as IHF) bind to double-stranded DNA and the two arms of the DNABII protein.

[0051] Figures 2A to 2D show the results of a direct binding ELISA performed to assess the binding of humanized monoclonal antibody variants to their corresponding peptides. Head or tail chimeric peptides were coated at 2 μg / mL onto 96-well plates, and an 8-dilution series of antibodies (starting at 50 μg / mL, 1:3 dilution) was added. Anti-human IgG Fc HRP conjugate antibody (1:7000, Jackson Immuno Research Laboratories, 109-035-098) was used as a secondary detection antibody. Standard direct ELISA protocols were followed, and absorbance was read at 450 nm using a microplate reader. EC50 was calculated. 50 The value was determined, and the humanized variant was found to have a considerable binding affinity. Figures 2A and 2B The antibody shows a humanized head chimeric peptide. Figures 2C and 2D The antibody shows a humanized tail chimeric peptide.

[0052] Figure 3 This is an in vitro model of a biomembrane established in an 8-well slide, which is reversed using a humanized head or tail chimeric peptide monoclonal antibody of this disclosure.

[0053] Figures 4A to 4G Provides a design for targeting the head-specific chimeric peptide IhfA5-mIhfB4 NTHI Comparison between the amino acid identity of the heavy and light chains of humanized monoclonal antibodies (see list) Figure 4A For detailed comparison, see Figures 4B to 4G Amino acid alignment was performed using NCBIblastp.

[0054] Figures 5A to 5G Provides designs for targeting the tail-specific chimeric peptides IhfA3-IhfB2 NTHI Comparison between the amino acid identity of the heavy and light chains of humanized monoclonal antibodies (see list) Figure 5A For detailed comparison, see Figure 5B to 5G Amino acid alignment was performed using NCBIblastp.

[0055] Figure 6 Provides a design for targeting IhfA5-mIhfB4 NTHIRelative biofilm disruption data for the humanized monoclonal antibody containing the head chimeric peptide. Biofilm disruption: NTHI 86-028NP colonies were collected from overnight cultures on chocolate agar and resuspended in brain heart infusion broth (sBHI) supplemented with 2 μg β-NAD and heme / ml medium. The density at 490 nm was then adjusted to 0.65, and the cultures were diluted 1:6 in sBHI and incubated at 37°C and 5% CO2 for 3 h. Next, the cultures were diluted 1:2500 in fresh sBHI, and 200 μl of the suspension was aliquoted into each well of an 8-well slide. The slides were then incubated at 37°C and 5% CO2 for 3 h. After 16 hours, 200 μl of fresh sBHI was added to each well, and the slides were incubated for another 8 h. At this point, the medium was aspirated from each well, and 5 μg of monoclonal antibody was added to each well. The biofilm was cultured for another 16 hours. It was then washed and stained with FM1-43FX bacterial cell membrane dye (Invitrogen) and fixed overnight at 4°C in 0.1M phosphate buffer (pH 7.4) containing 16% paraformaldehyde, 2.5% glutaraldehyde, and 4.0% acetic acid. The fixative was removed, and 200 μl of Hank balanced salt solution was added to each well. The biofilm was then observed using a Zeiss 800Meta laser scanning confocal microscope. Images were compiled using Zeiss Zen Black software, and biofilm biomass was calculated using COMSTAT 2.1 software. IhfA5-mIhfB4 NTHI K of head chimeric peptides A (Unit is 1 / M) is approximately 4E+05 to approximately 2E+08.

[0056] Figure 7 Provides a design for targeting IhfA3-IhfB2 NTHIRelative biofilm disruption data for humanized monoclonal antibodies with tail-chimeric peptides. Biofilm disruption: NTHI 86-028NP colonies were collected from overnight cultures on chocolate agar and resuspended in brain heart infusion broth (sBHI) supplemented with 2 μg β-NAD and heme / ml medium. The density at 490 nm was then adjusted to 0.65, and the cultures were diluted 1:6 in sBHI and incubated at 37°C and 5% CO2 for 3 h. Next, the cultures were diluted 1:2500 in fresh sBHI, and 200 μl of the suspension was aliquoted into each well of an 8-well slide. The slides were then incubated at 37°C and 5% CO2 for 3 h. After 16 hours, 200 μl of fresh sBHI was added to each well, and the slides were incubated for another 8 h. At this point, the medium was aspirated from each well, and 5 μg of monoclonal antibody was added to each well. The biofilm was cultured for another 16 hours. It was then washed and stained with FM1-43FX bacterial cell membrane dye (Invitrogen) and fixed overnight at 4°C in 0.1M phosphate buffer (pH 7.4) containing 16% paraformaldehyde, 2.5% glutaraldehyde, and 4.0% acetic acid. The fixative was removed, and 200 μl of Hank balanced salt solution was added to each well. The biofilm was then observed using a Zeiss 800Meta laser scanning confocal microscope. Images were compiled using Zeiss Zen Black software, and biofilm biomass was calculated using COMSTAT 2.1 software. IhfA3-IhfB2 NTHI K of tail-chimeric peptide A (Unit is 1 / M) is approximately 8E+06 to approximately 2E+09.

[0057] Figures 8A–8B show the in vitro disruption of biofilms formed by five human pathogens by a mouse monoclonal antibody-derived Fab fragment targeting the β-head domain. Figure 8A shows representative images of bacterial biofilms (false-colored white), revealing significant disruption of biofilms by 170 nM intact IgG or Fab targeting the β-head domain of the IHF. Orthogonal projections show a top view to depict the spatial distribution of the biofilm in the xy-plane, and a side view to represent the biofilm height in the z-plane (arrows). Scale bar, 20 μm. Figure 8B shows the biomass within each image quantified by COMSTAT2 software. Each assay was repeated three times on different dates, and mean ± SEM is shown. *P ≤ 0.05, **P ≤ 0.01, compared to the respective intact IgG or Fab (one-way ANOVA with multiple comparisons).

[0058] Figures 9A through 9D show the eradication of NTHI-resident biofilm mediated by the mouse monoclonal antibody β-head Fab and the breakdown of mucosal biofilm from the middle ear. Figure 9A shows the study timeline and treatments administered. A single dose of 342 nM Fab was delivered to each middle ear. Figure 9B shows the relative amounts of NTHI within the mucosal biofilm and adhering to the middle ear mucosa in the treatment group. Figure 9C shows the relative mucosal biofilm scores determined by six reviewers who were unaware of the treatment in the treatment group. Figures 9B and 9C: 6–8 middle ears per group, showing the values ​​for individual ears and the group mean. The groups in each figure, from left to right, are isotype control Fab, β-tail Fab, and β-head Fab. *P≤0.05, **P≤0.01, ***P≤0.001 (one-way ANOVA with multiple comparisons). Figure 9D shows representative images of the middle ear of chinchillas from each group, with the mean mucosal biofilm score of the ear indicated in the lower right box. TM, tympanic membrane; S, bony septum; MEM, middle ear mucosa; B, biofilm (circle). In one implementation, delivery of the mouse monoclonal antibody β-head Fab significantly reduced bacterial load in the middle ear and eradicated mucosal biofilms, while β-tail Fab not only failed to do so but was also associated with significant inflammation.

[0059] Figures 10A and 10B show the major pro-inflammatory cytokines in the middle ear fluid of animals treated with β-tail Fab derived from a 342 nM mouse monoclonal antibody. Figure 10A shows the relative amounts of pro-inflammatory cytokines in the middle ear fluid of chinchillas after NTHI provocation and Fab fragment treatment, as determined by flow cytometry microarray. *P≤0.05, **P≤0.01, both compared to β-head Fab (one-way ANOVA with multiple comparisons). Compared to the isotype control Fab (unpaired t-test). Figure 10B shows the relative mean concentrations of the anti-inflammatory cytokine IL-10 in the three Fab fragment treatment cohorts. *P≤0.05 vs. β-head Fab, ++P≤0.01 vs. β-tail Fabs or isotype control Fab (one-way ANOVA with multiple comparisons). 5–7 middle ear fluids were tested in each cohort. Mean cytokine concentrations ± SD are shown. For any figure (Figure 10A or 10B), cytokine results are shown from left to right for the isotype control Fab, β-tail Fab, and β-head Fab groups. In one implementation, delivery of β-head Fab resulted in a significant decrease in the concentrations of six pro-inflammatory cytokines and a significant increase in the concentration of the anti-inflammatory cytokine IL-10, supporting the relative inflammation or lack of inflammation shown in Figure 9D.

[0060] Figures 11A through 11D provide the clearance of NTHI mediated by head chimeric Fab from polyclonal rabbit IgG, eradication of established mucosal biofilms, and regression of experimental disease. Figure 11A shows the study timeline. A single dose of 342 nM Fab was delivered to each middle ear. Figure 11B shows the relative amounts of NTHI residing within the mucosal biofilm and adhering to the middle ear mucosa 1 or 7 days after completion of antibody treatment. Figure 11C shows the relative amounts of residual mucosal biofilm determined by six evaluators who were unaware of the treatment administered. Figures 11B and 11C: 6 middle ears per group, showing values ​​for individual ears and the mean for each group. The groups from left to right in each plot are initial serum Fab, tail chimeric Fab, and head chimeric Fab. *P≤0.05, **P≤0.01, ***P≤0.001 (one-way ANOVA with multiple comparisons). Figure 11D shows a representative image of the middle ear mucosal biofilm; the mean mucosal biofilm score is shown in the lower right box. TM, tympanic membrane; S, bony septum; MEM, middle ear mucosa; B, biofilm (circle). The rabbit polyclonal antibody Fab targeting the head chimeric peptide mediated rapid and sustained clearance of biofilm-resident NTH, eradicating established mucosal biofilms and resolving experimental OM. The rabbit polyclonal antibody Fab targeting the tail chimeric peptide did not induce clearance of biofilm-resident NTH or disease regression, but was associated with significant inflammation (Fig. 11D), similar to those mouse monoclonal antibodies Fab targeting the β-tail (see Fig. 9D).

[0061] Figures 12A and 12B show the in vitro disruption of bacterial biofilms by the humanized head chimeric peptide monoclonal antibody. Figure 12A shows representative images of bacterial biofilms (false-colored white) after 16 hours of incubation with HuTipMab or HuTailMab. Orthographic projections show top views to depict the spatial distribution of biofilms in the xy plane, and side views to represent biofilm height in the z-plane (arrows). Scale bar, 20 μm. As used herein, the term “HuTipMab” refers to a monoclonal antibody (Mab or mAb) containing an anti-head HC1 having the amino acid sequence of SEQ ID NO:1 and an anti-head LC1 having the amino acid sequence of SEQ ID NO:7. Figure 12B shows the percentage of remaining biofilm biomass after exposure to HuTipMab, determined by COMSTAT2 analysis, compared to HuTailMab. Mean ± SD is shown. Three experiments were performed at different dates. ***P ≤ 0.001 (unpaired t-test). HuTipMab significantly disrupted biofilms formed by a variety of respiratory pathogens in vitro. As used herein, the term "HuTailMab" refers to a monoclonal antibody (Mab or mAb) comprising an anti-tail HC1 having the amino acid sequence of SEQ ID NO:4 and an anti-tail LC1 having the amino acid sequence of SEQ ID NO:10.

[0062] Figures 13A through 13D show the breakdown of pre-existing NTHI biofilm in the middle ear by a humanized monoclonal antibody (HuTipMab) against the head chimeric peptide during experimental NTHI-induced OM. Figure 13A shows the study timeline and treatments. Figure 13B shows the relative amount of NTHI in the middle ear. Figure 13C shows the relative amount of NTHI mucosal biofilm retained in the middle ear after treatment with the human monoclonal antibody. Figures 13B and 13C: Six middle ears per group, showing the values ​​for individual ears and the group mean. The groups from left to right in each figure are saline, humanized monoclonal antibody against the tail chimeric peptide, and humanized monoclonal antibody against the head chimeric peptide. ****P≤0.0001 (one-way ANOVA with multiple comparisons). Figure 13D provides a representative image of the middle ear from each group; the mean mucosal biofilm score of the ear is shown in the lower right box. S, bony septum; MEM, middle ear mucosa; B, biofilm (circle). HuTipMab eradicates NTHI by breaking down mucosal biofilms, a rapid and sustained effect. It is also noteworthy that, after humanization, monoclonal antibodies against the tail chimeric peptide are no longer associated with significant inflammatory changes, which is exactly what has been observed with murine monoclonal antibodies against the β-tail (see Figure 9D) or rabbit polyclonal antibodies against the tail chimeric peptide, such as Fab (see Figure 11D).

[0063] Figures 14A and 14B show a significant reduction in pro-inflammatory cytokines in the middle ear fluid of animals treated with HuTipMab. The relative amounts of pro-inflammatory and anti-inflammatory cytokines in the middle ear fluid of chinchillas were determined by flow cytometry microarray after NTH challenge, 6 days after NTH challenge followed by treatment with humanized monoclonal antibody (Figure 14A, 1 day after treatment), and 13 days after NTH challenge followed by treatment with humanized monoclonal antibody (Figure 14B, 7 days after treatment). *P≤0.05 vs. saline, **P≤0.01 vs. saline, ***P≤0.001 vs. saline, ****P≤0.0001 vs. saline, +P≤0.05 vs. HuTipMab, ++P≤0.01 vs. HuTipMab, ++P≤0.001 vs. HuTipMab, ++++P≤0.0001 vs. HuTipMab (one-way ANOVA with multiple comparisons). Three to five middle ear fluid samples were tested in each group. Mean cytokine concentrations ± SD are shown. The levels of pro-inflammatory cytokines in animals treated with HuTailMab were now the same as those in animals treated with saline, which supports the lack of correlation between the acceptance of this now humanized monoclonal antibody and that of the mouse monoclonal antibody.

[0064] Figures 15A through 15D show the ascending of experimental OM in a virus-bacterial co-infection model after immunization with head-chimeric peptides. Figure 15A shows the study timeline and the delivered vaccine formulation. Figure 15B shows the relative amounts of NTHI in nasopharyngeal lavage fluid one day after bacterial challenge to ensure equal colonization of bacteria in all groups. Eight lavage fluids per group, normal saline, no significant difference, one-way ANOVA. Figure 15C shows many animals in each group with signs of experimental OM, namely inflammation and / or middle ear fluid, observed via uninformed experimenter video otoscopy. Eight animals per group, ****P ≤ 0.001 compared to dmlT or tail-chimeric peptides, Mantel-Cox test. Figure 15D shows representative images of the tympanic membrane from each group on day 11, with the highest disease incidence in the group immunized with head-chimeric peptides on that day. TM, tympanic membrane. Immunization with head-chimeric peptides prevents the development of multimicrobial OM and promotes rapid regression of the observed limited disease.

[0065] Detailed description

[0066] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. All nucleotide sequences provided herein are presented in 5' to 3' orientation. While any methods and materials similar to or equivalent to those described herein may be used in the practice or testing of this disclosure, specific, non-limiting exemplary methods, apparatuses, and materials are described hereby. All technical and patent publications referenced herein are incorporated herein by reference in their entirety. Nothing herein should be construed as an admission that this disclosure is not authorized by any prior invention prior to such disclosure.

[0067] Unless otherwise stated, the practice of this disclosure will employ conventional techniques within the scope of the art, including tissue culture, immunology, molecular biology, microbiology, cell biology, and recombinant DNA. See, for example, Sambrook and Russell eds, (2001) Molecular Cloning: A Laboratory Manual, 3 rdedition;the seriesAusubel et al.eds.(2007)Current Protocols in Molecular Biology;the seriesMethods in Enzymology(Academic Press,Inc.,N.Y.);MacPherson et al.(1991)PCR 1:A Practical Approach(IRL Press at Oxford University Press);MacPherson et al.(1995)PCR 2:A Practical Approach;Harlow and Lane eds.(1999)Antibodies,ALaboratory Manual;Freshney(2005)Culture of Animal Cells:A Manual of BasicTechnique,5 thedition; Gait ed. (1984) Oligonucleotide Synthesis; USPat. No. 4,683,195; Hames and Higgins eds. (1984) Nucleic Acid Hybridization; Anderson (1999) Nucleic Acid Hybridization; Hames and Higgins eds. (1984) Transcription and Translation; Immobilized Cells and Enzymes (IRL) Press (1986)); Perbal (1984) APractical Guide to Molecular Cloning; Miller and Calos eds, (1987) Gene TransferVectors for Mammalian Cells (Cold Spring Harbor Laboratory); Makrides ed. (2003) Gene Transfer and Expression in Mammalian Cells; Mayer and Walker eds. (1987) Immunochemical Methods in Cell and Molecular Biology (Academic Press, London); and Herzenberg et al. eds (1996) Weir's Handbook of Experimental Immunology.

[0068] All numerical names, such as pH, temperature, time, concentration, and molecular weight, including ranges, are approximate values, varying in increments of 1.0 or 0.1 (+) or (-), as applicable, or optionally varying by + / - 15%, or 10%, or 5%, or 2%. It should be understood that, although not always explicitly stated, all numerical names are preceded by the term "about." It should also be understood that, although not always explicitly stated, the reagents described herein are merely exemplary and their equivalents are known in the art.

[0069] As used in the specification and claims, the singular form includes the plural reference unless the context clearly specifies otherwise. For example, the term "polypeptide" includes multiple polypeptides, including mixtures thereof.

[0070] As used herein, the term "comprising" is intended to mean that a composition and method includes the listed elements, but does not exclude other elements. When used to define compositions and methods, "substantially composed of..." means excluding other elements that have any fundamental significance for the intended use of the combination. Thus, a composition substantially composed of the elements defined herein does not exclude trace contaminants and pharmaceutically acceptable carriers, such as phosphate-buffered saline, preservatives, etc., from separation and purification methods. "Comprising..." means excluding other components beyond the trace elements and the main method steps for administering the compositions disclosed herein. Examples defined by each of these transitional terms are within the scope of this disclosure.

[0071] A biofilm is an organized community of microorganisms (which may sometimes attach to surfaces that are organic or inorganic) and polymers (such as DNA) that they secrete, release, and / or become available in the extracellular environment due to bacterial lysis. Biofilms are highly resistant to microorganisms and antimicrobial agents. They feed on gingival tissue, teeth, and restorations, causing dental caries and periodontal disease, also known as periodontal plaque. They can also cause chronic middle ear infections. Biofilms can also form on the surfaces of dental implants, stents, conduits, and contact lenses. They grow on pacemakers, heart valve replacements, artificial joints, and other surgical implants. The Centers for Disease Control and Prevention estimates that more than 65% of hospital-acquired infections are caused by biofilms. They can cause chronic vaginal infections and lead to life-threatening systemic infections in people with compromised immune systems. Biofilms are also associated with many diseases. For example, patients with cystic fibrosis often develop antibiotic-resistant biofilms due to Pseudomonas infections. In one embodiment, the biofilm comprises a DNABII polypeptide or protein. In a further embodiment, the biofilm comprises IHF and / or HU. In yet another embodiment, the biofilm comprises IHFA and / or IHFB.

[0072] The term "disruption" is intended to reduce the formation of the DNA / protein matrix that is a component of microbial biofilms. In some embodiments, disrupting a biofilm means dispersing the biofilm, releasing microorganisms from the DNA / protein matrix of the biofilm, and optionally allowing host immune effectors and / or antibiotics to kill the microorganisms.

[0073] "DNABII polypeptides or proteins" refers to DNA-binding proteins or polypeptides composed of DNA-binding domains and therefore possessing specific or general affinity for microbial DNA. On one hand, they bind to the minor groove of DNA. Non-limiting examples of DNABII proteins include integration host factor (IHF) proteins and histone-like proteins (HU) from *E. coli* strain U93. Other DNA-binding proteins that may be associated with biofilms include DPS (Genbank accession number: CAA49169), H-NS (Genbank accession number: CAA47740), Hfq (Genbank accession number: ACE63256), CbpA (Genbank accession number: BAA03950), and CbpB (Genbank accession number: NP). _ 418813).

[0074] "Integration host factor" or "IHF" proteins are bacterial proteins used by bacteriophages to integrate their DNA into host bacteria. They also bind extracellular microbial DNA. In *E. coli*, the genes encoding the IHF protein subunits are the himA (Genbank accession number: POA6X7.1) and himD (POA6Y1.1) genes. Homologs of these genes are present in other organisms. In some embodiments, the term "IHF" refers to one or both of the two IHF subunits: integration host factor subunit α (IHFA or IhfA) and integration host factor subunit β (IHFB or IhfB).

[0075] "HU" or "histone-like protein from Escherichia coli strain U93" refers to a class of heterodimeric proteins commonly associated with E. coli. HU proteins are known to bind to DNA junctions. Related proteins have been isolated from other microorganisms. Laine et al. reported the complete amino acid sequence of HU in E. coli (Laine et al. (1980) Eur. J. Biochem 103(3) 447-481). Antibodies against HU proteins are commercially available from Abeam. The genes encoding the HU protein subunits in E. coli are hupA and hupB, corresponding to SEQ ID NO: 29 and 30, respectively. Homologs of these genes exist in other organisms, and peptides corresponding to these genes from other organisms can be found in Table 10 of WO 2011 / 123396.

[0076] The terms "surface antigen" or "surface protein" refer to proteins or peptides on the surface of cells, such as bacterial cells. Examples of outer membrane proteins are, for instance, OMP P5 (Genbank accession number: YP-004139079.1), OMP P2 (Genbank accession number: ZZX87199.1), and OMP P26 (Genbank accession number: YP-665091.1), while examples of surface antigens are rsPilA or recombinant soluble PilA (Genbank accession number: EFU96734.1) and type IV fimbriae (Genbank accession number: Yp-003864351.1).

[0077] The term "Haemophilus influenzae" refers to a pathogen that can cause many different infections, such as ear infections, eye infections, and sinusitis. Many different strains of Haemophilus influenzae have been isolated, possessing the IhfA, ihfB, and hupA genes or proteins. Some non-limiting examples of different Haemophilus influenzae strains include Rd KW20, 86-028NP, R2866, PittGG, PittEE, R2846, and 2019.

[0078] "Microbial DNA" refers to single-stranded or double-stranded DNA from microorganisms incorporated into biofilms.

[0079] "Inhibition, prevention or destruction" of biomembranes refers to the preventive or therapeutic reduction of the structure of biomembranes.

[0080] "Curved polynucleotide" refers to a double-stranded polynucleotide containing a small loop on one strand that does not pair with the other strand. In some embodiments, the loop is about 1 base to about 20 bases long, or optionally about 2 bases to about 15 bases long, or optionally about 3 bases to about 12 bases long, or optionally about 4 bases to about 10 bases long, or optionally has about 4, 5, 6, 7, 8, 9, or 10 bases.

[0081] "A polypeptide that competes with DNABII for binding, such as competing with IHF for binding in DNA binding" refers to a protein or peptide that competes with DNABII (e.g., IHF) for binding to bent or twisted DNA structures but does not form a biological membrane with the DNA. Examples include, but are not limited to, fragments of IHF that include one or more DNA-binding domains of IHF, or their biological equivalents.

[0082] The “object” for diagnosis or treatment is a cell or animal, such as a mammal or a human. Non-human animals receiving diagnosis or treatment are those infected animals or animal models, such as apes, rodents (e.g., rats, mice, chinchillas), canines (e.g., dogs), lagomorphs (e.g., rabbits), livestock, racing animals, and pets. The terms “object,” “host,” “individual,” and “patient” are used interchangeably herein to refer to an animal, typically a mammal. Non-limiting examples of mammals include humans, non-human primates (e.g., apes, gibbons, chimpanzees, orangutans, monkeys, macaques, etc.), domesticated animals (e.g., dogs and cats), farm animals (e.g., horses, cattle, goats, sheep, pigs), and laboratory animals (e.g., mice, rats, rabbits, guinea pigs). In some embodiments, the mammal is a human. A mammal can be of any age or at any developmental stage (e.g., an adult, adolescent, child, infant, or intrauterine mammal). A mammal can be male or female. In some embodiments, the subject is a human.

[0083] The terms “protein,” “peptide,” and “polypeptide” are used interchangeably and, in their broadest sense, refer to a complex of two or more subunit amino acids, amino acid analogs, or peptide mimics. Subunits may be linked by peptide bonds. In another embodiment, subunits may be linked by other bonds, such as esters, ethers, etc. A protein or peptide must contain at least two amino acids, and there is no limit to the maximum number of amino acids that can constitute a protein or peptide sequence. As used herein, the term “amino acid” refers to natural and / or non-natural or synthetic amino acids, including glycine as well as its D and L optical isomers, amino acid analogs, and peptide mimics.

[0084] "C-terminal polypeptide" means a polypeptide with at least 10, at least 15, at least 20, or at least 25 C-terminal amino acids or half a polypeptide. On the other hand, for a polypeptide containing 90 amino acids, the C-terminal polypeptide will include amino acids 46 through 90. In one aspect, the term means the C-terminal 20 amino acids starting from the carboxyl terminus.

[0085] The "head segment" of a DNABII polypeptide refers to the two arms that form the protein, taking IHFalpha and IHFbeta as examples (see...). Figure 1 DNABII peptides of this class. Non-limiting examples of this class include IhfA, A head fragment: NFELRDKSSRPGRNPKTGDVV, SEQ ID NO: 31, and IhfB, B head fragment: SLHHRQPRLGRNPKTGDSVNL, SEQ ID NO: 32.

[0086] The "tail segment" of a DNABII polypeptide refers to the region of a protein that is exposed to the bulk medium but not covered by DNA or other polypeptides.

[0087] An immunogenic dominant antigen refers to a protein region that is recognized and binds to an antibody with high affinity.

[0088] Immunoprotective antigens refer to regions of proteins that are recognized and bind to antibodies with high affinity to interfere with protein function; antibodies generated against immunoprotective antigens are characterized by enhanced or optimal efficacy against the target indication due to interference with protein function—in which case the ability to clear biofilms is improved.

[0089] The terms "polynucleotide" and "oligonucleotide" are used interchangeably and refer to a polymeric form of nucleotides of any length, whether deoxyribonucleotides or ribonucleotides or analogs thereof. Polynucleotides can have any three-dimensional structure and can perform any known or unknown function. The following are non-limiting examples of polynucleotides: genes or gene fragments (e.g., probes, primers, EST or SAGE tags), exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, RNAi, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. Polynucleotides can contain modified nucleotides, such as methylated nucleotides and nucleotide analogs. Modifications to the nucleotide structure can be conferred before or after polynucleotide assembly, if present. Nucleotide sequences can be broken down by non-nucleotide components. Polynucleotides can be further modified after polymerization, for example, by conjugation with labeled components. The term also refers to double-stranded and single-stranded molecules. Unless otherwise stated or required, any embodiment of the polynucleotide disclosed herein includes both double-stranded forms and each of two complementary single-stranded forms known or predicted to constitute a double-stranded form.

[0090] Polynucleotides consist of a specific sequence of four nucleotide bases: adenine (A); cytosine (C); guanine (G); thymine (T); and when the polynucleotide is RNA, uracil (U) replaces thymine. Therefore, the term "polynucleotide sequence" is a letter representation of a polynucleotide molecule. This letter representation can be entered into a database in a computer with a central processing unit and used for bioinformatics applications such as functional genomics and homology searches.

[0091] As used herein, the terms “isolated” or “recombinant” for nucleic acids such as DNA or RNA refer to molecules isolated from other DNA or RNA, respectively, present in natural sources of macromolecules and polypeptides. The term “isolated or recombinant nucleic acid” is intended to include nucleic acid fragments that do not exist naturally as fragments and are not found in their natural state. The term “isolated” is also used herein to refer to polynucleotides, polypeptides, and proteins isolated from other cellular proteins, and is intended to include purified and recombinant polypeptides. In other embodiments, the term “isolated or recombinant” means isolated from cells and other components, wherein cells, tissues, polynucleotides, peptides, polypeptides, proteins, antibodies, or fragments thereof are typically naturally bound together. For example, isolated cells are cells isolated from tissues or cells with different phenotypes or genotypes. Isolated polynucleotides are isolated from the 3' and 5' consecutive nucleotides that are typically linked to them in their natural or native environment (e.g., on chromosomes). As will be apparent to those skilled in the art, non-naturally occurring polynucleotides, peptides, polypeptides, proteins, antibodies, or fragments thereof do not need to be “isolated” to distinguish them from their naturally occurring counterparts.

[0092] Unless explicitly stated otherwise, it can be inferred that when this disclosure relates to polypeptides, proteins, polynucleotides, or antibodies, their equivalents or bioequivalents are included within the scope of this disclosure. As used herein, the term "bioequivalent" is intended to be synonymous with "equivalent" when referring to a reference protein, antibody, fragment, polypeptide, or nucleic acid, meaning those equivalents that have minimal homology while still retaining the desired structure or function. Unless specifically mentioned herein, any polynucleotide, polypeptide, or protein mentioned herein is expected to include its equivalent. In one aspect, an equivalent polynucleotide is a polynucleotide that hybridizes under stringent conditions to a polynucleotide or a polynucleotide complement thereof used in the methods described herein. In another aspect, an equivalent antibody or antigen-binding polypeptide means that it binds to a reference antibody or antigen-binding fragment with an affinity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or higher. In yet another aspect, its equivalent competes with an antibody or antigen-binding fragment for binding its antigen in a competitive ELISA assay. On the other hand, an isomorphic peptide means having at least about 80% homology or identity, or at least about 85%, or at least about 90%, or at least about 95%, or 98% homology or identity, and exhibiting biological activity substantially equivalent to a reference protein, peptide, or nucleic acid. Examples of biologically equivalent peptides are provided in Table 9 of WO 2011 / 123396, which identify conserved amino acid substitutions in the disclosed amino acid sequence.

[0093] A polynucleotide or polynucleotide region (or polypeptide or polypeptide region) having a certain percentage (e.g., 80%, 85%, 90%, or 95%) of “sequence identity” with another sequence means that, when aligned, the number of bases (or amino acids) is the same when comparing the two sequences. Alignment and homology percentages or sequence identity can be determined using software programs known in the art, such as those described in Current Protocols in Molecular Biology (Ausubel et al., eds. 1987), Supplement 30, section 7.7.18, Table 7.7.1. In some embodiments, alignment is performed using default parameters. A non-limiting exemplary alignment program is BLAST, using default parameters. Specifically, exemplary procedures include BLASTN and BLASTP, using the following default parameters: Genetic code=standard; filter=none; strand=both; cutoff=60; expect=10; Matrix=BLOSUM62; Descriptions=50 sequences; sort by=HIGH SCORE; Databases=non-redundant,GenBank+EMBL+DDBJ+PDB+GenBank CDS translations+SwissProtein+SPupdate+PIR. Details of these procedures can be found at: ncbi.nlm.nih.gov / cgi-bin / BLAST. Sequence identity and identity percentages are determined by merging them into clustalW (link: align.genome.jp, last accessed March 7, 2011).

[0094] "Homology," "identity," or "similarity" refers to the sequence similarity between two peptides or two nucleic acid molecules. Homology can be determined by comparing positions in each sequence, which can be aligned for comparison purposes. When a position in the compared sequences is occupied by the same base or amino acid, the molecules are homologous at that position. The degree of homology between sequences is a function of the number of shared matching or homologous positions. An "irrelevant" or "non-homologous" sequence has less than 40% identity or less than 25% identity with one of the sequences disclosed herein.

[0095] "Homology," "identity," or "similarity" can also refer to two nucleic acid molecules that hybridize under strict conditions.

[0096] "Hybridization" refers to a reaction in which one or more polynucleotides react to form a complex that is stabilized by hydrogen bonds between the bases of the nucleotide residues. Hydrogen bonds can occur through Watson-Crick base pairing, Hoogstein binding, or any other sequence-specific mechanism. The complex can consist of two strands forming a duplex, three or more strands forming a multi-stranded complex, a single self-hybridizing strand, or any combination thereof. Hybridization can constitute a step in a broader process, such as the initiation of a PCR reaction or the enzymatic cleavage of polynucleotides by ribozymes.

[0097] Examples of stringent hybridization conditions include: incubation temperatures of approximately 25°C to approximately 37°C; hybridization buffer concentrations of approximately 6×SSC to approximately 10×SSC; formamide concentrations of approximately 0% to approximately 25%; and wash solutions of approximately 4×SSC to approximately 8×SSC. Examples of moderate hybridization conditions include: incubation temperatures of approximately 40°C to approximately 50°C; buffer concentrations of approximately 9×SSC to approximately 2×SSC; formamide concentrations of approximately 30% to approximately 50%; and wash solutions of approximately 5×SSC to approximately 2×SSC. Examples of highly stringent conditions include: incubation temperatures of approximately 55°C to approximately 68°C; buffer concentrations of approximately 1×SSC to approximately 0.1×SSC; formamide concentrations of approximately 55% to approximately 75%; and wash solutions of approximately 1×SSC, 0.1×SSC, or deionized water. Typically, hybridization incubation times range from 5 minutes to 24 hours, with one, two, or more wash steps, and wash incubation times of approximately 1, 2, or 15 minutes. SSC is a 0.15M NaCl and 15mM citrate buffer. It is understood that equivalents of SSC using other buffer systems can be used.

[0098] As used herein, “expression” refers to the process of polynucleotides being transcribed into mRNA and / or the transcribed mRNA being subsequently translated into peptides, polypeptides, or proteins. If the polynucleotides are derived from genomic DNA, expression may include the splicing of mRNA in eukaryotic cells.

[0099] When applied to polynucleotides, the term "encoding" refers to a polynucleotide that, if in its native state or when manipulated by methods well known to those skilled in the art, can be transcribed and / or translated to produce a polypeptide and / or fragments thereof in mRNA, then the polynucleotide is said to encode a polypeptide. The antisense strand is the complementary sequence of such nucleic acid, from which the coding sequence can be deduced.

[0100] As used herein, the term “treatment” is used to mean obtaining a desired pharmacological and / or physiological effect. This effect may be preventative in relation to the complete or partial prevention of a disease or its signs or symptoms, and / or therapeutic in relation to the partial or complete cure of a disease and / or adverse effects attributable to the disease. As used herein, “treatment” can also refer to (1) preventing the occurrence of symptoms or disease in susceptible individuals or those not yet exhibiting symptoms of disease; (2) suppressing or preventing the development of disease; or (3) improving or resolving disease or its symptoms. As understood in the art, “treatment” is a method for obtaining a beneficial or desired outcome (including clinical outcomes). For the purposes of this art, a beneficial or desired outcome may include, but is not limited to, the reduction or improvement of one or more symptoms, a reduction in the severity of a disease (including disease), stabilization (i.e., non-deterioration) of a disease (including disease), delay or mitigation of a disease (including disease), progression, improvement or relief of a disease (including disease), condition, and remission (whether partial or complete), whether detectable or undetectable. In this respect, treatment does not include prevention.

[0101] Prevention refers to the prevention, either externally or internally, of disease or its effects on a system or object susceptible to disease or its effects. An example of this is preventing the formation of a biofilm in a system infected with microorganisms known to produce biofilms.

[0102] "Composition" is intended to represent a combination of an active agent and another compound or an inert (e.g., a detectable reagent or label) or active ingredient, such as an adjuvant, diluent, binder, stabilizer, buffer, salt, lipophilic solvent, preservative, adjuvant, etc., and includes a pharmaceutically acceptable carrier. The carrier also includes pharmaceutical excipients and additives such as proteins, peptides, amino acids, lipids, and carbohydrates (e.g., sugars, including monosaccharides, disaccharides, trisaccharides, tetrasaccharides, and oligosaccharides; derived sugars, such as sugar alcohols, aldonic acids, esterified sugars, etc.; and polysaccharides or sugar polymers), which may be present alone or in combination, comprising 1-99.99% by weight or volume, alone or in combination. Exemplary protein excipients include serum albumin, such as human serum albumin (HSA), recombinant human albumin (rHA), gelatin, casein, etc. Representative amino acid / antibody components that may also function in buffering capacity include alanine, arginine, glycine, arginine, betaine, histidine, glutamic acid, aspartic acid, cysteine, lysine, leucine, isoleucine, valine, methionine, phenylalanine, aspartame, etc. Carbohydrate excipients are also included within the scope of this technology, examples of which include, but are not limited to, monosaccharides such as fructose, maltose, galactose, glucose, D-mannose, sorbitol, etc.; disaccharides such as lactose, sucrose, trehalose, cellobiose, etc.; polysaccharides such as raffinose, melitriose, maltodextrin, dextran, starch, etc.; and sugar alcohols such as mannitol, xylitol, maltitol, lactitol, xylitol, sorbitol, and inositol.

[0103] "Pharmaceutical composition" is intended to include a combination of an active agent and an inert or active carrier, making the composition suitable for diagnostic or therapeutic use in vitro, in vivo or ex vivo.

[0104] "Pharmaceutically acceptable carrier" means any diluent, excipient, or carrier that can be used in the compositions disclosed herein. Pharmaceutically acceptable carriers include ion exchangers, alumina, aluminum stearate, lecithin, serum proteins such as human serum albumin, buffering substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts, or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol, and lanolin. Suitable drug carriers are described in standard reference texts in the art, such as Remington's Pharmaceutical Sciences, Mack Publishing Company. They can be selected based on the intended form of administration, i.e., oral tablets, capsules, elixirs, syrups, etc., and are consistent with routine pharmaceutical practice.

[0105] The compositions used according to this disclosure can be packaged in dosage units to facilitate administration and uniformity of dosage. The term "unit dose" or "dose" refers to a physically discrete unit applicable to the subject, each unit containing a predetermined amount of the composition, calculated based on the desired response to be produced in relation to its administration (i.e., appropriate route and regimen). The dosage, depending on the number of treatments and the unit dose, depends on the desired outcome and / or protection. The precise amount of the composition also depends on the practitioner's judgment and is specific to each individual. Factors influencing dosage include the subject's physical and clinical condition, route of administration, intended therapeutic goals (symptom relief vs. cure), and the potency, stability, and toxicity of the particular composition. In formulation, the solution is administered in a manner compatible with the dosage form and in an amount effective for treatment or prevention. The formulation is readily administered in various dosage forms, such as the injectable solution types described herein.

[0106] As disclosed herein, “bioactive agent” or active agent means one or more isolated or recombinant polypeptides, isolated or recombinant polynucleotides, carriers, isolated host cells or antibodies, and compositions comprising one or more of these.

[0107] "Administration" can be administered continuously or intermittently as a single dose throughout the treatment process. Methods for determining the most effective route of administration and dosage are known to those skilled in the art and will vary depending on the composition used for treatment, the purpose of treatment, the target cells being treated, and the patient being treated. Single or multiple administrations can be performed, with the dosage level and mode chosen by the treating physician. Suitable dosage formulations and methods of administration are known to those skilled in the art. The route of administration can also be determined, and methods for determining the most effective route of administration are known to those skilled in the art and will vary depending on the composition used for treatment, the purpose of treatment, the health condition or stage of disease, the patient being treated, and the target cells or tissues. Non-limiting examples of routes of administration include oral administration, nasal administration, injection, and topical application.

[0108] The pharmaceutical agents disclosed herein can be administered for treatment via any suitable route of administration. It should also be understood that the optimal route will vary depending on the recipient's condition and age, as well as the disease being treated.

[0109] As used herein, the term "contact" refers to a direct or indirect binding or interaction between two or more molecules. A specific example of a direct interaction is binding. A specific example of an indirect interaction is an entity acting on an intermediate molecule, which in turn acts on a second reference entity. Contacts, as used herein, include those occurring in solution, in solid phase, in vitro, in vitro, in cells, and in vivo. In vivo contact may be referred to as administration or delivery.

[0110] The term "effective amount" refers to an amount sufficient to achieve the desired effect. In the case of therapeutic or preventative applications, the effective amount will depend on the type and severity of the condition in question and the characteristics of the individual subject, such as general health status, age, sex, weight, and tolerance to the pharmaceutical composition. In the case of immunogenic compositions, in some embodiments, the effective amount is an amount sufficient to induce a protective response against the pathogen. In other embodiments, the effective amount of the immunogenic composition is an amount sufficient to induce antibody production against the antigen. In some embodiments, the effective amount is the amount required to confer passive immunization upon the subject in need. Regarding immunogenic compositions, in some embodiments, in addition to the factors described above, the effective amount will depend on the intended use, the degree of immunogenicity of the specific antigenic compound, and the health / responsiveness of the subject's immune system. Those skilled in the art will be able to determine the appropriate amount based on these and other factors.

[0111] In in vitro applications, in some embodiments, the effective amount will depend on the size and nature of the application. It also depends on the nature and sensitivity of the in vitro target and the method used. Those skilled in the art will be able to determine the effective amount based on these and other considerations. Depending on the implementation, the effective amount may include a single or multiple administrations of the composition.

[0112] The term "contact" refers to a direct or indirect binding or interaction between two or more molecules. A specific example of a direct interaction is binding. A specific example of an indirect interaction is an entity acting on an intermediate molecule, which in turn acts on a second reference entity. Contacts as used herein include those occurring in solution, in solid phase, in vitro, in vitro, in cells, and in vivo. In vivo contact may be referred to as administration or delivery.

[0113] The term "conjugated moiety" refers to a portion of a chimeric polypeptide that can be added to a separate chimeric polypeptide by forming a covalent bond with residues of the chimeric polypeptide. This moiety can bind directly to residues of the chimeric polypeptide, or it can form a covalent bond with a linker, which in turn forms a covalent bond with residues of the chimeric polypeptide.

[0114] "Peptide conjugate" refers to the association of one or more polypeptides with another chemical or biological compound through covalent or non-covalent bonding. In a non-limiting example, the "conjugation" of the polypeptide to the compound results in an improvement in the stability or efficacy of the polypeptide for its intended purpose. In one embodiment, the peptide is conjugated to a carrier, wherein the carrier is a liposome, micelle, or a pharmaceutically acceptable polymer.

[0115] Liposomes are microscopic vesicles composed of concentric lipid bilayers. Structurally, liposomes vary in size and shape from elongated tubular to spherical, with dimensions ranging from hundreds of angstroms to fractions of a millimeter. The lipids that form the vesicles are selected to achieve a specific degree of fluidity or rigidity in the final complex, thus providing the outer lipid component. These are neutral (cholesterol) or bipolar, including phospholipids such as phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol (PI), and sphingomyelin (SM), as well as other types of bipolar lipids, including but not limited to dioleoylphosphatidylethanolamine (DOPE), with hydrocarbon chain lengths in the range of 14-22, saturated, or having one or more C=C double bonds. Examples of lipids that can form stable liposomes alone or in combination with other lipid components are phospholipids, such as hydrogenated soybean phosphatidylcholine (HSPC), lecithin, phosphatidylethanolamine, lysophosphatidylcholine, lysophosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, cephalin, cardiolipin, phosphatidic acid, cerebroside, distearate phosphatidylethanolamine (DSPE), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), palmitoylphosphatidylcholine (POPC), palmitoyloleoylphosphatidylethanolamine (POPE), and dioleoylphosphatidylethanolamine 4-(N-maleimide-triethyl)cyclohexane-1-carboxylic acid ester (DOPE-mal). Other non-phosphorus lipids that can be incorporated into liposomes include stearylamine, dodecylamine, hexadecylamine, isopropyl myristate, triethanolamine-lauryl sulfate, alkylaryl sulfate, acetyl palmitate, glyceryl ricinoleate, hexadecyl stearate, amphoteric acrylic polymers, polyethoxylated fatty acid amides, and the aforementioned cationic lipids (DDAB, DODAC, DMRIE, DMTAP, DOGS, DOTAP (DOTMA), DOSPA, DPTAP, DSTAP, DC-Chol). Negatively charged lipids include vesicle-forming phosphatidic acid (PA), dipalmitoylphosphatidylglycerol (DPPG), dithioylphosphatidylglycerol (DOPG), and hexadecyl phosphate. Generally, liposomes can be classified into three categories based on their overall size and the nature of their layered structure. According to the December 1977 New York Academy of Sciences meeting, "Liposomes and Their Use in Biology and Medicine," the three categories are multilayered vesicles (MLV), small unilamellar vesicles (SUV), and large unilamellar vesicles (LUV). Bioactive agents can be encapsulated therein for administration according to the methods described herein.

[0116] Micelles are aggregates of surfactant molecules dispersed in a liquid colloid. Typical micelles in aqueous solutions form aggregates where a hydrophilic "head" region is in contact with the surrounding solvent, while a hydrophobic tail region is isolated at the center. This type of micelle is called a normal-phase micelle (oil-in-water micelle). Inverted-phase micelles have a head at the center and tails extending outwards (water-in-oil micelles). Micelles can be used to link polynucleotides, peptides, antibodies, or compositions described herein to facilitate efficient delivery to target cells or tissues.

[0117] The phrase "pharmaceutically acceptable polymer" refers to a group of compounds that can be conjugated to one or more polypeptides described herein. Conjugation of the polymer to the polypeptide is expected to prolong the half-life of the polypeptide in vivo and in vitro. Non-limiting examples include polyethylene glycol, polyvinylpyrrolidone, polyvinyl alcohol, cellulose derivatives, polyacrylates, polymethacrylates, sugars, polyols, and mixtures thereof. Bioactive agents can be conjugated to pharmaceutically acceptable polymers for administration according to the methods described herein.

[0118] "Gene delivery vector" is defined as any molecule capable of carrying an inserted polynucleotide into a host cell. Examples of gene delivery vectors are liposomes, micellar biocompatible polymers, including natural and synthetic polymers; lipoproteins; polypeptides; polysaccharides; lipopolysaccharides; artificial viral envelopes; metal particles; and bacteria or viruses, such as baculoviruses, adenoviruses, and retroviruses, bacteriophages, granules, plasmids, fungal vectors, and other recombinant vectors commonly used in the art that are described for expression in a variety of eukaryotic and prokaryotic hosts and can be used for gene therapy as well as simple protein expression.

[0119] The polynucleotides disclosed herein can be delivered to cells, tissues, or objects using gene delivery vectors. As used herein, “gene delivery,” “gene transfer,” “transduction,” etc., refer to the introduction of exogenous polynucleotides (sometimes called “transgenic”) into host cells, regardless of the method of introduction. Such methods include a variety of well-known techniques, such as vector-mediated gene transfer (via, for example, viral infection / transfection, or various other protein- or lipid-based gene delivery complexes) and techniques that facilitate the delivery of “naked” polynucleotides (e.g., electroporation, “gene gun” delivery, and various other techniques for introducing polynucleotides). The introduced polynucleotides can be maintained stably or transiently in the host cell. Stable maintenance typically requires that the introduced polynucleotide contains a replication origin compatible with the host cell or is integrated into a replicon of the host cell, such as an extrachromosomal replicon (e.g., a plasmid) or a nuclear or mitochondrial chromosome. As known in the art and described herein, many vectors are known to mediate the transfer of genes into mammalian cells.

[0120] As used in this article, the term "eDNA" refers to extracellular DNA found as a component of pathogenic biofilms.

[0121] A plasmid is an extrachromosomal DNA molecule that separates from chromosomal DNA and is capable of replicating independently of chromosomal DNA. In many cases, it is circular and double-stranded. Plasmids provide a mechanism for horizontal gene transfer within microbial communities and often provide a selective advantage under given environmental conditions. Plasmids may carry genes that induce resistance to naturally occurring antibiotics in a competitive environment, or the proteins they produce may act as toxins under similar conditions.

[0122] The "plasmids" used in genetic engineering are called "plasmid vectors." Many plasmids for this purpose are commercially available. The gene to be replicated is inserted into multiple copies of a plasmid containing the gene that makes the cell resistant to a specific antibiotic and a multiple cloning site (MCS, or multiple adapter). The multiple cloning site is a short region containing several commonly used restriction sites, allowing for easy insertion of DNA fragments at this location. Another major use of plasmids is the production of large quantities of proteins. In this case, researchers culture bacteria containing plasmids with the gene of interest. Just as bacteria produce proteins to confuse them with antibiotic resistance, they can also be induced to produce large quantities of proteins from the inserted gene. This is a cheap and simple method for large-scale production of genes or encoded proteins.

[0123] "Yeast artificial chromosome," or "YAC," refers to a vector used to clone large DNA fragments (greater than 100 kb, up to 3000 kb). It is an artificially constructed chromosome containing the telomeres, centromeres, and origin of replication sequences required for replication and preservation in yeast cells. It is constructed using initial circular plasmids, linearized using restriction endonucleases, and then DNA ligases can add sequences or genes of interest within the linear molecule using sticky ends. Yeast expression vectors, such as YAC, YIp (yeast integrative plasmid), and YEp (yeast free plasmid), are very useful because yeast itself is a eukaryotic cell, thus allowing the production of eukaryotic protein products with post-translational modifications. However, YAC has been found to be less stable than BAC, resulting in chimerism.

[0124] A “viral vector” is defined as a recombinant virus or viral particle containing polynucleotides to be delivered to host cells in vivo, in vitro, or outside the body. Examples of viral vectors include retroviral vectors, adenovirus vectors, adeno-associated virus vectors, alphavirus vectors, etc. Vectors based on infectious tobacco mosaic virus (TMV) can be used to manufacture proteins and have been reported to express Griffithsin in tobacco leaves (O'Keefe et al. (2009) Proc. Nat. Acad. Sci. USA 106(15):6099-6104). Alphavirus vectors, such as those based on Semliki Forest virus and those based on Sindbis virus, have also been developed for gene therapy and immunotherapy. See Schlesinger & Dubensky (1999) Curr. Opin. Biotechnol. 5:434-439 and Ying et al. (1999) Nat. Med. 5(7):823-827. In the context of gene transfer mediated by retroviral vectors, a vector construct refers to a polynucleotide containing a retroviral genome or a portion thereof, as well as a therapeutic gene.

[0125] As used herein, "retrovirus-mediated gene transfer" or "retrovirus transduction" has the same meaning, referring to the process by which a virus enters a cell and integrates its genome into the host cell's genome, thereby stably transferring a gene or nucleic acid sequence into the host cell. Viruses can enter host cells through their normal infection mechanisms or by being modified to bind to different host cell surface receptors or ligands. As used herein, a retroviral vector refers to a viral particle capable of introducing exogenous nucleic acids into cells through viral or virus-like entry mechanisms.

[0126] Retroviruses carry their genetic information in the form of RNA; however, once a virus infects a cell, the RNA is reverse transcribed into DNA and integrated into the genomic DNA of the infected cell. The integrated DNA form is called a provirus.

[0127] In the case of gene transfer mediated by DNA viral vectors, such as adenovirus (Ad) or adeno-associated virus (AAV), the vector construct refers to a polynucleotide containing the viral genome or a portion thereof and the transgene. Adenovirus (Ad) is a relatively well-characterized group of homologous viruses, including more than 50 serotypes. See, for example, PCT International Application Publication No. WO 95 / 27071. Ad does not need to integrate into the host cell genome. Recombinant Ad-derived vectors have also been constructed, particularly those that reduce the likelihood of recombination and the generation of wild-type viruses. See PCT International Application Publications Nos. WO 95 / 00655 and WO 95 / 11984. Wild-type AAV has high infectivity and specificity for integration into the host cell genome. See Hermonat & Muzyczka (1984) Proc. Natl. Acad. Sci. USA 81:6466-6470 and Lebkowski et al. (1988) Mol. Cell. Biol. 8:3988-3996.

[0128] Vectors containing promoters and cloning sites that operatively link multiple nucleotides are well known in the art. Such vectors are capable of transcribing RNA in vitro or in vivo and are commercially available from sources such as Stratagene (La Jolla, CA) and PromegaBiotech (Madison, Wis.). To optimize expression and / or in vitro transcription, it may be necessary to remove, add, or modify the 5' and / or 3' untranslated portions of the clone to eliminate additional, potentially inappropriate alternative translation start codons or other sequences that may interfere with or reduce expression at the transcriptional or translational level. Alternatively, a shared ribosome binding site may be inserted immediately at the 5' of the start codon to enhance expression.

[0129] Gene delivery vectors also include DNA / liposome complexes, micelles, and viral protein-DNA complexes targeting specific viruses. Liposomes containing targeting antibodies or fragments thereof can also be used in the methods disclosed herein. In addition to delivering polynucleotides to cells or cell populations, the direct introduction of the proteins described herein into cells or cell populations can be performed using non-limiting techniques of protein transfection, or other non-limiting techniques involving culturing under conditions that enhance the expression and / or promote the activity of the proteins disclosed herein.

[0130] As used herein, the terms “antibody” and “immunoglobulin” include complete antibodies and any antigen-binding fragments or single chains thereof. Therefore, the term “antibody” includes any molecule containing a protein or peptide that comprises at least a portion of an immunoglobulin molecule. The terms “antibody” and “immunoglobulin” also include any isotype of immunoglobulin, antibody fragments that retain antigen-specific binding, including but not limited to Fab, Fab', F(ab)2, Fv, scFv, dsFv, Fd fragments, dAb, VH, VL, VhH, and V-NAR domains; small bodies, dimers, trimers, tetramers, and κ bodies; and multispecific antibody fragments formed from one or more separate antibody fragments. Examples of such fragments include, but are not limited to, complementarity-determining regions (CDRs) of the heavy or light chain or its ligand-binding portion, variable regions of the heavy or light chain (also referred to herein as variable regions), constant regions of the heavy or light chain (also referred herein as constant regions), framework (FR) regions or any portion thereof, at least a portion of a binding protein, chimeric antibodies, humanized antibodies, single-chain antibodies, and fusion proteins comprising the antigen-binding portion of an antibody and non-antibody proteins. The variable regions of the heavy and light chains of immunoglobulin molecules contain binding domains that interact with antigens. The constant regions of antibodies (Abs) mediate the binding of immunoglobulins to host tissues. For example, when the term "anti" is used before a protein name, such as anti-DNABII, anti-IHF, anti-HU, or anti-OMP P5, it refers to monoclonal or polyclonal antibodies that bind to and / or have an affinity for a specific protein. For example, "anti-IHF" refers to an antibody that binds to the IHF protein. Specific antibodies may have an affinity for or bind to proteins other than those they target. For example, anti-IHF, while specifically produced against the IHF protein, may also bind to other proteins related by sequence or structural homology.

[0131] A complementarity-determining region (CDR) is a portion of the variable region of an antibody or T cell receptor, produced by B cells and T cells respectively, in which these molecules bind to their specific antigens (also called epitopes). In some embodiments, the terms "variable region" and "variable domain" are used interchangeably to refer to a polypeptide of the antibody light or heavy chain whose amino acid residue sequence varies considerably from one antibody to another and determines the conformation of the binding site, which confers the antibody specificity to a particular antigen. In further embodiments, the variable region is from about 90 amino acids to about 200 amino acids long, including but not limited to about 100 amino acids long, or optionally about 110 amino acids long, or optionally about 120 amino acids long, or optionally about 130 amino acids long, or optionally about 140 amino acids long, or optionally about 150 amino acids long, or optionally about 160 amino acids long, or optionally about 170 amino acids long, or optionally about 180 amino acids long, or optionally about 190 amino acids long. In some embodiments, as used herein, the variable region of an amino acid sequence refers to the first 100, 110, 120, 130, 140, or 150 amino acids (including or excluding the signal peptide, if applicable) of the amino acid sequence being the variable region.

[0132] A set of CDRs constitutes a complementary site, also known as an antigen-binding site, which is part of an antibody that recognizes and binds to an antigen. Three non-contiguous CDRs (CDR1, CDR2, and CDR3) are present on the variable region amino acid sequence of an antigen receptor, such as a heavy or light chain. As used herein, CDRn refers to a CDRn in or derived from an immunoglobulin chain, wherein the number n is selected from 1 to 3. In one embodiment, CDRLn refers to a CDRn in or derived from a light chain, wherein the number n is selected from 1 to 3; while CDRHn refers to a CDRHn in or derived from a heavy chain, wherein the number n is selected from 1 to 3. In some embodiments, a frame region (FR) refers to a portion of the variable region that is not a CDR. In some embodiments, FRn refers to an FR in or derived from a heavy or light chain, wherein the number n is selected from 1 to 4. In some embodiments, the variable region comprises or substantially consists of, or further consists of (optionally in the provided order, and further optionally from the amino terminus to the carboxyl terminus): FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4.

[0133] The variable regions and / or CDRs of antibodies or fragments thereof can be determined by those skilled in the art, for example, using publicly or commercially available tools. Non-limiting examples of such tools include IgBlast (accessible at www.ncbi.nlm.nih.gov / igblast / ), Scaligner (available from drugdesigntech at www.scaligner.com / ), IMGT rules and / or tools (see, e.g., www.imgt.org / IMGTScientificChart / Nomenclature / IMGT-FRCDRdefinition.html, also accessible at www.imgt.org / ), Chothia Canonical Assignment (accessible at www.bioinf.org.uk / abs / chothia.html), Antigen receptor Numbering AndReceptor CalssificatiIon (ANARCI, accessible at opig.stats.ox.ac.uk / webapps / newsabdab / sabpred / anarci / ), Kabat numbering methods / schemes (e.g., Kabat, EA, et al., (1991) Sequences of Proteins of Immunological Interest, Fifth (Edition, USDepartmentofHealth andHuman Services, NIH Publication No. 91-3242) or the Paratome web server (accessible at www.ofranlab.org / paratome / , see Vered Kunik, et al, Nucleic AcidsResearch, Volume 40, Issue W1, July 1, 2012, Pages W521–W524).

[0134] Antibodies can be polyclonal, monoclonal, multispecific (e.g., bispecific antibodies), or antibody fragments, as long as they exhibit the desired biological activity. Antibodies can be isolated from any suitable biological source, such as mice, rats, sheep, and dogs.

[0135] As used herein, the terms "polyclonal antibody" or "polyclonal antibody composition" refer to antibody preparations derived from different B cell lines. They are mixtures of immunoglobulin molecules secreted against specific antigens, each recognizing a different epitope.

[0136] As used herein, "monoclonal antibody" refers to an antibody obtained from a substantially homogeneous group of antibodies. Monoclonal antibodies are highly specific because each monoclonal antibody targets a single determinant on an antigen. Antibodies can be detectably labeled, for example with radioactive isotopes, enzymes that produce detectable products, fluorescent proteins, etc. Antibodies can be further conjugated to other parts, such as members of specific binding pairs, such as biotin (a member of the biotin-antibiotin specific binding pair). Antibodies can also be bound to solid supports, including but not limited to polystyrene plates or beads.

[0137] Monoclonal antibodies can be generated using hybridoma techniques or recombinant DNA methods known in the art. A hybridoma is a cell formed in the laboratory by fusing antibody-producing lymphocytes with non-antibody-producing cancer cells (typically myeloma or lymphoma). The hybridoma proliferates and produces a series of samples containing a specific monoclonal antibody. Alternative techniques for generating or selecting antibodies include exposing lymphocytes in vitro to the antigen of interest, and screening antibody display libraries in cells, phages, or similar systems.

[0138] As used herein, the term "human antibody" is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. Human antibodies disclosed herein may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutations in vivo). However, the term "human antibody" as used herein is not intended to include antibodies in which a CDR sequence derived from another mammalian species, such as a mouse, has been grafted onto a human frame sequence. Therefore, as used herein, the term "human antibody" refers to an antibody in which substantially every part of the protein (e.g., CDR, frame, C...) is... L C H Structural domains (e.g., C) H1 C H2 C H3Human antibodies (VL, VH) are substantially non-immunogenic in humans and exhibit only minor sequence changes or variations. Similarly, antibodies designated for primates (monkeys, baboons, chimpanzees, etc.), rodents (mice, rats, rabbits, guinea pigs, hamsters, etc.) and other mammals refer to such species, subgenus, genus, subfamily, or family-specific antibodies. Furthermore, chimeric antibodies include any combination of the above. Such changes or alterations optionally preserve or reduce immunogenicity in humans or other species relative to unmodified antibodies. Therefore, human antibodies differ from chimeric or humanized antibodies. It should be noted that human antibodies can be produced by non-human animals or prokaryotic or eukaryotic cells capable of expressing functionally rearranged human immunoglobulin (e.g., heavy chain and / or light chain) genes. Furthermore, when a human antibody is a single-chain antibody, it may contain a linker peptide not present in naturally occurring human antibodies. For example, Fv may contain a linker peptide connecting the heavy chain variable region and the light chain variable region, such as 2 to 8 glycine or other amino acid residues. Such linker peptides are considered to be of human origin.

[0139] As used herein, a human antibody is “derived from” a specific germline sequence if it is obtained from a system that uses a human immunoglobulin sequence, such as by immunizing transgenic mice carrying the human immunoglobulin gene or by screening a human immunoglobulin gene library. Human antibodies “derived from” a human germline immunoglobulin sequence can be identified by comparing the amino acid sequence of the human antibody with that of a human germline immunoglobulin. Selected human antibodies typically have at least 90% amino acid sequence identity with the amino acid sequence encoded by the human germline immunoglobulin gene and, when compared with germline immunoglobulin amino acid sequences from other species (e.g., mouse germline sequences), contain the amino acid residues that identify the human antibody as human. In some cases, a human antibody may have at least 95%, or even at least 96%, 97%, 98%, or 99% amino acid sequence identity with the amino acid sequence encoded by the germline immunoglobulin gene. Typically, human antibodies derived from a specific human germline sequence differ from the amino acid sequence encoded by the human germline immunoglobulin gene by no more than 10 amino acids. In some cases, human antibodies may show no more than 5, or even no more than 4, 3, 2 or 1, amino acid differences from the amino acid sequences encoded by germline immunoglobulin genes.

[0140] As used herein, the terms “humanized antibody” or “humanized immunoglobulin” refer to a human / non-human chimeric antibody containing a minimal sequence derived from a non-human immunoglobulin. In most cases, a humanized antibody is a human immunoglobulin (recipient antibody) in which residues from the recipient’s variable region or fragments thereof (e.g., 1, 2, 3, 4, 5, or all six CDRs) are replaced with residues from a non-human species (donor antibody) (e.g., a mouse, rat, rabbit, or non-human primate) possessing the desired specificity, affinity, and ability to form a variable region or fragments thereof (e.g., 1, 2, 3, 4, 5, or all six CDRs). Humanized antibodies may contain residues not found in the recipient or donor antibody. Humanized antibodies may also optionally contain at least a portion of the immunoglobulin’s (typically human) constant region (Fc), one or more amino groups in the frame region, constant region, or CDR. Non-human antibodies are those in which the amino acid is replaced by an amino acid from a corresponding position in a human antibody. Not wishing to be bound by theory, humanized antibodies produce a reduced immune response in the human host compared to the non-humanized version of the same antibody. Humanized antibodies can have conserved amino acid substitutions that do not substantially affect antigen binding or other antibody function. The conserved substitution group includes: glycine-alanine, valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, serine-threonine, and asparagine-glutamine. Specifically, humanized antibodies as disclosed herein specifically bind to DNABII peptides or fragments thereof (e.g., head chimeric peptides or tail chimeric peptides) within a specific range of one or more of the following: EC 50 K on K off K A and / or K D Furthermore, it inhibits or releases specific cytokines when treating the target. In another embodiment, a humanized antibody that specifically binds to the head region of a DNABII peptide (e.g., a head chimeric peptide) disrupts biological membranes both in vivo and in vitro. Moreover, while the humanization process is a rationally designed process, it can produce unintended changes (positive or negative) in aspects such as binding affinity, antigen specificity, or physical properties (e.g., solubility or aggregation); therefore, the properties of a humanized antibody cannot be inherently predicted from the properties of the original non-human antibody.

[0141] In one embodiment, the antibody, as used herein, may be a recombinant antibody. As used herein, the term "recombinant antibody" includes all antibodies prepared, expressed, produced, or isolated in a recombinant manner, such as antibodies isolated from transgenic or transchromosomal animals (e.g., mice) transfected with immunoglobulin genes or from hybridomas prepared therefrom, antibodies isolated from host cells transformed to express antibodies (e.g., transfectomas), antibodies isolated from recombinant combined antibody libraries, and antibodies prepared, expressed, produced, or isolated by any other means involving splicing an immunoglobulin (Ig) gene sequence to other DNA sequences. However, in some embodiments, such recombinant antibodies may be mutagenized in vitro (or, when using Ig sequence transgenic animals, in vivo somatic cell mutagenization), so that the amino acid sequences of the VH and VL regions of the recombinant antibody may be sequences not naturally present in an in vivo antibody germline library. Methods for preparing these antibodies are described herein.

[0142] In one implementation, the antibody, as used herein, may be a chimeric antibody. As used herein, a chimeric antibody is an antibody whose light chain and heavy chain genes are typically constructed by genetic engineering from antibody variable region and constant region genes belonging to different species.

[0143] As used herein, the term "antibody derivative" includes full-length antibodies or antibody fragments in which one or more amino acids are chemically modified, for example, by means of alkylation, PEGylation, acylation, esterification, or amide formation, for the purpose of linking the antibody to a second molecule. This includes, but is not limited to, PEGylated antibodies, cysteine-PEGylated antibodies, and variants thereof.

[0144] As used herein, the term "tag" means a directly or indirectly detectable compound or component conjugated directly or indirectly to the composition to be detected, such as an N-terminal histidine tag (N-His), a magnetically active isotope, for example, 115 Sn、 117 Sn and 119 Sn, a non-radioactive isotope, such as 13 C and 15N, a polynucleotide or protein, such as an antibody, to produce a “labeled” component. The term also includes sequences conjugated to polynucleotides that will provide a signal upon expression of the inserted sequence, such as green fluorescent protein (GFP). The label itself can be detectable (e.g., radioisotope labeling or fluorescent labeling), or, in the case of enzyme labeling, can catalyze a chemical change in a detectable substrate compound or component. Labels can be suitable for small-scale assays or, more importantly, for high-throughput screening. Therefore, suitable labels include, but are not limited to, magnetically active isotopes, non-radioactive isotopes, radioactive isotopes, fluorescent dyes, chemiluminescent compounds, dyes, and proteins (including enzymes). Labels can be detected simply or quantified. A response to a simple detection typically includes a response in which its presence is only confirmed, while a quantified response typically includes a response with a quantifiable (e.g., numerically reportable) value, such as intensity, polarization, and / or other properties. In luminescent or fluorescent assays, a detectable response can be generated directly using a luminescent or fluorophore associated with the assay component that actually binds, or indirectly using a luminescent or fluorophore associated with another component (e.g., a reporter molecule or indicator). Examples of luminescent labels that generate signals include, but are not limited to, bioluminescence and chemiluminescence. Detectable luminescent responses typically include a change or appearance of the luminescent signal. Suitable methods and luminescent groups for determining components using luminescent labels are known in the art and are described, for example, in Haugland, Richard P. (1996) Handbook of Fluorescent Probes and Research Chemicals (6). th Examples of luminescent probes include, but are not limited to, jellyfish luminescent proteins and luciferases.

[0145] As used herein, the term "immunoconjugate" includes antibodies or antibody derivatives linked to or connected to a second reagent, such as cytotoxic agents, detectable reagents, radioactive reagents, targeting agents, human antibodies, humanized antibodies, chimeric antibodies, synthetic antibodies, semi-synthetic antibodies, or multispecific antibodies.

[0146] Examples of suitable fluorescent labels include, but are not limited to, fluorescein, rhodamine, tetramethylrhodamine, eosin, erythrosine, coumarin, methylcoumarin, pyrene, malachite green, stilbene, Lucifer Yellow, Cascade Blue™, and Texas Red. Other suitable optical dyes are described in Haugland, Richard P. (1996) Handbook of Fluorescent Probes and Research Chemicals (6th ed.).

[0147] In another aspect, fluorescent labels are functionalized to facilitate covalent bonding with cellular components (e.g., cell surface markers) present on or in the cell or tissue surface. Suitable functional groups include, but are not limited to, isothiocyanate groups, amino groups, haloacetyl groups, maleimides, succinimides, and sulfonyl halides, all of which can be used to attach fluorescent labels to a second molecule. The choice of functional group for the fluorescent label will depend on the bonding site with the linker, reagent, marker, or second labeling agent.

[0148] "Eukaryotic cells" encompass all life forms except for anucleate protozoa. They are easily distinguished by their membrane-bound nuclei. Animals, plants, fungi, and protozoa are eukaryotic organisms, whose cells are organized into complex structures by an inner membrane and a cytoskeleton. The most characteristic membrane-bound structure is the nucleus. Unless otherwise specified, the term "host" includes eukaryotic hosts, including, for example, yeast, higher plant, insect, and mammalian cells. Non-limiting examples of eukaryotic cells or hosts include apes, cattle, pigs, mice, rats, birds, reptiles, and humans.

[0149] Prokaryotic cells typically lack a nucleus or any other membrane-bound organelles and are divided into two domains: bacteria and archaea. In addition to chromosomal DNA, these cells can also contain genetic information in circular loops called episomes. Bacterial cells are very small, about the size of an animal mitochondria (approximately 1-2 μm in diameter and 10 μm in length). Prokaryotic cells have three main shapes: rod-shaped, spherical, and spiral. Unlike eukaryotes, bacterial cells do not undergo the complex process of replication; instead, they divide through binary fission. Examples include, but are not limited to, Bacillus, Escherichia coli, and Salmonella.

[0150] "Natural" antigens are polypeptides, proteins, or fragments containing epitopes isolated from natural biological sources that can specifically bind to antigen receptors in a target, particularly T-cell antigen receptors (TCRs).

[0151] The terms “antigen” and “antigenicity” refer to molecules that can be recognized by antibodies or otherwise act as members of antibody-ligand pairs. “Specific binding” or “binding” refers to the interaction of an antigen with the variable regions of the heavy and light chains of immunoglobulins. Antibody-antigen binding can occur in vivo or in vitro. Those skilled in the art will understand that macromolecules, including proteins, nucleic acids, fatty acids, lipids, lipopolysaccharides, and polysaccharides, have the potential to act as antigens. Those skilled in the art will further understand that nucleic acids encoding proteins with the potential to act as antibody ligands necessarily encode antigens. Those skilled in the art will further understand that antigens are not limited to full-length molecules but can also include partial molecules. The term “antigen” is an adjective describing a molecule that possesses antigenic properties. This term includes immunogenic substances, i.e., immunogens, and substances that induce immune non-reactivity or incompetence, i.e., allergens.

[0152] "Modified antigens" are antigens that have a primary sequence different from the corresponding wild-type antigen. Modified antigens can be prepared by synthetic or recombinant methods, including but not limited to antigenic peptides that are differentially modified during or after translation, such as through phosphorylation, glycosylation, cross-linking, acylation, proteolytic cleavage, or linkage to antibody molecules, membrane molecules, or other ligands (Ferguson et al. (1988) Ann. Rev. Biochem. 57:285-320). The synthetic or modified antigens disclosed herein are intended to bind to the same TCR as the native epitope.

[0153] In this article, "autoantigens," also referred to as natural or wild-type antigens, are antigenic peptides that induce little or no immune response in a subject due to the subject's own tolerance to the antigen. An example of an autoantigen is the melanoma-specific antigen gp100.

[0154] "Immune response" broadly refers to the antigen-specific response of lymphocytes to foreign substances. The terms "immunogen" and "immunogenicity" refer to molecules capable of inducing an immune response. All immunogens are antigens; however, not all antigens are immunogenic. The immune response disclosed herein can be humoral (through antibody activity) or cell-mediated (through T cell activation). This response can occur in vivo or in vitro. Those skilled in the art will understand that a variety of macromolecules, including proteins, nucleic acids, fatty acids, lipids, lipopolysaccharides, and polysaccharides, have the potential to be immunogenic. Those skilled in the art will further understand that nucleic acids encoding molecules capable of inducing an immune response necessarily encode immunogens. Those skilled in the art will further understand that immunogens are not limited to full-length molecules but can include partial molecules.

[0155] The term "passive immunization" refers to the transfer of immunity from one object to another through antibody transfer. Passive immunization can occur naturally, as when maternal antibodies are transferred to a fetus. It can also occur artificially when an antibody composition is administered to a non-immune object. The antibody donor and recipient can be human or non-human objects. Antibodies can be polyclonal or monoclonal, can be produced in vitro or in vivo, and, depending on the implementation, can be purified, partially purified, or unpurified. In some embodiments described herein, passive immunization is conferred on the desired object by administering an antibody or antigen-binding fragment that specifically recognizes or binds to a specific antigen. In some embodiments, passive immunization is conferred by administering isolated or recombinant polynucleotides encoding antibodies or antigen-binding fragments that specifically recognize or bind to a specific antigen.

[0156] In the context of this disclosure, "ligand" is a polypeptide. In one aspect, as used herein, the term "ligand" refers to any molecule that binds to a specific site on another molecule. In other words, a ligand confers specificity on a protein in a reaction with an immune effector cell or an antibody against the protein or DNA against the protein. In one aspect, a ligand site within a protein binds directly to a complementary binding site on an immune effector cell.

[0157] As used herein, the interchangeable terms "solid support" or "solid material" are not limited to a particular type of support. Instead, a wide variety of supports are known and available to those skilled in the art. Solid supports include silica gel, resins, derived plastic films, glass beads, cotton, plastic beads, and alumina gel. As used herein, "solid support" also includes synthetic antigen-presenting matrices, cells, and liposomes. A suitable solid support can be selected based on the desired end use and suitability for various protocols. For example, for peptide synthesis, a solid support may refer to a resin, such as polystyrene (e.g., PAM-resin obtained from Bachem Inc., Peninsula Laboratories, etc.). Resin (obtained from Aminotech, Canada), polyamide resin (obtained from Peninsula Laboratories), and polystyrene resin grafted with polyethylene glycol. Rapp Polymere (Tubingen, Germany) or polydimethylacrylamide resin (available from Milligen / Biosearch, CA).

[0158] Examples of solid-phase supports include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylase, natural and modified cellulose, polyacrylamide, gabbro, and magnetite. The nature of the support can be either soluble or insoluble to some extent. The support material can have virtually any possible structural configuration, as long as the coupling molecules can bind polynucleotides, peptides, or antibodies. Therefore, the support structure can be spherical, such as beads, or cylindrical, such as the inner surface of a test tube or the outer surface of a rod. Alternatively, the surface can be flat, such as sheets, test strips, or polystyrene beads. Those skilled in the art will recognize many other carriers suitable for binding antibodies or antigens, or will be able to identify these carriers using routine experiments.

[0159] As used herein, biological samples or specimens may be obtained from an object, cell line, or cultured cells or tissues. Exemplary samples include, but are not limited to, cell samples, tissue samples, fluid samples such as blood and other biologically derived fluid samples (including, but not limited to, ocular fluid (aqueous humor and vitreous fluid), peripheral blood, serum, plasma, ascites, urine, cerebrospinal fluid (CSF), sputum, saliva, bone marrow, synovial fluid, aqueous humor, amniotic fluid, cerumen, breast milk, bronchoalveolar lavage fluid, semen, prostatic fluid, Copper's fluid or pre-ejaculate fluid, female ejaculation, sweat, tears, sac fluid, pleural effusion, pericardial fluid, ascites, lymph, chyme, chyle, bile, interstitial fluid, menstrual blood, pus, sebum, vomitus, vaginal secretions / irrigation fluid, synovial fluid, mucosal secretions, fecal water, pancreatic juice, lavage fluid from sinus cavities, bronchopulmonary aspirate, blastocyst fluid, or umbilical cord blood). In one embodiment, the biological sample is suspected of having a biofilm. In another embodiment, the biological sample includes a biofilm.

[0160] As used herein, the term "signal peptide" or "signal polypeptide" refers to the amino acid sequence typically present at the N-terminus of a newly synthesized secretory or membrane polypeptide or protein. Its function is to guide the polypeptide to a specific cellular location, such as across the cell membrane, into the cell nucleus, or into the cell nucleus. In some embodiments, the signal peptide is removed after localization. Examples of signal peptides are well known in the art. Non-limiting examples are those described in U.S. Patent Nos. 8,853,381, 5,958,736, and 8,795,965.

[0161] As used herein, the term "chimera" or "chimeric peptide" refers to a recombinant polypeptide comprising, or substantially constituting, two or more segments or domains of a DNABII polypeptide directly or indirectly (e.g., through a linker). In one embodiment, these domains are conformational head domains and / or conformational tail domains. Additionally or alternatively, the two or more segments or domains are derived from the same or different DNABII polypeptides. In one embodiment, the chimeric peptide comprises, or substantially constituting, an IhfA head domain and an IhfB head domain directly or indirectly (e.g., through a linker). In another embodiment, the chimeric peptide comprises, or substantially constituting, an IhfA tail domain and an IhfB tail domain directly or indirectly (e.g., through a linker). The "conformational head domain" of a polypeptide refers to the polypeptide containing the primary amino acid sequence in which the structure has antiparallel β bands, which have sharp turns typically mediated by proline residues. The "head" of an IHF polypeptide is shown in WO2018 / 129078. Figure 1 middle.

[0162] In some implementations, the head chimeric peptide IhfA5-mIhfB4NTHI The peptide comprises, or substantially comprises, the following polypeptide sequence: RPGRNPX1TGDVVPVSARRVV-X-FSLHHRQPRLGRNPX1TGDSV (SEQ ID NO:38), wherein “X” is an optional amino acid linker sequence, optionally comprising 1 to 20 amino acids (or substantially comprising, or comprising); and wherein “X1” is any amino acid, or “X1” is selected from amino acids Q, R, K, S, or T. In another embodiment, “X1” is K or Q. In a further embodiment, the head chimeric peptide IhfA5-mIhfB4 NTHI Contains, or substantially consists of, the following polypeptide sequence: RPGRNPKTGDVVPVSARRVV-X-FSLHHRQPRLGRNPKTGDSV (SEQ ID NO:39), wherein "X" is an optional amino acid linker sequence, optionally containing 1 to 20 amino acids (or substantially consisting of, or consisting of). In a further embodiment, the head chimeric peptide IhfA5-mIhfB4 NTHI Contains, or substantially consists of, the following polypeptide sequence, or is composed of: RPGRNPKTGDVVPVSARRVVGPSLFSLHHRQPRLGRNPKTGDSV (SEQ ID NO:40).

[0163] In some implementations, the tail-chimeric peptide IhfA3-IhfB2 NTHI Contains, or substantially constitutes, the following polypeptide sequence: FLEEIRLSLESGQDVKLSGF-X-TLSAKEIENMVKDILEFISQ (SEQ ID NO:41), wherein “X” is an optional amino acid linker sequence, optionally comprising 1 to 20 amino acids (or substantially constitutes, or constitutes, thereof). In some embodiments, the linker is selected from any one or more of SEQ ID NO:42-49. In one embodiment, the tail-chimeric peptides IhfA3-IhfB2 NTHI Contains, or substantially consists of, the following polypeptide sequence: FLEEIRLSLESGQDVKLSGFGPSLTLSAKEIENMVKDILEFISQ (SEQ ID NO:50).

[0164] As used in this article, the term "EC" 50 "" refers to the concentration of an antibody or fragment thereof that induces an intermediate response between baseline and maximum after a specific exposure time (e.g., binding between an antibody or fragment thereof and its target).

[0165] This paper uses several parameters to describe the binding and dissociation reactions of receptor (R, such as an antibody or a fragment thereof) and ligand (L, such as the target of an antibody or a fragment thereof) molecules, which are formalized as follows: The reaction proceeds at a rate constant k. on and dissociation rate constant k off To characterize, their units are respectively M -1 s -1 and s -1 In equilibrium, the forward binding transition R+L→RL should be balanced by the reverse non-binding transition RL→R+L. That is, k on [R][L]=k off [RL], where [R], [L], and [RL] represent the concentrations of unbound free receptor, unbound free ligand, and receptor-ligand complex, respectively. Furthermore, the equilibrium dissociation constant "K" is also present. D "It can be calculated as k" off / k on That is, [R]x[L] / [RL], while the equilibrium association constant "K" A "It can be calculated as k" on / k off That is, [RL] / ([R]x[L].

[0166] As used herein, the term "cytokine" refers to small proteins (approximately 5-20 kDa) that are important in cell signaling, including but not limited to chemokines, interferons, interleukins (ILs), lymphokines, and tumor necrosis factor, but typically excluding hormones. Cytokines are peptides that cannot cross the lipid bilayer of a cell to enter the cytoplasm. Inflammatory or pro-inflammatory cytokines are signaling molecules (cytokines) secreted by immune cells such as helper T cells (Th) and macrophages, as well as certain other pro-inflammatory cell types. They include (but are not limited to) interleukin-1 (IL-1), IL-12, and IL-18, tumor necrosis factor-α (TNF-α), interferon-γ (IFNγ), and granulocyte-macrophage colony-stimulating factor (GM-CSF) and play an important role in mediating innate immune responses. Inflammatory cytokines are primarily produced and involved in the upregulation of inflammatory responses. The term "anti-inflammatory cytokines" includes immunomodulatory molecules that control pro-inflammatory cytokine responses. Cytokines work in conjunction with specific cytokine inhibitors and soluble cytokine receptors to regulate the human immune response. Major anti-inflammatory cytokines include interleukin (IL)-1 receptor antagonists, IL-4, IL-6, IL-10, IL-11, and IL-13. Specific cytokine receptors for IL-1, tumor necrosis factor-α, and IL-18 can also act as inhibitors of pro-inflammatory cytokines. Methods for measuring cytokine levels (including anti-inflammatory and pro-inflammatory cytokines) are well known in the art. For example, serum cytokine levels can be measured using commercially available enzyme-linked immunosorbent assay (ELISA) kits.

[0167] As used herein, the term "anti-infective" refers to a drug that can inhibit the spread of infectious organisms or completely kill infectious organisms. This term includes, but is not limited to, antibiotics, antifungals, anthelmintics, antimalarials, antiprotozoal drugs, antituberculosis drugs, and antiviral drugs. Antifungals are also known as antifungal agents. They kill or inactivate fungi and are used to treat fungal infections, including yeast infections. As a non-limiting example, polyene antifungals are not absorbed when taken orally and are therefore used to treat gastrointestinal fungal infections, such as thrush. Another non-limiting example is azole antifungal agents, which are synthetic, broad-spectrum antifungal agents. Echinocandins are non-competitive inhibitors of (1,3)β-d-glucan synthase and target lipopeptide molecules in the fungal cell wall. Other examples include flavoxim U / F (griseofulvin), Grifulvin V (Pro), Lamisil (Pro), Gris-PEG (Pro), Ancobon (Pro), Fuvicin P / G, and Terbinex (Pro). More anti-infective drugs can be found, for example, at www.drugbank.ca / categories / DBCAT000065. The term "antiviral" refers to a class of drugs used to treat viral infections. Most antiviral drugs target a specific virus, while broad-spectrum antiviral drugs are effective against multiple viruses. Unlike most antibiotics, antiviral drugs do not destroy their target pathogens; instead, they inhibit their development. Some of the ways they may work include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking later stages of viral assembly. Non-limiting examples of antiviral agents can be found, for example, at www.drugbank.ca / categories / DBCAT000066.

[0168] As used herein, the term "antiparasitic drug" refers to a class of drugs used to treat parasitic diseases, such as those caused by worms, amoebas, ectoparasites, parasitic fungi, and protozoa. Non-limiting examples of antiparasitic drugs can be found, for example, at www.drugbank.ca / categories / DBCAT000522.

[0169] Implementing the pattern of this disclosure

[0170] antibody composition

[0171] This disclosure provides an isolated antibody comprising a heavy chain (HC) variable domain sequence and a light chain (LC) variable domain sequence, wherein the heavy and light chain immunoglobulin variable domain sequences form an antigen-binding site that binds to an epitope of a DNABII protein. In some embodiments, the antibody or a fragment thereof binds to a DNABII peptide (e.g., the head region of a DNABII peptide, including but not limited to: the head region of IHF or HU, the head region of IHFA or IHFB, and / or the head chimeric peptide IhfA5-mIhfB4). NTHI ; and / or the tail region of the DNABII peptide, including but not limited to: the tail region of IHF or HU, the tail region of IHFA or IHFB, and / or the tail chimeric peptide IhfA3-IhfB2. NTHI In one embodiment, the antibody or a fragment thereof binds to the head chimeric peptide IhfA5-mIhfB4. NTHI In another embodiment, the antibody or a fragment thereof binds to the tail-shaped chimeric peptide IhfA3-IhfB2. NTHI .

[0172] In one aspect, this document provides an antibody or an antigen-binding fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable domain sequence and / or a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, aa 25 to aa 144 selected from SEQ ID NO: 1-6, 13, 24 or 26, or an equivalent thereof, and wherein the LC immunoglobulin variable domain sequence comprises, or substantially comprises, aa 21 to aa 132 selected from SEQ ID NO: 7-9, 14 or 25, aa 21 to aa 132 selected from SEQ ID NO: 10-12 or 27, or an equivalent thereof, or substantially comprises, or consists of, aa 21 to aa 132, or an equivalent thereof, and wherein the antibody or antigen-binding fragment thereof comprises, or consists of, aa 21 to aa 132, selected from SEQ ID NO: 7-9, 14 or 25, or an equivalent thereof, or substantially comprises, aa 21 to aa 132, selected from SEQ ID NO: 10-12 or 27.

[0173] In another aspect, this document provides antibodies or antigen-binding fragments thereof comprising, or substantially consisting of, heavy chains (HC) and / or light chains (LC), wherein the HC comprises, or substantially consists of, sequences selected from aa 25 to aa 473 of SEQ ID NO: 1-6, 13, 24 or 26, or equivalents thereof, and the LC comprises, or substantially consists of, sequences selected from aa 21 to aa 239 of SEQ ID NO: 7-9, 14 or 25, aa 21 to aa 233 of SEQ ID NO: 10-12 or 27, or equivalents thereof, or substantially consists of, or consists of, the same.

[0174] In another aspect, this document provides antibodies or antigen-binding fragments thereof comprising, or substantially consisting of, heavy chains (HC) and / or light chains (LC), wherein the HC comprises, or substantially consists of, sequences selected from SEQ ID NO:1-6, 13, 24 or 26, or equivalents thereof, and the LC comprises, or substantially consists of, sequences selected from SEQ ID NO:7-12, 14, 25 or 27 ....

[0175] In another aspect, this document provides antibodies or antigen-binding fragments thereof comprising, or substantially comprising, heavy chain (HC) immunoglobulin variable domain sequences and / or light chain (LC) immunoglobulin variable domain sequences, wherein the HC immunoglobulin variable domain sequences comprise, or substantially comprise, sequences of amino acid (aa) 25 to 144 selected from SEQ ID NO: 1-6, 13, 24 or 26, or equivalents thereof, and wherein the LC immunoglobulin variable domain sequences comprise, or substantially comprise, sequences of aa 21 to aa 132 selected from SEQ ID NO: 6-9, 14 or 25, aa 21 to aa 126 selected from SEQ ID NO: 10-12 or 27, or equivalents thereof, or substantially comprise, or consist of, sequences ...

[0176] In another aspect, this document provides an antibody or an antigen-binding fragment thereof comprising, or substantially comprising, the following CDR sequences: any one, any two, or all three CDRs selected from equivalents of SEQ ID NO: 1-6, 13, 24, or 26, or each thereof; and / or any one, any two, or all three CDRs selected from equivalents of SEQ ID NO: 7-12, 14, 25, or 27, or each thereof.

[0177] In another aspect, this document provides an antibody or an antigen-binding fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, aa 25 to aa 144 selected from SEQ ID NO:13, 24 or 26, or equivalents thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, aa 21 to aa 132 selected from SEQ ID NO:14 or 25, aa 21 to aa 126 selected from SEQ ID NO:27, or equivalents thereof, or substantially comprises, or substantially comprises, aa 21 to aa 126. In another aspect, this document provides antibodies or antigen-binding fragments thereof comprising, or substantially comprising, heavy chain (HC) immunoglobulin variable domain sequences and / or light chain (LC) immunoglobulin variable domain sequences, wherein the HC immunoglobulin variable domain sequences comprise, or substantially comprise, sequences of aa 25 to aa 144 selected from SEQ ID NO: 1-6, 13, 24 or 26 or equivalents thereof, and the LC immunoglobulin variable domain sequences comprise, or substantially comprise, sequences of aa 21 to aa 132 selected from SEQ ID NO: 7-9, 14 or 25, sequences of aa 21 to aa 126 selected from SEQ ID NO: 10-12 or 27 or equivalents thereof, and substantially comprise, or substantially comprise, sequences of aa 21 to aa 126 selected from SEQ ID NO: 10-12 or 27.

[0178] This document also provides antibodies or antigen-binding fragments thereof comprising, or substantially comprising, heavy chain (HC) immunoglobulin variable domain sequences and light chain (LC) immunoglobulin variable domain sequences, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 25 to aa 144 of SEQ ID NO:1 or an equivalent thereof, and wherein the LC immunoglobulin variable domain sequence comprises, or substantially comprises, any one amino acid sequence of aa 21 to aa 132 of SEQ ID NO:7-9, 14 or 25, aa 21 to aa 126 of SEQ ID NO:10-12 or 27 or an equivalent thereof, or substantially comprises, or comprises, an antibody or antigen-binding fragment thereof. In another aspect, this document provides an antibody or an antigen-binding fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, an amino acid sequence of aa 25 to aa 144 of SEQ ID NO:2 or an equivalent thereof, and wherein the LC immunoglobulin variable domain sequence comprises, or substantially comprises, an amino acid sequence of aa 21 to aa 132 of SEQ ID NO:7-9, 14 or 25, aa 21 to aa 126 of SEQ ID NO:10-12 or 27 or an equivalent thereof, or an amino acid sequence of each thereof. In another aspect, this document also provides antibodies or antigen-binding fragments thereof comprising, or substantially comprising, heavy chain (HC) immunoglobulin variable domain sequences and light chain (LC) immunoglobulin variable domain sequences, wherein the HC immunoglobulin variable domain sequences comprise, or substantially comprise, amino acid sequences of aa 25 to aa 144 of SEQ ID NO:3 or equivalents thereof, and wherein the LC immunoglobulin variable domain sequences comprise, or substantially comprise, any amino acid sequence of aa 21 to aa 132 of SEQ ID NO:7-9, 14 or 25, aa 21 to aa 126 of SEQ ID NO:10-12 or 27 or equivalents thereof, or substantially comprise, or consist of, such amino acids.

[0179] In another aspect, this document provides an antibody or an antigen-binding fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, an amino acid sequence of aa 25 to aa 144 of SEQ ID NO:4 or an equivalent thereof, and wherein the LC immunoglobulin variable domain sequence comprises, or substantially comprises, an amino acid sequence of aa 21 to aa 132 of SEQ ID NO:7-9, 14 or 25, aa 21 to aa 126 of SEQ ID NO:10-12 or 27 or an equivalent thereof, or an amino acid sequence of each thereof. This document provides antibodies or antigen-binding fragments thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable domain sequences and light chain (LC) immunoglobulin variable domain sequences, wherein the HC immunoglobulin variable domain sequences comprise, or substantially comprise, amino acid sequences of aa 25 to aa 144 of SEQ ID NO:5 or equivalents thereof, and wherein the LC immunoglobulin variable domain sequences comprise, or substantially comprise, any amino acid sequence of aa 21 to aa 132 of SEQ ID NO:7-9, 14 or 25, aa 21 to aa 126 of SEQ ID NO:10-12 or 27 or equivalents thereof, or substantially comprise, or consist of, such amino acids. This document provides antibodies or antigen-binding fragments thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable domain sequences and light chain (LC) immunoglobulin variable domain sequences, wherein the HC immunoglobulin variable domain sequences comprise, or substantially comprise, amino acid sequences of aa 25 to aa 144 of SEQ ID NO:6 or equivalents thereof, and wherein the LC immunoglobulin variable domain sequences comprise, or substantially comprise, any amino acid sequence of aa 21 to aa 132 of SEQ ID NO:7-9, 14 or 25, aa 21 to aa 126 of SEQ ID NO:10-12 or 27 or equivalents thereof, or substantially comprise, or consist of, such amino acids.

[0180] In another aspect, this document provides an antibody or an antigen-binding fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, an amino acid sequence of aa 25 to aa 144 of any one of SEQ ID NO: 1-6, 13, 24 or 26, or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, an amino acid sequence of aa 21 to aa 132 of SEQ ID NO: 7, or an equivalent thereof, or substantially comprises, or consists of, the same. This document provides antibodies or antigen-binding fragments thereof comprising, or substantially comprising, heavy chain (HC) immunoglobulin variable domain sequences and light chain (LC) immunoglobulin variable domain sequences, wherein the HC immunoglobulin variable domain sequences comprise, or substantially comprise, amino acid sequences of aa 25 to aa 144 of any one of SEQ ID NO: 1-6, 13, 24 or 26, or equivalents thereof, and wherein the LC immunoglobulin variable domain sequences comprise, or substantially comprise, amino acid sequences of aa 21 to aa 132 of SEQ ID NO: 8, or equivalents thereof, or substantially comprise, or consist of, the same. In another aspect, this document provides an antibody or an antigen-binding fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, an amino acid sequence of aa 25 to aa 144 of any one of SEQ ID NO: 1-6, 13, 24 or 26, or an equivalent thereof, and wherein the LC immunoglobulin variable domain sequence comprises, or substantially comprises, an amino acid sequence of aa 21 to aa 132 of SEQ ID NO: 9, or an equivalent thereof, or wherein the LC immunoglobulin variable domain sequence comprises, or substantially comprises, an amino acid sequence of aa 21 to aa 132 of SEQ ID NO: 9, or an equivalent thereof, or wherein the LC immunoglobulin variable domain sequence comprises, or substantially comprises, an amino acid sequence of aa 21 to aa 132 of SEQ ID NO: 9, or an equivalent thereof, and ....

[0181] In another aspect, this document provides an antibody or an antigen-binding fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, an amino acid sequence of aa 25 to aa 144 of any one of SEQ ID NO: 1-6, 13, 24 or 26, or an equivalent thereof, and wherein the LC immunoglobulin variable domain sequence comprises, or substantially comprises, an amino acid sequence of aa 21 to aa 126 of SEQ ID NO: 10, or an equivalent thereof, or ... and wherein the LC immunoglobulin variable domain sequence comprises, or substantially comprises, an amino acid sequence of aa 21 to aa 126 of SEQ ID NO: 10, or an equivalent thereof. This document provides antibodies or antigen-binding fragments thereof comprising, or substantially comprising, heavy chain (HC) immunoglobulin variable domain sequences and light chain (LC) immunoglobulin variable domain sequences, wherein the HC immunoglobulin variable domain sequences comprise, or substantially comprise, amino acid sequences of aa 25 to aa 144 of any one of SEQ ID NO: 1-6, 13, 24 or 26, or equivalents thereof, and wherein the LC immunoglobulin variable domain sequences comprise, or substantially comprise, amino acid sequences of aa 21 to aa 126 of SEQ ID NO: 11, or equivalents thereof, or substantially comprise, or consist of, the same. This document provides antibodies or antigen-binding fragments thereof comprising, or substantially comprising, heavy chain (HC) immunoglobulin variable domain sequences and light chain (LC) immunoglobulin variable domain sequences, wherein the HC immunoglobulin variable domain sequences comprise, or substantially comprise, amino acid sequences of aa 25 to aa 144 of any one of SEQ ID NO: 1-6, 13, 24 or 26, or equivalents thereof, and wherein the LC immunoglobulin variable domain sequences comprise, or substantially comprise, amino acid sequences of aa 21 to aa 126 of SEQ ID NO: 12, or equivalents thereof, or substantially comprise, or consist of, the same.

[0182] In another aspect, this document provides an antibody or an antigen-binding fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 25 to aa 144 of SEQ ID NO:1 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 132 of SEQ ID NO:7 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 132 of SEQ ID NO:7 or an equivalent thereof. In one embodiment, this document provides an antibody or an antigen-binding fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 25 to aa 144 of SEQ ID NO:1 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 132 of SEQ ID NO:8 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 132 of SEQ ID NO:8. In another embodiment, this document provides an antibody or an antigen-binding fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 25 to aa 144 of SEQ ID NO:1 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 132 of SEQ ID NO:9 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 132 of SEQ ID NO:9.

[0183] In another aspect, this document provides an antibody or an antigen-binding fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 25 to aa 144 of SEQ ID NO:2 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 132 of SEQ ID NO:7 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 132 of SEQ ID NO:7 or an equivalent thereof. In another aspect, this document provides an antibody or an antigen-binding fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 25 to aa 144 of SEQ ID NO:2 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 132 of SEQ ID NO:8 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 132 of SEQ ID NO:8 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 132 of SEQ ID NO:8. In another aspect, this document provides an antibody or an antigen-binding fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 25 to aa 144 of SEQ ID NO:2 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 132 of SEQ ID NO:9 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 132 of SEQ ID NO:9 or an equivalent thereof.

[0184] In another aspect, this document provides an antibody or an antigen-binding fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 25 to aa 144 of SEQ ID NO:3 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 132 of SEQ ID NO:7 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 132 of SEQ ID NO:7 or an equivalent thereof. In another aspect, this document provides an antibody or an antigen-binding fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 25 to aa 144 of SEQ ID NO:3 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 132 of SEQ ID NO:8 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 132 of SEQ ID NO:8 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 132 of SEQ ID NO:8. In one embodiment, this document provides an antibody or an antigen-binding fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 25 to aa 144 of SEQ ID NO:3 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 132 of SEQ ID NO:9 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 132 of SEQ ID NO:9 or an equivalent thereof.

[0185] This document also provides antibodies or antigen-binding fragments thereof comprising, or substantially comprising, heavy chain (HC) immunoglobulin variable domain sequences and light chain (LC) immunoglobulin variable domain sequences, wherein the HC immunoglobulin variable domain sequences comprise, or substantially comprise, the amino acid sequences aa 25 to aa 144 of SEQ ID NO:4 or equivalents thereof, and the LC immunoglobulin variable domain sequences comprise, or substantially comprise, the amino acid sequences aa 21 to aa 126 of SEQ ID NO:10 or equivalents thereof, or substantially comprise, or substantially comprise, the amino acid sequences aa 21 to aa 126 of SEQ ID NO:10. In another aspect, this document also provides antibodies or antigen-binding fragments thereof comprising, or substantially comprising, heavy chain (HC) immunoglobulin variable domain sequences and light chain (LC) immunoglobulin variable domain sequences, wherein the HC immunoglobulin variable domain sequences comprise, or substantially comprise, the amino acid sequences of aa 25 to aa 144 of SEQ ID NO:4 or equivalents thereof, and the LC immunoglobulin variable domain sequences comprise, or substantially comprise, the amino acid sequences of aa 21 to aa 126 of SEQ ID NO:11 or equivalents thereof, and the LC immunoglobulin variable domain sequences comprise, or substantially comprise, the amino acid sequences of aa 21 to aa 126 of SEQ ID NO:11 or equivalents thereof, and the LC immunoglobulin variable domain sequences comprise, or substantially comprise, the amino acid sequences of aa 21 to aa 126 of SEQ ID NO:11. In another aspect, this document also provides antibodies or antigen-binding fragments thereof comprising, or substantially comprising, heavy chain (HC) immunoglobulin variable domain sequences and light chain (LC) immunoglobulin variable domain sequences, wherein the HC immunoglobulin variable domain sequences comprise, or substantially comprise, the amino acid sequences of aa 25 to aa 144 of SEQ ID NO:4 or equivalents thereof, and the LC immunoglobulin variable domain sequences comprise, or substantially comprise, the amino acid sequences of aa 21 to aa 126 of SEQ ID NO:12 or equivalents thereof, and the LC immunoglobulin variable domain sequences comprise, or substantially comprise, the amino acid sequences of aa 21 to aa 126 of SEQ ID NO:12 or equivalents thereof, and the LC immunoglobulin variable domain sequences comprise, or substantially comprise, the amino acid sequences of aa 21 to aa 126 of SEQ ID NO:12.

[0186] In one embodiment, this document provides an antibody or an antigen-binding fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 25 to aa 144 of SEQ ID NO:5 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 126 of SEQ ID NO:10 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 126 of SEQ ID NO:10 or an equivalent thereof. In another embodiment, this document provides an antibody or an antigen-binding fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 25 to aa 144 of SEQ ID NO:5 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 126 of SEQ ID NO:11 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 126 of SEQ ID NO:11 or an equivalent thereof. In another aspect, this document provides an antibody or an antigen-binding fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 25 to aa 144 of SEQ ID NO:5 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 126 of SEQ ID NO:12 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 126 of SEQ ID NO:12 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 126 of SEQ ID NO:12.

[0187] In another embodiment, this document provides an antibody or an antigen-binding fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 25 to aa 144 of SEQ ID NO:6 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 126 of SEQ ID NO:10 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 126 of SEQ ID NO:10 or an equivalent thereof. In one aspect, this document provides an antibody or an antigen-binding fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 25 to aa 144 of SEQ ID NO:6 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 126 of SEQ ID NO:11 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 126 of SEQ ID NO:11 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 126 of SEQ ID NO:11. In one embodiment, this document provides an antibody or an antigen-binding fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 25 to aa 144 of SEQ ID NO:6 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 126 of SEQ ID NO:12 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 126 of SEQ ID NO:12 or an equivalent thereof.

[0188] In one aspect, this document provides an antibody or fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable domain sequence and / or a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence aa 25 to aa 144 of SEQ ID NO:24 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence aa 21 to aa 132 of SEQ ID NO:25 or an equivalent thereof, and the antibody or fragment thereof binds to the head region of a DNABII peptide (including, but not limited to, the head region of IHF or HU, the head region of IHFA or IHFB, and / or the head chimeric peptide IhfA5-mIhfB4). NTHIIn one embodiment, the antibody or a fragment thereof binds to the head chimeric peptide IhfA5-mIhfB4. NTHIIn another embodiment, the fragment is an antigen-binding fragment. In one embodiment, this document provides an antibody or a fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable domain sequence and / or a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 25 to aa 144 of SEQ ID NO:1 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 132 of SEQ ID NO:7 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 132 of SEQ ID NO:7. In another embodiment, this document provides an antibody or a fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable domain sequence and / or a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 25 to aa 144 of SEQ ID NO:1 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 132 of SEQ ID NO:8 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 132 of SEQ ID NO:8 or an equivalent thereof. In another embodiment, this document provides an antibody or fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable domain sequence and / or a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 25 to aa 144 of SEQ ID NO:1 or equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 132 of SEQ ID NO:9 or equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 132 of SEQ ID NO:9. In one embodiment, this document provides an antibody or a fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable domain sequence and / or a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence aa25 to aa144 of SEQ ID NO:2 or equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence aa21 to aa132 of SEQ ID NO:7 or equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence aa21 to aa132 of SEQ ID NO:7.In another embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) immunoglobulin variable domain sequence and / or a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or is substantially composed of, the amino acid sequence of aa 25 to aa 144 of SEQ ID NO:2 or equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 132 of SEQ ID NO:8 or equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 132 of SEQ ID NO:8. In another embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) immunoglobulin variable domain sequence and / or a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or is substantially composed of, the amino acid sequence of aa 25 to aa 144 of SEQ ID NO:2 or equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 132 of SEQ ID NO:9 or equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 132 of SEQ ID NO:9. In one embodiment, the antibody or fragment thereof comprises, or substantially comprises, a heavy chain (HC) immunoglobulin variable domain sequence and / or a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence aa25 to aa144 of SEQ ID NO:3 or equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence aa21 to aa132 of SEQ ID NO:7 or equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence aa21 to aa132 of SEQ ID NO:7 or equivalent thereof. In another embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) immunoglobulin variable domain sequence and / or a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or is substantially composed of, the amino acid sequence of aa 25 to aa 144 of SEQ ID NO:3 or equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 132 of SEQ ID NO:8 or equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 132 of SEQ ID NO:8.In another embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) immunoglobulin variable domain sequence and / or a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or is substantially composed of, the amino acid sequence of aa 25 to aa 144 of SEQ ID NO:3 or equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 132 of SEQ ID NO:9 or equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 132 of SEQ ID NO:9.

[0189] On the other hand, this document provides an antibody or a fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence aa 25 to aa 144 of SEQ ID NO:26 or equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence aa 21 to aa 126 of SEQ ID NO:27 or equivalent thereof, and the antibody or a fragment thereof. In another embodiment, the antibody or fragment thereof binds to the tail region of a DNABII peptide (including, but not limited to, the tail region of IHF or HU, the tail region of IHFA or IHFB, and / or the tail chimeric peptide IhfA3-IhfB2). NTHI In one embodiment, the antibody or a fragment thereof binds to the tail-chimeric peptide IhfA3-IhfB2. NTHIIn another embodiment, the fragment is an antigen-binding fragment. In one embodiment, the antibody or its fragment comprises, or substantially comprises, a heavy chain (HC) immunoglobulin variable domain sequence and / or a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 25 to aa 144 of SEQ ID NO:4 or its equivalents, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 126 of SEQ ID NO:10 or its equivalents, and so on. In another embodiment, the fragment is an antigen-binding fragment. In one embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) immunoglobulin variable domain sequence and / or a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or is substantially composed of, the amino acid sequence of aa 25 to aa 144 of SEQ ID NO:4 or equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 126 of SEQ ID NO:11 or equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 126 of SEQ ID NO:11 or equivalent thereof. In another embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) immunoglobulin variable domain sequence and / or a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or is substantially composed of, the amino acid sequence of aa 25 to aa 144 of SEQ ID NO:4 or equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 126 of SEQ ID NO:12 or equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 126 of SEQ ID NO:12 or equivalent thereof. In one embodiment, the antibody or fragment thereof comprises, or substantially comprises, a heavy chain (HC) immunoglobulin variable domain sequence and / or a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 25 to aa 144 of SEQ ID NO:5 or its equivalents, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 126 of SEQ ID NO:10 or its equivalents, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 21 to aa 126 of SEQ ID NO:10. In another embodiment, the antibody or fragment thereof comprises, or substantially comprises, a heavy chain (HC) immunoglobulin variable domain sequence and / or a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 25 to aa 144 of SEQ ID NO:5 or its equivalents, and the LC ...

[0190] The antibody or fragment thereof comprises, or substantially comprises, the amino acid sequence of aa 25 to aa 144 of SEQ ID NO:5, or an equivalent thereof, or substantially comprises, or consists of, the amino acid sequence of aa 21 to aa 126 of SEQ ID NO:11, or an equivalent thereof, or substantially comprises, or consists of, the amino acid sequence of aa 21 to aa 126 of SEQ ID NO:11. In another embodiment, the antibody or fragment thereof comprises, or substantially comprises, the heavy chain (HC) immunoglobulin variable domain sequence and / or the light chain (LC) immunoglobulin variable domain sequence, or substantially comprises, or consists of, the HC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of aa 25 to aa 144 of SEQ ID NO:5, or an equivalent thereof, or substantially comprises, or consists of, the amino acid sequence of aa 21 to aa 126 of SEQ ID NO:12, or an equivalent thereof, or substantially comprises, or consists of, the amino acid sequence of aa 21 to aa 126 of SEQ ID NO:12. In one embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) immunoglobulin variable domain sequence and / or a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or is substantially composed of, the amino acid sequence of aa 25 to aa 144 of SEQ ID NO:6 or equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 126 of SEQ ID NO:10 or equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 126 of SEQ ID NO:10 or equivalent thereof. In another embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) immunoglobulin variable domain sequence and / or a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or is substantially composed of, the amino acid sequence of aa 25 to aa 144 of SEQ ID NO:6 or equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 126 of SEQ ID NO:11 or equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 126 of SEQ ID NO:11 or equivalent thereof. In another embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) immunoglobulin variable domain sequence and / or a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or is substantially composed of, the amino acid sequence of aa 25 to aa 144 of SEQ ID NO:5 or equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 126 of SEQ ID NO:12 or equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 126 of SEQ ID NO:12 or equivalent thereof.

[0191] In one aspect, this document provides an antibody or a fragment thereof comprising, or substantially consisting of, a heavy chain (HC) and / or a light chain (LC), wherein the HC comprises, or substantially consists of, the amino acid sequence of SEQ ID NO:24 or its equivalent, and the LC comprises, or substantially consists of, the amino acid sequence of SEQ ID NO:25 or its equivalent, and the LC comprises, or substantially consists of, the amino acid sequence of SEQ ID NO:25. In another embodiment, the antibody or fragment thereof binds to the head region of a DNABII peptide (including, but not limited to, the head region of IHF or HU, the head region of IHFA or IHFB, and / or the head chimeric peptide IhfA5-mIhfB4). NTHI In one embodiment, the antibody or a fragment thereof binds to the head chimeric peptide IhfA5-mIhfB4. NTHIIn another embodiment, the fragment is an antigen-binding fragment. In one embodiment, the antibody or its fragment comprises, or is substantially composed of, a heavy chain (HC) and / or a light chain (LC), wherein the HC comprises, or is substantially composed of, the amino acid sequence of SEQ ID NO:1 or its equivalent, and the LC comprises, or is substantially composed of, the amino acid sequence of SEQ ID NO:7 or its equivalent. In another embodiment, the antibody or its fragment comprises, or is substantially composed of, a heavy chain (HC) and / or a light chain (LC), wherein the HC comprises, or is substantially composed of, the amino acid sequence of SEQ ID NO:1 or its equivalent, and the LC comprises, or is substantially composed of, the amino acid sequence of SEQ ID NO:8 or its equivalent. In another embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) and / or a light chain (LC), wherein the HC comprises, or is substantially composed of, the amino acid sequence of SEQ ID NO:1 or its equivalent, and the LC comprises, or is substantially composed of, the amino acid sequence of SEQ ID NO:9 or its equivalent, or is substantially composed of, or is substantially composed of, or is substantially composed of, or is substantially composed of, or is substantially composed of, or is substantially composed of, the amino acid sequence of SEQ ID NO:2 or its equivalent, and the LC comprises, or is substantially composed of, the amino acid sequence of SEQ ID NO:7 or its equivalent, and is substantially composed of, or is substantially composed of, or is substantially composed of, or is substantially composed of, the amino acid sequence of SEQ ID NO:7. In another embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) and / or a light chain (LC), wherein the HC comprises, or is substantially composed of, the amino acid sequence of SEQ ID NO:2 or its equivalent, and the LC comprises, or is substantially composed of, the amino acid sequence of SEQ ID NO:8. In another embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) and / or a light chain (LC), wherein the HC comprises, or is substantially composed of, the amino acid sequence of SEQ ID NO:2 or its equivalent, and the LC comprises, or is substantially composed of, the amino acid sequence of SEQ ID NO:9. In one embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) and / or a light chain (LC), wherein the HC comprises, or is substantially composed of, the amino acid sequence of SEQ ID NO:3 or its equivalent, and the LC comprises, or is substantially composed of, the amino acid sequence of SEQ ID NO:7 or its equivalent, or is substantially composed of, or is composed of, the amino acid sequence of SEQ ID NO:7.In another embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) and / or a light chain (LC), wherein the HC comprises, or is substantially composed of, the amino acid sequence of SEQ ID NO:3 or its equivalent, and the LC comprises, or is substantially composed of, the amino acid sequence of SEQ ID NO:8. In another embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) and / or a light chain (LC), wherein the HC comprises, or is substantially composed of, the amino acid sequence of SEQ ID NO:3 or its equivalent, and the LC comprises, or is substantially composed of, the amino acid sequence of SEQ ID NO:9 or its equivalent.

[0192] In another aspect, this document provides an antibody or a fragment thereof comprising, or substantially comprising, a heavy chain (HC) and a light chain (LC), wherein the HC comprises, or substantially comprises, the amino acid sequence of SEQ ID NO:26 or its equivalent, and the LC comprises, or substantially comprises, the amino acid sequence of SEQ ID NO:27 or its equivalent, and the LC comprises, or substantially comprises, the amino acid sequence of SEQ ID NO:27. In another embodiment, the antibody or fragment thereof binds to the tail region of a DNABII peptide (including, but not limited to, the tail region of IHF or HU, the tail region of IHFA or IHFB, and / or the tail chimeric peptide IhfA3-IhfB2). NTHI In one embodiment, the antibody or a fragment thereof binds to the tail-chimeric peptide IhfA3-IhfB2. NTHIIn another embodiment, the fragment is an antigen-binding fragment. In one embodiment, the antibody or its fragment comprises, or is substantially composed of, a heavy chain (HC) and / or a light chain (LC), wherein the HC comprises, or is substantially composed of, the amino acid sequence of SEQ ID NO:4 or its equivalent, and the LC comprises, or is substantially composed of, the amino acid sequence of SEQ ID NO:10 or its equivalent. In another embodiment, the antibody or its fragment comprises, or is substantially composed of, a heavy chain (HC) and / or a light chain (LC), wherein the HC comprises, or is substantially composed of, the amino acid sequence of SEQ ID NO:4 or its equivalent, and the LC comprises, or is substantially composed of, the amino acid sequence of SEQ ID NO:11 or its equivalent. In one embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) and / or a light chain (LC), wherein the HC comprises, or is substantially composed of, the amino acid sequence of SEQ ID NO:4 or its equivalent, and the LC comprises, or is substantially composed of, the amino acid sequence of SEQ ID NO:12 or its equivalent. In another embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) and / or a light chain (LC), wherein the HC comprises, or is substantially composed of, the amino acid sequence of SEQ ID NO:5 or its equivalent, and the LC comprises, or is substantially composed of, the amino acid sequence of SEQ ID NO:10 or its equivalent. In another embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) and / or a light chain (LC), wherein the HC comprises, or is substantially composed of, the amino acid sequence of SEQ ID NO:5 or its equivalent, and the LC comprises, or is substantially composed of, the amino acid sequence of SEQ ID NO:11 or its equivalent. In another embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) and / or a light chain (LC), wherein the HC comprises, or is substantially composed of, the amino acid sequence of SEQ ID NO:5 or its equivalent, and the LC comprises, or is substantially composed of, the amino acid sequence of SEQ ID NO:12 or its equivalent. In one embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) and / or a light chain (LC), wherein the HC comprises, or is substantially composed of, the amino acid sequence of SEQ ID NO:6 or its equivalent, and the LC comprises, or is substantially composed of, the amino acid sequence of SEQ ID NO:10 or its equivalent, or is substantially composed of, or is composed of, the amino acid sequence of SEQ ID NO:10.In another embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) and / or a light chain (LC), wherein the HC comprises, or is substantially composed of, the amino acid sequence of SEQ ID NO:6 or its equivalent, and the LC comprises, or is substantially composed of, the amino acid sequence of SEQ ID NO:11. In another embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) and / or a light chain (LC), wherein the HC comprises, or is substantially composed of, the amino acid sequence of SEQ ID NO:6 or its equivalent, and the LC comprises, or is substantially composed of, the amino acid sequence of SEQ ID NO:12 or its equivalent.

[0193] In another aspect, this document provides an antibody or a fragment thereof comprising, or substantially consisting of, a heavy chain (HC) and / or a light chain (LC), wherein the HC comprises, or substantially consists of, the amino acid sequence of aa 25 to aa 473 of SEQ ID NO:24, or an equivalent thereof, and the LC comprises, or substantially consists of, the amino acid sequence of aa 21 to aa 239 of SEQ ID NO:25, or an equivalent thereof, or a equivalent thereof. In another embodiment, the antibody or fragment thereof binds to the head region of a DNABII peptide (including, but not limited to, the head region of IHF or HU, the head region of IHFA or IHFB, and / or the head chimeric peptide IhfA5-mIhfB4). NTHI In one embodiment, the antibody or a fragment thereof binds to the head chimeric peptide IhfA5-mIhfB4. NTHIIn another embodiment, the fragment is an antigen-binding fragment. In one embodiment, the antibody or its fragment comprises, or is substantially composed of, a heavy chain (HC) and / or a light chain (LC), wherein the HC comprises, or is substantially composed of, the amino acid sequence of aa 25 to aa 473 of SEQ ID NO:1, or its equivalents, and the LC comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 239 of SEQ ID NO:7, or its equivalents, and the LC comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 239 of SEQ ID NO:8. In another embodiment, the antibody or its fragment comprises, or is substantially composed of, a heavy chain (HC) and / or a light chain (LC), wherein the HC comprises, or is substantially composed of, the amino acid sequence of aa 25 to aa 473 of SEQ ID NO:1, or its equivalents, and the LC comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 239 of SEQ ID NO:8, or its equivalents, and the LC comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 239 of SEQ ID NO:8. In one embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) and / or a light chain (LC), wherein the HC comprises, or is substantially composed of, the amino acid sequence of aa 25 to aa 473 of SEQ ID NO:1, or an equivalent thereof, and the LC comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 239 of SEQ ID NO:9, or an equivalent thereof, or an equivalent thereof. In another embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) and / or a light chain (LC), wherein the HC comprises, or is substantially composed of, the amino acid sequence of aa 25 to aa 473 of SEQ ID NO:2, or an equivalent thereof, and the LC comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 239 of SEQ ID NO:7, or an equivalent thereof. In another embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) and / or a light chain (LC), wherein the HC comprises, or is substantially composed of, the amino acid sequence of aa25 to aa473 of SEQ ID NO:2, or an equivalent thereof, and the LC comprises, or is substantially composed of, the amino acid sequence of aa21 to aa239 of SEQ ID NO:8, or an equivalent thereof, or an equivalent thereof.In one embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) and / or a light chain (LC), wherein the HC comprises, or is substantially composed of, the amino acid sequence of aa 25 to aa 473 of SEQ ID NO:1, or its equivalents, and the LC comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 239 of SEQ ID NO:9, or its equivalents, and the LC comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 239 of SEQ ID NO:7, or its equivalents, and the LC comprises, or is substantially composed of, the amino acid sequence of aa 25 to aa 473 of SEQ ID NO:3, or its equivalents, and the LC comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 239 of SEQ ID NO:7 ...5 to aa 473 of SEQ ID NO:3, or its equivalents, and the LC comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 239 of SEQ ID NO:7, or its equivalents, and the LC comprises, or is substantially composed of, the amino acid sequence of aa 25 to aa 473 of SEQ ID NO:1, or its equivalents, and the LC comprises, or is substantially composed of, the amino acid sequence of In another embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) and / or a light chain (LC), wherein the HC comprises, or is substantially composed of, the amino acid sequence of aa 25 to aa 473 of SEQ ID NO:3, or its equivalents, and the LC comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 239 of SEQ ID NO:8. In another embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) and / or a light chain (LC), wherein the HC comprises, or is substantially composed of, the amino acid sequence of aa 25 to aa 473 of SEQ ID NO:3, or its equivalents, and the LC comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 239 of SEQ ID NO:9.

[0194] In another aspect, this document provides an antibody or a fragment thereof comprising, or substantially consisting of, a heavy chain (HC) and a light chain (LC), wherein the HC comprises, or substantially consists of, the amino acid sequence of aa 25 to aa 473 of SEQ ID NO:26, or an equivalent thereof, and the LC comprises, or substantially consists of, the amino acid sequence of aa 21 to aa 233 of SEQ ID NO:27, or an equivalent thereof, or a equivalent thereof. In another embodiment, the antibody or fragment thereof binds to the tail region of a DNABII peptide (including, but not limited to, the tail region of IHF or HU, the tail region of IHFA or IHFB, and / or the tail chimeric peptide IhfA3-IhfB2). NTHI In one embodiment, the antibody or a fragment thereof binds to the tail-chimeric peptide IhfA3-IhfB2. NTHIIn another embodiment, the fragment is an antigen-binding fragment. In one embodiment, the antibody or its fragment comprises, or is substantially composed of, a heavy chain (HC) and / or a light chain (LC), wherein the HC comprises, or is substantially composed of, the amino acid sequence of aa 25 to aa 473 of SEQ ID NO:4, or an equivalent thereof, and the LC comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 233 of SEQ ID NO:10, or an equivalent thereof, or an equivalent thereof. In another embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) and / or a light chain (LC), wherein the HC comprises, or is substantially composed of, the amino acid sequence of aa 25 to aa 473 of SEQ ID NO:4, or an equivalent thereof, and the LC comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 233 of SEQ ID NO:11, or an equivalent thereof, or an equivalent thereof. In another embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) and / or a light chain (LC), wherein the HC comprises, or is substantially composed of, the amino acid sequence of aa 25 to aa 473 of SEQ ID NO:4, or an equivalent thereof, and the LC comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 233 of SEQ ID NO:12, or an equivalent thereof, or an equivalent thereof. In one embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) and / or a light chain (LC), wherein the HC comprises, or is substantially composed of, the amino acid sequence of aa 25 to aa 473 of SEQ ID NO:5, or its equivalents, and the LC comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 233 of SEQ ID NO:10, or its equivalents, or its equivalents, or its equivalents, or its equivalents, or its equivalents, or its equivalents, or its equivalents, or its equivalents, or its equivalents, or its equivalents, or its equivalents, wherein the HC comprises, or is substantially composed of, the amino acid sequence of aa 25 to aa 473 of SEQ ID NO:5, or its equivalents, and the LC comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 233 of SEQ ID NO:11, or its equivalents ...In another embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) and / or a light chain (LC), wherein the HC comprises, or is substantially composed of, the amino acid sequence of aa 25 to aa 473 of SEQ ID NO:5, or its equivalents, and the LC comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 233 of SEQ ID NO:12, or its equivalents, and the LC comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 233 of SEQ ID NO:12. In another embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) and / or a light chain (LC), wherein the HC comprises, or is substantially composed of, the amino acid sequence of aa 25 to aa 473 of SEQ ID NO:6, or its equivalents, and the LC comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 233 of SEQ ID NO:10, or its equivalents, and the LC comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 233 of SEQ ID NO:10. In another embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) and / or a light chain (LC), wherein the HC comprises, or is substantially composed of, the amino acid sequence of aa 25 to aa 473 of SEQ ID NO:6, or its equivalents, and the LC comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 233 of SEQ ID NO:11, or its equivalents, or its equivalents, or its equivalents, or its equivalents, or its equivalents, or its equivalents, or its equivalents, or its equivalents, or its equivalents, or its equivalents, wherein the HC comprises, or is substantially composed of, the amino acid sequence of aa 25 to aa 473 of SEQ ID NO:6, or its equivalents, or its equivalents, and the LC comprises, or is substantially composed of, the amino acid sequence of aa 21 to aa 233 of SEQ ID NO:12, or its equivalents ...

[0195] In one aspect, this document provides an antibody or a fragment thereof comprising, or substantially comprising, or comprising: any one, any two, or all three CDRs selected from equivalents of SEQ ID NO: 1-3 or 24; and / or any one, any two, or all three CDRs selected from equivalents of SEQ ID NO: 7-9 or 25. In another embodiment, the antibody or fragment thereof binds to the head region of a DNABII peptide (including, but not limited to, the head region of IHF or HU, the head region of IHFA or IHFB, and / or the head chimeric peptide IhfA5-mIhfB4). NTHI In one embodiment, the antibody or a fragment thereof binds to the head chimeric peptide IhfA5-mIhfB4. NTHIIn another embodiment, the fragment is an antigen-binding fragment. In one embodiment, this document provides an antibody or a fragment thereof comprising, or substantially comprising, the following CDR sequences: all three CDRs of a sequence selected from SEQ ID NO: 1-3 or 24 or equivalents thereof; and / or all three CDRs of a sequence selected from SEQ ID NO: 7-9 or 25 or equivalents thereof.

[0196] In another embodiment, this document provides an antibody or a fragment thereof comprising, or substantially comprising, the following CDR sequences: any one, any two, or all three CDRs selected from equivalents of SEQ ID NO: 4-6 or 26; and / or any one, any two, or all three CDRs selected from equivalents of SEQ ID NO: 10-12 or 27. In another embodiment, the antibody or fragment thereof binds to the tail region of a DNABII peptide (including, but not limited to, the tail region of IHF or HU, the tail region of IHFA or IHFB, and / or the tail chimeric peptides IhfA3-IhfB2). NTHI In one embodiment, the antibody or a fragment thereof binds to the tail-chimeric peptide IhfA3-IhfB2. NTHI In another embodiment, the fragment is an antigen-binding fragment. In one embodiment, this document provides an antibody or a fragment thereof comprising, or substantially comprising, the following CDR sequences: all three CDRs of a sequence selected from equivalents of SEQ ID NO:4-6 or 26 or each thereof; and / or all three CDRs of a sequence selected from equivalents of SEQ ID NO:10-12 or 27 or each thereof.

[0197] In some embodiments, the antibody or fragment thereof provided herein further comprises one or more signal peptides. In one embodiment, the signal peptide comprises, or substantially comprises, any one of amino acids (aa)1 to aa 24 from any one of SEQ ID NO: 1-6, 13, 24, or 26. In another embodiment, the signal peptide comprises, or substantially comprises, any one of aa 1 to aa 20 from any one of SEQ ID NO: 7-12, 14, 25, and 27. In a further embodiment, the signal peptide is located at the amino terminus of the variable region of the light chain. Alternatively or optionally, the same signal peptide or different signal peptides are located at the amino terminus of the variable region of the heavy chain.

[0198] The antibodies or fragments thereof provided herein may be monospecific or bispecific. In one embodiment, the antibody or fragment thereof is trispecific, tetraspecific, or pentaspecific. Alternatively or additionally, the antibody is selected from IgA (e.g., IgA1 or IgA2), IgD, IgE, IgG (e.g., IgG1, IgG2, IgG3, or IgG4), or IgM antibodies. In one embodiment, the antibody further comprises a constant region selected from: an IgA constant region (e.g., an IgA1 constant region or an IgA2 constant region), an IgD constant region, an IgE constant region, an IgG constant region (e.g., an IgG1 constant region, an IgG2 constant region, an IgG3 constant region, or an IgG4 constant region), or an IgM constant region.

[0199] In some embodiments, the amino acid sequence equivalent comprises, or is substantially composed of, a polypeptide having at least about 80% (including about 80% to 100%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%) amino acid identity with the amino acid sequence. Alternatively or preferably, the amino acid sequence equivalent comprises, or is substantially composed of, a polypeptide encoded by a multinucleotide that hybridizes to the complementary sequence of the multinucleotide encoding the amino acid sequence under highly stringent conditions. In a further embodiment, the amino acid sequence equivalent comprises, or is substantially composed of, a polypeptide having at least about 80% (including about 80% to 100%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%) amino acid identity with the amino acid sequence. In some embodiments, an equivalent of an amino acid sequence (e.g., an antibody or fragment thereof, or any one or more of SEQ ID NO:1-14 and 24-26 disclosed herein, including but not limited to aa 25 to aa 144 of SEQ ID NO:13, 24 or 26, aa 21 to aa 132 of SEQ ID NO:14 or 25, aa 21 to aa 126 of SEQ ID NO:27, aa 25 to aa 473 of SEQ ID NO:13, 24 or 26, aa 21 to aa 239 of SEQ ID NO:14 or 25, aa 21 to aa 233 of SEQ ID NO:27) comprises, or is substantially composed of, a polypeptide comprising one or all of the CDRs of the amino acid sequence. Additionally or optionally, the polypeptide has at least about 80% (including about 80% to 100%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%) amino acid identity with the amino acid sequence.

[0200] In some embodiments, an equivalent of an amino acid sequence (e.g., an antibody, a fragment thereof, its complementarity-determining region (CDR), or a CDR-containing polypeptide) lacks an amino acid difference in the CDR compared to the amino acid sequence. However, an equivalent of an amino acid sequence (e.g., an antibody, a fragment thereof, its complementarity-determining region (CDR), or a CDR-containing polypeptide) may include one or more amino acid differences in non-CDR regions compared to the amino acid sequence, such as, but not limited to, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acid differences, provided that the three-dimensional arrangement of the CDR and / or the CDR is maintained. In some embodiments, an isomorphic polypeptide of an amino acid sequence (e.g., an antibody, a fragment thereof, its complementarity-determining region (CDR) or a CDR-containing polypeptide) has at least about 80% (including about 80% to 100%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%) amino acid identity with the amino acid sequence, provided that the three-dimensional arrangement of the CDR and / or the CDR is maintained.

[0201] Non-limiting examples of such non-CDR regions include frame regions (FR), constant regions, Fc regions, pFc' regions, heavy chain (CH) constant domains (e.g., CH1, CH2, CH3, or CH4), light chain (CL) constant domains, or hinge regions. In one embodiment, such amino acid differences may be conserved amino acid substitutions and / or may not alter the three-dimensional arrangement of the antibody, its fragments, its CDR, or CDR-containing polypeptides. In another embodiment, the isomorph may include conserved amino acid substitutions at the CDR boundary, such as one or two amino acids at the amino terminus, carboxyl terminus, or both of the CDR.

[0202] In one aspect, this document provides one or more CDRs (e.g., any one, two, three, four, five, or six CDRs) of antibodies or fragments thereof as disclosed herein. In one embodiment, a set of CDRs is provided that comprises, or substantially consists of, one or more CDRs (e.g., any one, two, three, four, five, or six CDRs) of antibodies or fragments thereof as disclosed herein. In one embodiment, a set of CDRs is provided that comprises, or substantially consists of, the variable regions CDRL1, CDRL2, and CDRL3 as disclosed herein. In another embodiment, a set of CDRs is provided that comprises, or substantially consists of, the variable regions CDRH1, CDRH2, and CDRH3 as disclosed herein. In another embodiment, a set of CDRs is provided, comprising, substantially comprising, or consisting of, a variable region CDRL1, CDRL2, and CDRL3 as disclosed herein and another variable region CDRH1, CDRH2, and CDRH3 as disclosed herein. In some embodiments, the set of CDRs constitutes complementary sites. Additionally or alternatively, the set of CDRs specifically binds to DNABII peptides (e.g., head and / or tail regions, including but not limited to: head regions of IHF or HU, head regions of IHFA or IHFB, head chimeric peptides IhfA5-mIhfB4). NTHI The tail region of IHF or HU, the tail region of IHFA or IHFB, and / or the tail chimeric peptide IhfA3-IhfB2 NTHI In another embodiment, an antibody, a fragment thereof, or their respective equivalents are provided that comprises, or substantially constitutes, any one or more CDRs as disclosed herein. In yet another embodiment, an antibody, a fragment thereof, or their respective equivalents are provided that comprises, or substantially constitutes, the group of CDRs disclosed herein.

[0203] In some embodiments, the CDRs of SEQ ID NO: 1-13 are illustrated in the table below. In some embodiments, CDRH1 of any one of SEQ ID NO: 1-6, 13, 24, or 26 comprises, or is substantially composed of, amino acids (aa) 50 to aa 57 of SEQ ID NO: 1-6, 13, 24, or 26. In some embodiments, CDRH2 of any one of SEQ ID NO: 1-6, 13, 24, or 26 comprises, or is substantially composed of, amino acids (aa) 75 to aa 82 of SEQ ID NO: 1-6, 13, 24, or 26. In some embodiments, CDRH3 of any one of SEQ ID NO: 1-6, 13, 24, or 26 comprises, or is substantially composed of, amino acids (aa) 121 to aa 133 of SEQ ID NO: 1-6, 13, 24, or 26. In some embodiments, CDRL1 of any one of SEQ ID NO:7-9, 14, or 25 comprises, or is substantially composed of, amino acids (aa) 47 to aa 57 of SEQ ID NO:7-9, 14, or 25. In some embodiments, CDRL2 of any one of SEQ ID NO:7-9, 14, or 25 comprises, or is substantially composed of, amino acids (aa) 75 to aa 77 of SEQ ID NO:7-9, 14, or 25. In some embodiments, CDRL3 of any one of SEQ ID NO:7-9, 14, or 25 comprises, or is substantially composed of, amino acids (aa) 114 to aa 122 of SEQ ID NO:7-9, 14, or 25. In some embodiments, CDRL1 of any one of SEQ ID NO:10-12 or 27 comprises, or is substantially composed of, amino acids (aa) 47 to aa 52 of SEQ ID NO:10-12 or 27. In some embodiments, CDRL2 of any one of SEQ ID NO:10-12 or 27 comprises, or is substantially composed of, amino acids (aa) 70 to aa 72 of SEQ ID NO:10-12 or 27. In some embodiments, CDRL3 of any one of SEQ ID NO:10-12 or 27 comprises, or is substantially composed of, amino acids (aa) 109 to aa 116 of SEQ ID NO:10-12 or 27.

[0204]

[0205]

[0206] In some implementations, the CDRs in the following two tables are provided.

[0207]

[0208]

[0209]

[0210] SEQ:SEQ ID NO

[0211]

[0212]

[0213]

[0214] SEQ:SEQ ID NO

[0215] In some embodiments, another CDR is provided, which is the CDR identified herein and further includes one, two, three, four, five, six, seven, or eight amino acids at the amino terminus, carboxyl terminus, or both in the corresponding variable region sequence. Alternatively or additionally, another CDR is provided, which is the CDR identified herein and truncated by one, two, three, four, five, six, seven, or eight amino acids at the amino terminus, carboxyl terminus, or both in the corresponding variable region sequence. For example, CDR1 of SEQ ID NO:1 may be amino acids 50 to 57 of SEQ ID NO:1. However, CDR1 of SEQ ID NO:1 may also begin at amino acid 42, or 43, or 44, or 45, or 46, or 47, or 48, or 49, or 50, or 51, or 52, or 53, or 54, or 55, or 56, or 57, or 58 of SEQ ID NO:1. Furthermore, CDR1 of SEQ ID NO:1 may end at amino acid 49, or 50, or 51, or 52, or 53, or 54, or 55, or 56, or 57, or 58, or 59, or 60, or 61, or 62, or 63, or 64, or 65 of SEQ ID NO:1, provided that CDR1 ends after its beginning. Alternatively, the CDR may be about 1, or about 2, or about 3, or about 4, or about 5, or about 6, or about 7, or about 8, or about 9, or about 10, or about 11, or about 12, or about 13, or about 14, or about 15 amino acids long.

[0216] In some embodiments, the CDR2 of any one of SEQ ID NO:1-6 comprises, or is substantially composed of, amino acids 71 ​​to 85 of each of SEQ ID NO:1-6. In some embodiments, the CDR3 of any one of SEQ ID NO:1-6 comprises, or is substantially composed of, amino acids 121 to 133 of each of SEQ ID NO:1-6. In some embodiments, the CDR2 of any one of SEQ ID NO:7-9 comprises, or is substantially composed of, amino acids 71 ​​to 81 of each of SEQ ID NO:7-9. In some embodiments, the CDR3 of any one of SEQ ID NO:7-9 comprises, or is substantially composed of, amino acids 114 to 121 of each of SEQ ID NO:7-9. In some embodiments, the CDR2 of any one of SEQ ID NO:10-12 comprises, or is substantially composed of, amino acids 66 to 76 of each of SEQ ID NO:10-12. In some embodiments, the CDR3 of any one of SEQ ID NO:10-12 comprises, or is substantially composed of, amino acids 109 to 115 of each of SEQ ID NO:10-12.

[0217] In some embodiments, the CDR1 of any one of SEQ ID NO:1-6 comprises, or is substantially composed of, amino acids 50 to 57 of each of SEQ ID NO:1-6. In some embodiments, the CDR2 of any one of SEQ ID NO:1-6 comprises, or is substantially composed of, amino acids 75 to 82 of each of SEQ ID NO:1-6. In some embodiments, the CDR3 of any one of SEQ ID NO:1-6 comprises, or is substantially composed of, amino acids 121 and 122 of each of SEQ ID NO:1-6. In some embodiments, the CDR1 of any one of SEQ ID NO:7-9 comprises, or is substantially composed of, amino acids 47 to 57 of each of SEQ ID NO:7-9. In some embodiments, the CDR2 of any one of SEQ ID NO:7-9 comprises, or is substantially composed of, amino acids 75 to 77 of each of SEQ ID NO:7-9. In some embodiments, the CDR3 of any one of SEQ ID NO:7-9 comprises, or is substantially composed of, amino acids 114 to 120 of each of SEQ ID NO:7-9. In some embodiments, the CDR1 of any one of SEQ ID NO:10-12 comprises, or is substantially composed of, amino acids 47 to 52 of each of SEQ ID NO:10-12. In some embodiments, the CDR2 of any one of SEQ ID NO:10-12 comprises, or is substantially composed of, amino acids 70 to 72 of each of SEQ ID NO:10-12. In some embodiments, the CDR3 of any one of SEQ ID NO:10-12 contains, or is substantially composed of, amino acids 109 and 110 of each of SEQ ID NO:10-12.

[0218] In some embodiments, the CDR1 of any one of SEQ ID NO:1-6 comprises, or is substantially composed of, amino acids 47 to 59 of each of SEQ ID NO:1-6. In some embodiments, the CDR2 of any one of SEQ ID NO:1-6 comprises, or is substantially composed of, amino acids 74 to 83 of each of SEQ ID NO:1-6. In some embodiments, the CDR1 of any one of SEQ ID NO:7-9 comprises, or is substantially composed of, amino acids 44 to 59 of each of SEQ ID NO:7-9. In some embodiments, the CDR2 of any one of SEQ ID NO:7-9 comprises, or is substantially composed of, amino acids 74 to 81 of each of SEQ ID NO:7-9. In some embodiments, the CDR3 of any one of SEQ ID NO:7-9 comprises, or is substantially composed of, amino acids 114 to 122 of each of SEQ ID NO:7-9. In some embodiments, the CDR1 of any one of SEQ ID NO:10-12 comprises, or is substantially composed of, amino acids 44 to 54 of each of SEQ ID NO:10-12. In some embodiments, the CDR2 of any one of SEQ ID NO:10-12 comprises, or is substantially composed of, amino acids 79 to 76 of each of SEQ ID NO:10-12. In some embodiments, the CDR3 of any one of SEQ ID NO:10-12 comprises, or is substantially composed of, amino acids 109 to 116 of each of SEQ ID NO:10-12.

[0219] In one aspect, one or more variable regions of antibodies or fragments thereof as disclosed herein, and / or one or more equivalents of the variable regions are provided. In a further embodiment, an antibody, a fragment thereof, or their respective equivalents are provided comprising, substantially consisting of, or consisting of: the variable regions as disclosed herein and / or one or more equivalents of the variable regions. Furthermore or alternatively, the one or more variable regions specifically bind to DNABII peptides (e.g., head and / or tail regions, including but not limited to: head regions of IHF or HU, head regions of IHFA or IHFB, head chimeric peptides IhfA5-mIhfB4). NTHI The tail region of IHF or HU, the tail region of IHFA or IHFB, and / or the tail chimeric peptide IhfA3-IhfB2 NTHIIn some embodiments, the variable region is selected from: amino acids (aa) 25 to aa 144 of SEQ ID NO: 1-6, 13, 24 and 26; aa 21 to aa 132 of SEQ ID NO: 7-9, 14 and 25; aa 21 to aa 126 of SEQ ID NO: 10-12 or 27; amino acids 24 to amino acid 144 of SEQ ID NO: 1-6, 13, 24 and 26; amino acids 20 to amino acid 132 of SEQ ID NO: 7-12, 14, 25 and 27; amino acids 20 to amino acid 126 of SEQ ID NO: 7-12, 14, 25 and 27.

[0220] In a further embodiment, the variable region or its equivalent is the variable region as disclosed herein and further comprises, at its amino terminus or carboxyl terminus or both, or an additional 1, 2, 3, 4, 5, 6, 7, or 8 amino acids in the corresponding sequence provided herein with SEQ ID NO. Alternatively or additionally, the variable region or its equivalent is the variable region as disclosed herein and truncated at its amino terminus or carboxyl terminus or both, or by 1, 2, 3, 4, 5, 6, 7, or 8 amino acids. For example, SEQ ID NO:1 may be amino acids 50 to 57 of SEQ ID NO:1. However, the variable region or its equivalents associated with the variable region composed of amino acids 24 to 144 of SEQ ID NO: 1 may also begin with amino acids 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, or 32 of SEQ ID NO: 1. Further, the variable region or its equivalents associated with the variable region composed of amino acids 24 to 144 of SEQ ID NO: 1 may also end with amino acids 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, or 152 of SEQ ID NO: 1, provided that the variable region ends after its beginning. Alternatively, the variable region may be approximately 90 amino acids long to approximately 200 amino acids long, for example, approximately 100 amino acids long, or approximately 110 amino acids long, or approximately 120 amino acids long, or approximately 130 amino acids long, or approximately 140 amino acids long, or approximately 150 amino acids long, or approximately 160 amino acids long, or approximately 170 amino acids long, or approximately 180 amino acids long, or approximately 190 amino acids long, or approximately 200 amino acids long.

[0221] In addition, or alternatively, an equivalent of the antibody or its fragment may, compared to the antibody or its fragment, include one or more (e.g., but not limited to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25) amino acid differences in regions other than the variable domain (referred to herein as non-VH regions). Such non-VH regions include, but are not limited to, constant regions, Fc regions, pFc' regions, heavy chain constant (CH) domains (e.g., CH1, CH2, CH3, or CH4), light chain constant (CL) domains, or hinge regions. Those skilled in the art will understand that the antibodies, fragments thereof, or their respective equivalents disclosed herein can be further modified in the non-VH region (e.g., to increase the assembly of heavy and light chains, to directly or indirectly conjugate with detectable or purifiable markers or drugs, to increase or decrease complement activation, to enhance or decrease antibody-dependent cytotoxicity (ADCC), or to increase or decrease the activation and recruitment of immune cells), thereby providing further equivalents.

[0222] In some embodiments, the equivalent further comprises up to 50, 30, 25, 15, 10, or 5 random amino acids at the N-terminus, C-terminus, or both. In some embodiments, the amino acid sequence equivalent comprises, or substantially consists of, the amino acid sequence truncated at the N-terminus, C-terminus, or both by, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, or 25 amino acids. Such addition or truncation may not alter the three-dimensional arrangement of the CDR and / or the three-dimensional arrangement of the antibody, its fragment, its CDR, or the polypeptide containing the CDR.

[0223] In some embodiments, the antibody or a fragment thereof comprises a signal peptide at the N-terminus of VH and / or the N-terminus of VL. In one embodiment, the VH signal peptide is different from the VL signal peptide. In another embodiment, the VL signal peptide and the VH signal peptide are the same. In yet another embodiment, the signal peptide comprises, or substantially comprises, the amino acid sequence of amino acids 1-24 of SEQ ID NO:1. In still another embodiment, the signal peptide comprises, or substantially comprises, the amino acid sequence of amino acids 1-20 of SEQ ID NO:7. In some embodiments, an isomorph of the antibody or a fragment thereof comprises a signal peptide different from that of the antibody, provided that the signal peptide of the isomorph, like that of the antibody, directs VH and / or VL to the same cellular location.

[0224] In some embodiments, an equivalent of the antibody or its fragment retains at least 50% (e.g., at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 99%) or improves one or more functional activities of the antibody or fragment. Such functional activities include, but are not limited to, the activation of DNABII peptides (e.g., head and / or tail regions, including, but not limited to, the head region of IHF or HU, the head region of IHFA or IHFB, and the head chimeric peptide IhfA5-mIhfB4). NTHI The tail region of IHF or HU, the tail region of IHFA or IHFB, and / or the tail chimeric peptide IhfA3-IhfB2 NTHI The binding specificity, binding affinity, and / or affinity of [the organism] prevent the formation of biofilms in vivo or in vitro, or disrupt biofilms in vivo or in vitro. Methods for quantifying such functional activities are illustrated in the examples.

[0225] On the other hand, antibodies or fragments thereof that compete with the antibodies or fragments thereof disclosed herein for binding epitopes are provided. These antibodies or fragments may be polyclonal, monoclonal, and / or humanized antibodies.

[0226] In one aspect, the antibody is a bispecific antibody or a trispecific, tetraspecific, or pentaspecific antibody. In another aspect, the antibody is an IgA, IgD, IgE, IgG, or IgM antibody. In yet another aspect, the antibody further comprises a constant region selected from the constant regions of IgA, IgD, IgE, IgG, or IgM. In one specific aspect, the constant region is the IgG1 constant region. In yet another aspect, antibodies that compete with the antibodies disclosed herein for binding epitopes are provided. These can be identified using conventional techniques such as competitive ELISA.

[0227] The antibodies disclosed herein may be polyclonal, monoclonal, or humanized. On one hand, the antibody binds to the “head” region of a DNABII peptide (e.g., HU or IHF (e.g., IhfA and IhfB)). On the other hand, the antibody binds to the “tail” region of a DNABII peptide (e.g., HU or IHF (e.g., IhfA and IhfB)). As described above, this disclosure provides antigen-binding fragments. The antigen-binding fragment is any one of Fab, F(ab')2, Fab', scFv, or Fv, which can be prepared using conventional techniques known to those skilled in the art. In some aspects of the antibodies provided herein, the antibody is a soluble Fab. In another aspect, this disclosure provides Fab fragments of antibodies as disclosed herein, wherein the antibody specifically binds to the head region of a DNABII peptide (including, but not limited to, the head region of IHF or HU, the head region of IHFA or IHFB, and / or the head chimeric peptide IhfA5-mIhfB4). NTHIIn one aspect of this disclosure, DNABII is an IHF or HU peptide. In a specific aspect, DNABII is an IHF peptide.

[0228] As described above, this disclosure provides equivalents of antibody and antigen-binding fragments. The equivalent may comprise a polypeptide having at least 80% amino acid identity with the polypeptide, or a polypeptide encoded by a polynucleotide that hybridizes to a complementary sequence of a polynucleotide encoding the polypeptide under highly stringent conditions.

[0229] In some respects of the antibodies provided herein, the antibodies, their fragments, peptides, or CDRs are present at half maximum effective concentrations (EC50) of less than 500 ng / mL, or less than 250 ng / mL, or less than 200 ng / mL, or less than 150 ng / mL, or less than 100 ng / mL, or less than 90 ng / mL, or less than 80 ng / mL, or less than 70 ng / mL, or less than 65 ng / mL, or less than 60 ng / mL, or less than 55 ng / mL, or less than 50 ng / mL, or less than 45 ng / mL, or less than 40 ng / mL, or less than 35 ng / mL, or less than 30 ng / mL. 50 ) binds to DNABII proteins (including but not limited to: the head region of IHF or HU, the head region of IHFA or IHFB, and the head chimeric peptide IhfA5-mIhfB4). NTHI The tail region of IHF or HU, the tail region of IHFA or IHFB, and / or the tail chimeric peptide IhfA3-IhfB2 NTHI In a further embodiment, the ELISA method shown in the examples is used to determine such EC. 50 .

[0230] In some aspects of the antibodies presented in this article, antibodies, their fragments, peptides, or CDRs are specified in less than 10. -4 M, 10 -5 M, 10 - 6 M, 10 -7 M, 10 -8 M, 10 -9 M, 10 -10 M, 10 -11 M or 10 -12 The equilibrium constant K of M D Binding to DNABII proteins (including but not limited to: the head region of IHF or HU, the head region of IHFA or IHFB, and the head chimeric peptide IhfA5-mIhfB4). NTHI The tail region of IHF or HU, the tail region of IHFA or IHFB, and / or the tail chimeric peptide IhfA3-IhfB2 NTHIIn one embodiment, the antibody, its fragment, peptide, or CDR is expressed as follows: K D Binding to DNABII protein: below 1000 nM, or below 900 nM, or below 800 nM, or below 700 nM, or below 600 nM, or below 500 nM, or below 400 nM, or below 300 nM, or below 200 nM, or below 100 nM, or below 90 nM, or below 80 nM, or below 70 nM, or below 60 nM, or below 50 nM, or below 40 nM, or below 30 nM, or below 20 nM, or below 15 nM, or below 10 nM, or below 9 nM, or below 8 nM, or below 7 nM, or below 6 nM, or below 5 nM, or below 4 nM, or below 3 nM, or below 2 nM, or below 1 nM. In one embodiment, this K D This was determined using the surface plasmon resonance (SPR) method shown in the examples. In some aspects of the antibodies provided herein, the antigen-binding site specifically binds to the DNABII protein.

[0231] In some aspects of the antibodies provided herein, antibodies, their fragments, peptides, or CDRs are referred to as K below. off Binding to DNABII proteins (including but not limited to: the head region of IHF or HU, the head region of IHFA or IHFB, and the head chimeric peptide IhfA5-mIhfB4). NTHI The tail region of IHF or HU, the tail region of IHFA or IHFB, and / or the tail chimeric peptide IhfA3-IhfB2 NTHI (): Below 1.0E-02s -1 or below 9.0E-03s -1 or below 8.0E-03s -1 or below 7.0E-03s -1 or below 6.0E-03s -1 or below 5.0E-03s -1 or below 4.0E-03s -1 or below 3.0E-03s -1 or below 2.0E-03s -1 or below 1.0E-03s -1 or below 9.0E-04s -1 or below 8.0E-04s -1 or below 7.0E-04s -1 or below 6.0E-04s -1 or below 5.0E-04s -1 or below 4.0E-04s -1 or below 3.0E-04s-1 or below 2.0E-04s -1 or below 1.0E-04s -1 or below 9.0E-05s -1 or below 8.0E-05s -1 or below 7.0E-05s -1 or below 6.0E-05s -1 or below 5.0E-05s -1 or below 4.0E-05s -1 or below 3.0E-05s -1 or below 2.0E-05s -1 or below 1.0E-05s -1 In one implementation, this K off It was determined using the surface plasmon resonance (SPR) method shown in the examples.

[0232] In some aspects of the antibodies provided herein, antibodies, their fragments, peptides, or CDRs are referred to as K below. on Binding to DNABII proteins (including but not limited to: the head region of IHF or HU, the head region of IHFA or IHFB, and the head chimeric peptide IhfA5-mIhfB4). NTHI The tail region of IHF or HU, the tail region of IHFA or IHFB, and / or the tail chimeric peptide IhfA3-IhfB2 NTHI ): Below 9.0E-02M -1 s -1 or below 8.0E-02M -1 s -1 or below 7.0E-02M -1 s -1 or below 6.0E-02M -1 s -1 or below 5.0E-02M -1 s -1 or below 4.0E-02M -1 s -1 or below 3.0E-02M -1 s -1 or below 2.0E-02M -1 s -1 or below 1.0E-02M -1 s -1 or below 9.0E-03M -1 s -1 or below 8.0E-03M -1 s -1 or below 7.0E-03M -1 s-1 or below 6.0E-03M -1 s -1 or below 5.0E-03M -1 s -1 or below 4.0E-03M -1 s -1 or below 3.0E-03M -1 s -1 or below 2.0E-03M -1 s -1 or below 1.0E-03M -1 s -1 or below 9.0E-04M -1 s -1 or below 8.0E-04M -1 s -1 or below 7.0E-04M -1 s -1 or below 6.0E-04M -1 s -1 or below 5.0E-04M -1 s -1 or below 4.0E-04M -1 s -1 or below 3.0E-04M -1 s -1 or below 2.0E-04M -1 s -1 or below 1.0E-04M -1 s -1 or below 9.0E-05M -1 s -1 or below 8.0E-05M -1 s -1 or below 7.0E-05M -1 s -1 or below 6.0E-05M -1 s -1 or below 5.0E-05M -1 s -1 or below 4.0E-05M -1 s -1 or below 3.0E-05M -1 s -1 or below 2.0E-05M -1 s -1 or below 1.0E-05M -1 s -1 In one implementation, this K on It was determined using the surface plasmon resonance (SPR) method shown in the examples.

[0233] In some aspects of the invention, regarding IhfA5-mIhfB4 NTHI Association constant K of head chimeric peptide A (1 / M) is approximately 3E+05 to approximately 2E+08. On the other hand, K A It is about 3E+05 to about 1E+08, or about 2E+05 to about 1E+08, or about 1E+05 to about 1E+08, or about 1E+06 to about 1E+08, or about 1E+07 to about 1E+08, or about 1E+04 to about 1E+09, or about 1E+05 to about 1E+09, or about 1E+06 to about 1E+09, or about 1E+07 to about 1E+09, or about 1E+08 to about 1E+09, or about 1E+04 to about 1E+09, or about 1E+03 to about 1E+10.

[0234] In another aspect, regarding IhfA5-mIhfB4 NTHI dissociation constant K of head chimeric peptide D (M) is about 5E-09 to about 3E-06, or about 1E-09 to about 1E-06, or about 1E-08 to about 1E-05, or about 1E-07 to about 1E-05, or about 1E-06 to about 1E-05, or about 1E-09 to about 1E-08, or about 1E-08 to about 1E-07, or about 1E-9 to about 1E-08, or about 1E-10 to about 1E-09, or about 1E-11 to about 1E-10.

[0235] On the one hand, regarding IhfA3-IhfB2 NTHI K of tail-chimeric peptide A (1 / M) is about 7E+06 to about 2E+09, or about 1E+05 to about 1E+08, or about 1E+06 to about 1E+08, or about 1E+07 to about 1E+08, or about 1E+04 to about 1E+09, or about 1E+05 to about 1E+09, or about 1E+06 to about 1E+09, or about 1E+07 to about 1E+09, or about 1E+08 to about 1E+09, or about 1E+04 to about 1E+09, or about 1E+03 to about 1E+10, or about 1E+03 to about 1E+11, or about 1E+03 to about 1E+12, or about 1E+09 to about 1E+10, or about 1E+10 to about 1E+11, or about 1E+11 to about 1E+12.

[0236] In another aspect, regarding IhfA3-IhfB2 NTHI K of tail-chimeric peptide D(M) is about 6E-10 to about 2E-07, or about 1E-09 to about 1E-06, or about 1E-08 to about 1E-05, or about 1E-07 to about 1E-05, or about 1E-06 to about 1E-05, or about 1E-09 to about 1E-08, or about 1E-08 to about 1E-07, or about 1E-9 to about 1E-08, or about 1E-10 to about 1E-09, or about 1E-11 to about 1E-10, or about 1E-11 to about 1E-12.

[0237] In some aspects of the antibodies provided in this article, they bind to the head regions of DNABII proteins (including but not limited to: the head regions of IHF or HU, the head regions of IHFA or IHFB, and the head chimeric peptide IhfA5-mIhfB4). NTHI The antibodies, fragments, peptides, or CDRs thereof reduce the biomass of biomembranes in vitro by at least about 10%, or at least about 15%, or at least about 20%, or at least about 25%, or at least about 30%, or at least about 35%, or at least about 40%, or at least about 45%, or at least about 50%, or at least about 55%, or at least about 60%, or at least about 65%, or at least about 70%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%. In some aspects of the antibodies provided herein, they bind to the tail regions of DNABII proteins (including, but not limited to, the tail regions of IHF or HU, the tail regions of IHFA or IHFB, and the tail chimeric peptides IhfA3-IhfB2). NTHI The antibody, fragment, peptide, or CDR of the substance reduces the biomass of the biofilm in vitro by less than about 1%, or less than about 2%, or less than about 3%, or less than about 4%, or less than about 5%, or less than about 6%, or less than about 7%, or less than about 8%, or less than about 9%, or less than about 10%, or less than about 12%, or less than about 15%, or less than about 20%, or less than about 25%, or less than about 30%, or less than about 35%, or less than about 40%, or less than about 45%, or less than about 50%. In one embodiment, such change in biomass is determined using the method shown in Example 3 or 4.

[0238] In some aspects of the antibodies provided in this article, they bind to the head regions of DNABII proteins (including but not limited to: the head regions of IHF or HU, the head regions of IHFA or IHFB, and the head chimeric peptide IhfA5-mIhfB4). NTHIAntibodies, fragments, peptides, or CDRs thereof reduce bacterial load in a target by at least about 10%, or at least about 15%, or at least about 20%, or at least about 25%, or at least about 30%, or at least about 35%, or at least about 40%, or at least about 45%, or at least about 50%, or at least about 55%, or at least about 60%, or at least about 65%, or at least about 70%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99%. In some aspects of the antibodies provided herein, they bind to the tail region of the DNABII protein (including, but not limited to, the tail region of IHF or HU, the tail region of IHFA or IHFB, and the tail chimeric peptide IhfA3-IhfB2). NTHI The antibody, fragment, peptide, or CDR reduces the bacterial load in the target by less than about 1%, or less than about 2%, or less than about 3%, or less than about 4%, or less than about 5%, or less than about 6%, or less than about 7%, or less than about 8%, or less than about 9%, or less than about 10%, or less than about 12%, or less than about 15%, or less than about 20%, or less than about 25%, or less than about 30%, or less than about 35%, or less than about 40%, or less than about 45%, or less than about 50%. In one embodiment, such a change in bacterial load is determined using the method shown in the examples.

[0239] In some aspects of the antibodies provided in this article, they bind to the head regions of DNABII proteins (including but not limited to: the head regions of IHF or HU, the head regions of IHFA or IHFB, and the head chimeric peptide IhfA5-mIhfB4). NTHI Antibodies, fragments, peptides, or CDRs thereof reduce middle ear obstruction in subjects with otitis media (OM) by at least about 10%, or at least about 15%, or at least about 20%, or at least about 25%, or at least about 30%, or at least about 35%, or at least about 40%, or at least about 45%, or at least about 50%, or at least about 55%, or at least about 60%, or at least about 65%, or at least about 70%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99%. In some aspects of the antibodies provided herein, they bind to the tail region of the DNABII protein (including, but not limited to, the tail region of IHF or HU, the tail region of IHFA or IHFB, and the tail chimeric peptide IhfA3-IhfB2). NTHIAntibodies, fragments, peptides, or CDRs of [a specific substance] reduce middle ear obstruction in subjects with otitis media (OM) by less than about 1%, or less than about 2%, or less than about 3%, or less than about 4%, or less than about 5%, or less than about 6%, or less than about 7%, or less than about 8%, or less than about 9%, or less than about 10%, or less than about 12%, or less than about 15%, or less than about 20%, or less than about 25%, or less than about 30%, or less than about 35%, or less than about 40%, or less than about 45%, or less than about 50%. In one embodiment, such changes in middle ear obstruction are determined in an experimental otitis media (OM) model using the methods shown in the examples.

[0240] In some aspects of the antibodies provided in this article, they bind to the head regions of DNABII proteins (including but not limited to: the head regions of IHF or HU, the head regions of IHFA or IHFB, and the head chimeric peptide IhfA5-mIhfB4). NTHI Antibodies, fragments, peptides, or CDRs of [specific substances] reduce the relative mucosal biofilm score and / or biomass score in subjects with mucosal biofilms (e.g., those with OM) by at least about 10%, or at least about 15%, or at least about 20%, or at least about 25%, or at least about 30%, or at least about 35%, or at least about 40%, or at least about 45%, or at least about 50%, or at least about 55%, or at least about 60%, or at least about 65%, or at least about 70%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99%. In one embodiment, the binding is to the head region of the DNABII protein (including, but not limited to, the head region of IHF or HU, the head region of IHFA or IHFB, the head chimeric peptide IhfA5-mIhfB4). NTHI Antibodies, fragments, peptides, or CDRs thereof reduce the relative mucosal biofilm score and / or biomass score in subjects with mucosal biofilms (e.g., those with OM) by at least about 0.5, or at least about 1, or at least about 1.5, or at least about 2, or at least about 2.5, or at least about 3, or at least about 3.5, or at least about 4. In some aspects of the antibodies provided herein, they bind to the tail regions of DNABII proteins (including, but not limited to, the tail regions of IHF or HU, the tail regions of IHFA or IHFB, and the tail chimeric peptides IhfA3-IhfB2). NTHIAntibodies, fragments, peptides, or CDRs of [a specific substance] reduce the relative mucosal biofilm score and / or biomass score in subjects with mucosal biofilms (e.g., those with OM) by less than about 1%, or less than about 2%, or less than about 3%, or less than about 4%, or less than about 5%, or less than about 6%, or less than about 7%, or less than about 8%, or less than about 9%, or less than about 10%, or less than about 12%, or less than about 15%, or less than about 20%, or less than about 25%, or less than about 30%, or less than about 35%, or less than about 40%, or less than about 45%, or less than about 50%. In one embodiment, such changes in middle ear obstruction are determined in an experimental otitis media (OM) model using the methods shown in the examples. In one embodiment, binding to the tail region of DNABII proteins (including, but not limited to, the tail region of IHF or HU, the tail region of IHFA or IHFB, and the tail chimeric peptides IhfA3-IhfB2) is [the specific substance]. NTHI Antibodies, fragments, peptides, or CDRs of [a specific substance] reduce the relative mucosal biofilm score and / or biomass score in subjects with mucosal biofilms (e.g., those with OM) to less than about 0.1, or less than about 0.2, or less than about 0.3, or less than about 0.4, or less than about 0.5, or less than about 0.6, or less than about 0.7, or less than about 0.8, or less than about 0.9, or less than about 1, or less than about 1.5, or less than about 2, or less than about 2.5. In one embodiment, such scores are determined using the methods shown in the examples.

[0241] In some embodiments, the DNABII protein is HU or IHF. In further embodiments, the DNABII protein is IhfA, IhfB, or both. In yet another embodiment, an antibody, fragment thereof, peptide, or CDR binds to the head or tail region of the DNABII protein (including, but not limited to, the head region of IHF or HU, the head region of IHFA or IHFB, and the head chimeric peptide IhfA5-mIhfB4). NTHI The tail region of IHF or HU, the tail region of IHFA or IHFB, and / or the tail chimeric peptide IhfA3-IhfB2 NTHI In one implementation, the antibody, its fragment, peptide, or CDR binds to IhfA5-mIhfB4. NTHI Head-specific chimeric peptide. In another embodiment, the antibody, its fragment, peptide, or CDR binds to IhfA3-IhfB2. NTHI Tail-end chimeric peptide.

[0242] In some respects of the antibodies presented in this article, the antibodies are soluble Fab.

[0243] In some aspects of the antibodies presented herein, the HC and LC variable domain sequences are components of the same polypeptide chain. In other aspects of the antibodies presented herein, the HC and LC variable domain sequences are components of different polypeptide chains.

[0244] In some respects of the antibodies presented in this article, the antibodies are full-length antibodies.

[0245] In some respects of the antibodies presented in this article, the antibodies are chimeric or humanized.

[0246] In some aspects of the antibodies described herein, the antibodies contain an Fc domain. In some aspects of the antibodies described herein, the antibodies are non-human animal antibodies, such as rat, sheep, bovine, canine, cat, or rabbit antibodies. In some aspects of the antibodies described herein, the antibodies are human antibodies or humanized antibodies, or are non-immunogenic in humans.

[0247] In some aspects of the antibodies provided herein, the antibodies comprise human antibody framework regions. Examples of framework regions that can fuse with LC and HC sequences are known in the art, and such examples are provided in SEQ ID NO:15-23, or equivalents of each thereof.

[0248] In other respects, one or more amino acid residues in the CDR of the antibody presented herein are substituted with another amino acid. Substitution can be "conserved" in the sense of substitution within the same amino acid family. Naturally occurring amino acids can be divided into four families, and conserved substitutions will occur within these families.

[0249] 1) Amino acids with basic side chains: lysine, arginine, histidine.

[0250] 2) Amino acids with acidic side chains: aspartic acid, glutamic acid.

[0251] 3) Amino acids with uncharged polar side chains: asparagine, glutamine, serine, threonine, tyrosine.

[0252] 4) Amino acids with nonpolar side chains: glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan, cysteine.

[0253] In another aspect, one or more amino acid residues may be added to or deleted from one or more CDRs of the antibody. Such additions or deletions may occur at the N or C terminus of the CDR or within the CDR.

[0254] By altering the amino acid sequence of an antibody's CDR through the addition, deletion, or substitution of amino acids, various effects can be achieved, such as increasing the binding affinity to the target antigen.

[0255] It should be understood that antibodies of this disclosure containing this modified CDR sequence still bind to the DNABII protein with similar specificity and sensitivity profiles as the disclosed antibodies. This can be detected by binding assays, such as ELISA or SPR.

[0256] In another respect, antibodies are characterized by both immunodominance and immunoprotection, as determined by appropriate assays and screening methods.

[0257] On the other hand, antibodies can be modified using conventional techniques, which can increase the antibody's half-life, such as PEGylation, PEG mimicry, polysialylation, HES glycosylation, or glycosylation.

[0258] Antibody and antigen-binding fragments may also contain detectable or purified labels.

[0259] Antibodies and their derivatives

[0260] This disclosure also provides antibodies for use in the methods disclosed herein to bind and / or specifically recognize and bind to isolated peptides. The antibodies can be any of the various antibodies described herein, and non-limiting examples of such antibodies include polyclonal antibodies, monoclonal antibodies, chimeric antibodies, human antibodies, veneered antibodies, biantibodies, humanized antibodies, antibody derivatives, recombinant humanized antibodies, or their respective equivalents (e.g., derivatives) or fragments. On one hand, the fragment contains, or is substantially composed of, the CDR of the antibody. On the other hand, the antibody is detectably labeled or further contains a detectably labeled conjugated thereto.

[0261] This document also provides hybridoma cell lines for producing the monoclonal antibodies disclosed herein. Further, this document provides compositions comprising, substantially consisting of, or composed of the above embodiments. This document also provides polynucleotides encoding the amino acid sequences of the said antibodies and fragments, and methods for recombinantly or chemically synthesizing the said antibody peptides and fragments thereof. The antibody peptides may be produced in eukaryotic or prokaryotic cells, or by other methods known in the art and described herein.

[0262] Examples of CDR sequences include, but are not limited to, the following components, or substantially constitute, or constitute: the heavy chain variable region of an antibody or fragment thereof contains, or substantially constitutes, or constitutes: a polypeptide encoded by the following polynucleotide sequence.

[0263] Antibodies can be produced using conventional techniques known in the art and well described in the literature. Several methods exist for producing polyclonal antibodies. For example, polyclonal antibodies are typically produced by immunizing suitable mammals (e.g., but not limited to, chickens, goats, guinea pigs, hamsters, horses, mice, rats, and rabbits). Injecting an antigen into the mammal induces B lymphocytes to produce antigen-specific immunoglobulins. Immunoglobulins can be purified from the mammalian serum.

[0264] Variations in this method include altering the adjuvant, route and site of administration, injection volume at each site, and number of sites per animal to achieve optimal animal production and humane handling. For example, adjuvants are commonly used to improve or enhance immune responses to antigens. Most adjuvants provide an antigen reservoir at the injection site, allowing the antigen reservoir to be released into draining lymph nodes. Other adjuvants include surfactants and immunostimulatory molecules that promote the concentration of protein antigen molecules over a large surface area. Non-limiting examples of adjuvants used for the production of polyclonal antibodies include Freund's adjuvant, the Ribi adjuvant system, and Titermax. Polyclonal antibodies can be produced using methods known in the art, some of which are described in U.S. Patents 7,279,559; 7,119,179; 7,060,800; 6,709,659; 6,656,746; 6,322,788; 5,686,073; and 5,670,153.

[0265] Monoclonal antibodies can be produced using conventional hybridoma techniques known in the art and described in detail in the literature. For example, hybridomas are produced by fusing suitable immortalized cell lines with antibody-producing cells, such as myeloma cell lines, including but not limited to Sp2 / 0, Sp2 / 0-AG14, NSO, NS1, NS2, AE-1, L.5, P3X63Ag8,653, Sp2 SA3, Sp2 MAI, Sp2 SS1, Sp2 SA5, U397, MIA 144, ACT IV, MOLT4, DA-1, JURKAT, WEHI, K-562, COS, RAJI, NIH 313, HL-60, MLA 144, NAMAIWA, and NEURO. 2A, CHO, PerC.6, YB2 / O, etc., or allogeneic myeloma, its fusion products, or any cells or fusion cells derived therefrom, or any other suitable cell line known in the art (see, for example, atcc.org, lifetech.com, last accessed November 26, 2007), said antibody-producing cells such as, but not limited to, isolated or cloned spleen cells, peripheral blood cells, lymphocytes, tonsillar cells or other cells containing immune cells or B cells, or any other cells expressing heavy or light chains. Cells containing fixed or variable sequences, frame sequences, or CDR sequences, which are endogenous or heterologous nucleic acids, recombinant or endogenous, viral, bacterial, algal, prokaryotic, amphibian, insect, reptile, fish, mammalian, rodent, equine, sheep, goat, primate, eukaryotic, genomic DNA, cDNA, rDNA, mitochondrial DNA or RNA, chloroplast DNA or RNA, hnRNA, mRNA, tRNA, single-stranded, double-stranded, triple-stranded, hybrid, etc., or any combination thereof. Antibody-producing cells may also be obtained from peripheral blood of humans or other suitable animals that have been immunized with the target antigen and then screened for target activity, or, in a particular embodiment, spleen or lymph nodes. Any other suitable host cells may also be used to express heterologous or endogenous nucleic acids encoding antibodies, specific fragments of or variants thereof. Fusion cells (hybridomas) or recombinant cells may be isolated using selective culture conditions or other suitable known methods and cloned by limiting dilution or cell sorting or other known methods.

[0266] Other suitable methods for generating or isolating antibodies with the desired specificity can be used, including, but not limited to, methods for selecting recombinant antibodies from peptide or protein libraries (e.g., but not limited to, phage, ribosome, oligonucleotide, cDNA, etc. display libraries); for example, libraries can be obtained from various commercial suppliers such as MorphoSys (Martinsreid / Planegg, Del.), BioInvent (Lund, Sweden), and Affitech (Oslo, Norway). Methods known in the art are described in patent literature, some of which include U.S. Patents 4,704,692; 5,723,323; 5,763,192; 5,814,476; 5,817,483; 5,824,514; and 5,976,862. Alternative approaches rely on the immunization of transgenic animals (e.g., SCID mice, Nguyen et al. (1977) Microbiol. Immunol. 41:901-907 (1997); Sandhu et al. (1996) Crit, Rev. Biotechnol. 16:95-118; Eren et al. (1998) Mumma 93:154-161) that are capable of producing human antibody libraries as known in the art and / or as described herein. Such techniques include, but are not limited to, ribosome display (Wanes et al. (1997) Proc. Natl. Acad. Sci. USA 94:4937-4942; Hanes et al. (1998) Proc. Natl. Acad. Sci. USA 95:14130-14135); single-cell antibody production techniques (e.g., selective lymphocyte antibody method (“SLAM”) (US Pat. No. 5, 627, 052; Wen et al. (1987) J. Immunol 17:887-892; Babcook et al. (1996) Proc. Natl. Acad. Sci. USA 93:7843-7848)); gel microdroplets and flow cytometry (Powell et al. (1990) Biotechnol. 8:333-337; One Cell). Systems (Cambridge, Mass.); Gray et al. (1995) J.Imm.Meth. 182:155-163; and Kenny et al. (1995) Bio.Technol. 13:787-790); B-cell screening method (Steenbakkers et al. (1994) Molec.Biol.Reports 19:125-134).

[0267] The antibody derivatives disclosed herein can also be prepared by delivering polynucleotides encoding the antibodies disclosed herein to a suitable host, such as to provide transgenic animals or mammals, like goats, cattle, horses, sheep, etc., that produce such antibodies in their emulsions. These methods are known in the art and are described, for example, in U.S. Patents 5,827,690; 5,849,992; 4,873,316; 5,849,992; 5,994,616; 5,565,362; and 5,304,489.

[0268] The term "antibody derivative" includes post-translational modifications to the linear polypeptide sequence of an antibody or fragment. For example, U.S. Patent 6,602,684B1 describes a method for producing an antibody in a modified diol form, comprising an intact antibody molecule, an antibody fragment, or a fusion protein including a region corresponding to the Fc region of an immunoglobulin, having enhanced Fe-mediated cytotoxicity, and a glycoprotein thus produced.

[0269] The antibodies disclosed herein also include modified derivatives, which are produced by covalently linking any type of molecule to the antibody such that the covalent link does not prevent the antibody from producing an anti-idiotype reaction. Antibody derivatives include, but are not limited to, antibodies modified by glycosylation, acetylation, polyethylene glycolation, phosphorylation, amidation, derivatization by known protecting / blocking groups, proteolytic cleavage, or linkage to cellular ligands or other proteins. Additionally, the derivatives may contain one or more non-classical amino acids.

[0270] Antibody derivatives can also be prepared by delivering the polynucleotides disclosed herein to provide transgenic plants and cultured plant cells (e.g., but not limited to tobacco, maize, and duckweed) that produce such antibodies, specific portions, or variants in plant parts or from cells cultured from them. For example, Cramer et al. (1999) Curr. Top. Microbol. Immunol. 240:95-118 and references cited therein describe the production of transgenic tobacco leaves expressing large amounts of recombinant proteins using, for example, inducible promoters. Transgenic maize has been used to express mammalian proteins at commercial production levels with bioactivity comparable to those produced in other recombinant systems or purified from natural sources. See, for example, Hood et al. (1999) Adv. Exp. Med. Biol. 464:127-147 and references cited therein. Antibody derivatives, including antibody fragments such as single-chain antibodies (scFvs), are also produced in large quantities from transgenic plant seeds, including tobacco seeds and potato tubers. See, for example, Conrad et al. (1998) Plant Mol. Biol. 38:101-109 and the references cited therein. Therefore, antibodies can also be produced using transgenic plants according to known methods.

[0271] Antibody derivatives can also be generated, for example, by adding exogenous sequences to modify immunogenicity or to reduce, enhance, or modify binding, affinity, binding rate, dissociation rate, specificity, half-life, or any other suitable characteristic. Typically, some or all of the non-human or human CDR sequences are retained, while the non-human sequences in the variable and constant regions are replaced by human or other amino acids or from other isotypes in the variable or constant regions.

[0272] Typically, CDR residues are directly and substantially involved in influencing antigen binding. Humanization or engineering of antibodies can be performed using any known method, such as, but not limited to, those described in U.S. Patents 5,723,323; 5,976,862; 5,824,514; 5,817,483; 5,814,476; 5,763,192; 5,723,323; 5,766,886; 5,714,352; 6,204,023; 6,180,370; 5,693,762; 5,530,101; 5,585,089; 5,225,539; and 4,816,567.

[0273] The chimeric, humanized, or primate-like antibodies disclosed herein can be prepared based on the sequence of a reference monoclonal antibody prepared using standard molecular biology techniques. DNA encoding heavy and light chain immunoglobulins can be obtained from hybridomas of interest and engineered using standard molecular biology techniques to include non-reference (e.g., human) immunoglobulin sequences. For example, to generate chimeric antibodies, a mouse variable region can be linked to a human constant region using methods known in the art (US Patent No. 4,816,567). To generate humanized antibodies, a mouse CDR region can be inserted into a human frame using methods known in the art (US Patent Nos. 5,225,539 and 5,530,101; 5,585,089; 5,693,762 and 6,180,370). Similarly, to generate primate-like antibodies, a mouse CDR region can be inserted into a primate frame using methods known in the art (WO 93 / 02108 and WO 99 / 55369).

[0274] Techniques for preparing partial to fully human antibodies are known in the art and any such technique can be used. According to one embodiment, fully human antibody sequences are prepared in transgenic mice engineered to express human heavy and light chain antibody genes. Various such transgenic mouse strains have been prepared that can produce different classes of antibodies. Hybridoma cell lines can be prepared by fusing B cells from transgenic mice that produce the desired antibodies to continuously produce the desired antibodies.(See, for example, Russel et al. (2000) Infection and Immunity April 2000:1820-1826; Gallo et al. (2000) European J. of Immun. 30:534-540; Green (1999) J. of Immun. Methods 231:11-23; Yang et al. (1999A) J. of Leukocyte Biology 66:401-410; Yang (1999B) Cancer Research 59(6):1236-1243; Jakobovits (1998) Advanced Drug Reviews 31:33-42; Green and Jakobovits (1998) J. Exp. Med. 188(3):483-495; Jakobovits (1998) Exp. Opin. Invest. Drugs 7(4):607-614; Tsuda et al. (1997) Genomics 42:413-421; Sherman-Gold (1997) Genetic Engineering News 17(14); Mendez et al. (1997) Nature Genetics 15:146-156; Jakobovits (1996) Weir's Handbook of Experimental Immunology, The Integrated Immune System Vol. IV, 194.1-194.7; Jakobovits (1995) Current Opinion in Biotechnology 6:561-566; Mendez et al. (1995) Genomics 26:294-307; Jakobovits (1994) Current Biology 4(8):761-763; Arbones et al. (1994) Immunity 1(4):247-260; Jakobovits (1993) Nature 362(6417):255-258; Jakobovits et al. (1993) Proc. Natl. Acad. Sci. USA 90(6):2551-2555; and U.S. Pat. No. 6,075,181.).

[0275] The antibodies disclosed herein can also be modified to produce chimeric antibodies. Chimeric antibodies are those in which the domains of the antibody heavy and light chains are encoded by DNA from multiple species. See, for example, U.S. Patent No. 4,816,567.

[0276] Alternatively, the antibodies disclosed herein can also be modified to produce conformal antibodies. Conformal antibodies are antibodies in which the external amino acid residues of an antibody from one species are carefully replaced, or “conformed,” with residues from a second species, so that the antibody from the first species will not be immunogenic in the second species, thus reducing the immunogenicity of the antibody. Since the antigenicity of a protein depends primarily on the nature of its surface, the immunogenicity of an antibody can be reduced by replacing exposed residues that are different from those typically found in another mammalian species. This careful replacement of external residues should have little or no effect on internal domains or interdomain contacts. Therefore, ligand-binding properties should not be affected by changes limited to the variable region framework residues. This process is called “conformation” because only the outer surface or skin of the antibody is altered, while the supporting residues remain undisturbed.

[0277] The “fitting” procedure utilizes available sequence data of variable domains of human antibodies (compiled by Kabat et al. (1987) Sequences of Proteins of Immunological Interest, 4th ed., Bethesda, Md., National Institutes of Health), updates to this database, and other accessible U.S. and foreign databases (nucleic acids and proteins). Non-limiting examples of methods for generating fitting antibodies include EP 519596; U.S. Patent No. 6,797,492; and described in Padlan et al. (1991) Mol. Immunol. 28(4-5):489-498.

[0278] The term "antibody derivative" also includes "biantibodies," which are small antibody fragments having two antigen-binding sites, wherein the fragment contains a heavy chain variable domain (VH) linked to a light chain variable domain (VL) in the same polypeptide chain. (See, for example, EP 404,097; WO 93 / 11161; and Hollinger et al. (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448.) By using linkers that are too short to pair between the two domains on the same chain, these domains are forced to pair with complementary domains of another chain, creating two antigen-binding sites. (See also U.S. Patent 6,632,926 to Chen et al., which discloses an antibody variant having one or more amino acids inserted into the hypervariable region of the parent antibody and having a binding affinity for the target antigen that is at least about 2 times stronger than that of the parent antibody.)

[0279] The term “antibody derivative” also includes engineered antibody molecules, fragments, and single domains, such as scFv, dAb, nanobodies, microbodies, monoclonal antibodies, and Affibodies & Hudson (2005) Nature Biotech 23(9):1126-36; U.S. Patent Application Publication No. 2006 / 0211088; PCT International Application Publication No. WO 2007 / 059782; U.S. Patent No. 5,831,012).

[0280] The term "antibody derivative" further includes "linear antibody". Procedures for preparing linear antibodies are known in the art and described in Zapata et al. (1995) Protein Eng. 8(10):1057-1062. In short, these antibodies contain a pair of tandem Ed fragments (VH-C). H 1-VH-C H 1) They form a pair of antigen-binding regions. Linear antibodies can be bispecific or monospecific.

[0281] The antibodies disclosed herein can be recovered and purified from recombinant cell cultures using known methods, including but not limited to protein A purification, ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, cellulose phosphate chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxyapatite chromatography, and lectin chromatography. High-performance liquid chromatography (“HPLC”) can also be used for purification.

[0282] The antibodies disclosed herein include naturally purified products, products of chemical synthesis procedures, and products produced from eukaryotic hosts via recombinant technology, including, for example, yeast, higher plant, insect, and mammalian cells, or products produced from prokaryotic hosts as described above. Numerous antibody production systems are described in Birch & Radner (2006) Adv. Drug Delivery Rev. 58:671-685.

[0283] If the antibody to be tested binds to a protein or peptide, then the antibody to be tested is equivalent to the antibody provided in this invention. An antibody may also have the same specificity as the antibody disclosed herein without excessive experimentation by determining whether the antibody being tested prevents the antibody disclosed herein from binding to a protein or peptide with which it normally reacts. If the antibody being tested competes with the antibody disclosed herein, as shown by reduced binding of the monoclonal antibody disclosed herein, then the two antibodies may bind to the same or closely related epitopes. Alternatively, the antibody disclosed herein can be pre-incubated with a protein with which it normally reacts, and it can be determined whether the ability of the antibody being tested to bind to the antigen is inhibited. If the antibody being tested is inhibited, then it is very likely to have the same or closely related epitope specificity as the antibody disclosed herein.

[0284] The term "antibody" is also intended to include antibodies of all immunoglobulin isotypes and subclasses. Specific isotypes of monoclonal antibodies can be prepared directly by selection from the initial fusion, or secondaryly by isolating class-converting variants from parental hybridomas secreting different isotypes of monoclonal antibodies using sib selection techniques according to procedures described in Steplewski et al. (1985) Proc. Natl. Acad. Sci. USA 82:8653 or Spira et al. (1984) J. Immunol. Methods 74:307. Alternatively, recombinant DNA technology can be used.

[0285] The isolation of other monoclonal antibodies with the specificity of the monoclonal antibodies described herein can also be accomplished by those skilled in the art by generating anti-idiotype antibodies. Herlyn et al. (1986) Science 232:100. Anti-idiotype antibodies are antibodies that recognize unique determinants present on the monoclonal antibody of interest.

[0286] In some aspects disclosed herein, detectably or therapeutically labeling antibodies would be useful. Suitable labeling methods have been described above. Methods for binding antibodies to these reagents are known in the art. For illustrative purposes only, antibodies may be labeled with detectable portions, such as radioactive atoms, chromophores, fluorophores, etc. Such labeled antibodies can be used in diagnostic techniques in vivo or in isolated test samples.

[0287] Conjugation of antibodies to low molecular weight haptens can improve the sensitivity of the antibody in an assay. The hapten can then be specifically detected by a second reaction. For example, commonly used haptens are biotin (which reacts with avidin), or dinitrophenol, pyridoxal, and fluorescein, which can react with specific anti-hapten antibodies. See Harlow and Lane (1988) above.

[0288] The variable regions of the antibodies disclosed herein can be modified by mutating amino acid residues within the VH and / or VL CDR 1, CDR 2, and / or CDR 3 regions to improve one or more binding properties of the antibody (e.g., affinity). Mutations can be introduced by site-directed mutagenesis or PCR-mediated mutagenesis, and the effects on antibody binding or other functional properties of interest can be assessed in appropriate in vitro or in vivo assays. In some embodiments, conserved modifications are introduced, and typically no more than one, two, three, four, or five residues within the CDR regions are altered. Mutations can be amino acid substitutions, additions, or deletions.

[0289] Antibodies can be modified in a framework to reduce immunogenicity, for example, by “reverting mutations” of one or more framework residues to the corresponding germline sequences.

[0290] Furthermore, the antibodies disclosed herein can be engineered to include modifications within the Fc region to alter one or more functional properties of the antibody, such as serum half-life, complement fixation, Fc receptor binding, and / or antigen-dependent cytotoxicity. Such modifications include, but are not limited to, altering the number of cysteine ​​residues in the hinge region to promote light and heavy chain assembly or increase or decrease antibody stability (US Patent No. 5,677,425), and amino acid mutations in the Fc hinge region to reduce the antibody's biological half-life (US Patent No. 6,165,745).

[0291] Furthermore, the antibodies disclosed herein can be chemically modified. The glycosylation of the antibody can be altered, for example, by modifying one or more glycosylation sites within the antibody sequence to increase the antibody's affinity for the antigen (US Patent Nos. 5,714,350 and 6,350,861). Alternatively, to increase antibody-dependent cell-mediated cytotoxicity, low-fucosylated antibodies with reduced fucosylation content or antibodies with increased bisecting GlcNac structures can be obtained by expressing the antibody in host cells with altered glycosylation mechanisms (Shields, R. Let et al. (2002) J. Biol. Chem. 277:26733-26740; Umana et al. (1999) Nat. Biotech. 17:176-180).

[0292] The antibodies disclosed herein can be PEGylated to increase their biological half-life by reacting an antibody or a fragment thereof with polyethylene glycol (PEG) or a reactive ester or aldehyde derivative of PEG, with one or more PEG groups attached to the antibody or antibody fragment. Antibody PEGylation can be performed by acylation or alkylation with a reactive PEG molecule (or a similar reactive water-soluble polymer). As used herein, the term "polyethylene glycol" is intended to cover any form of PEG that has been used to derive other proteins, such as mono(C1-C10)alkoxy- or aryloxy-polyethylene glycol or polyethylene glycol-maleimide. The antibody to be PEGylated can be a non-glycosylated antibody. Methods for PEGylating proteins are known in the art and can be applied to the antibodies disclosed herein (EP 0154316 and EP 0401384).

[0293] Furthermore, antibodies can be chemically modified by conjugating or fusing the antigen-binding region of the antibody with a serum protein such as human serum albumin to increase the half-life of the resulting molecule. This method is described, for example, in EP 0322094 and EP0486525.

[0294] The antibodies or fragments thereof disclosed herein can be conjugated with diagnostic agents for diagnostic purposes, such as monitoring the development or progression of a disease and determining the efficacy of a given treatment regimen. Examples of diagnostic agents include enzymes, cofactors, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, and positron-emitting metal and non-radioactive paramagnetic metal ions using various positron emission tomography (PET) scans. Detectable substances can be directly conjugated or conjugated to antibodies or fragments thereof, or indirectly conjugated or conjugated via adapters using techniques known in the art. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase. Examples of suitable cofactor complexes include streptavidin / biotin and avidin / biotin. Examples of suitable fluorescent materials include umbelliferone, luciferin, luciferin isothiocyanate, rhodamine, dichlorotriazineamine luciferin, dansyl chloride, or phycoerythrin. Examples of luminescent materials include luminol. Examples of bioluminescent materials include luciferase, luciferin, and jellyfish luminescent proteins. Examples of suitable radioactive substances include... 125 I, 131I, Indium-111, Lutetium-171, Bismuth-212, Bismuth-213, Astatine-211, Copper-62, Copper-64, Copper-67, Yttrium-90, Iodine-125, Iodine-131, Phosphorus-32, Phosphorus-33, Scandium-47, Silver-111, Gallium-67, Praseodymium-142, Samarium-153, Terbium-161, Dysprosium-166, Holmium-1 66, Rhenium-186, Rhenium-188, Rhenium-189, Lead-212, Radium-223, Actinium-225, Iron-59, Selenium-75, Arsenic-77, Strontium-89, Molybdenum-99, Rhodium-1105, Palladium-109, Praseodymium-143, Promethium-149, Erbium-169, Iridium-194, Gold-198, Gold-199, and Lead-211. Monoclonal antibodies can be indirectly conjugated to radioactive metal ions using bifunctional chelating agents covalently linked to the antibody. Chelating agents can be conjugated via amides (amities) (Meares et al. (1984) Anal. Biochem. 142: 68-78); thiol groups of amino acid residues (Koyama (1994) Chem. Abstr. 120: 217-262); and carbohydrate groups (Rodwell et al. (1986) PNAS USA 83: 2632-2636; Quadri et al. (1993) Nucl. Med. Biol. 20: 559-570).

[0295] Furthermore, the antibodies or fragments thereof disclosed herein can be conjugated to therapeutic agents. Suitable therapeutic agents include paclitaxel, cytochalasin B, bacitracin D, ethidium bromide, imidin, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, doxorubicin, daunorubicin, dihydroxyanthraquinone, mitoxantrone, styromycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol and puromycin, antimetabolites (such as methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine). Fludarabine, 5-fluorouracil, dicarbazine, hydroxyurea, asparaginase, gemcitabine, cladribine), alkylating agents (such as chloroethylamine, thiamethoxam, chloramphenicol, melphalan, carmustine (BSNU), lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, dacarbazine (DTIC), procarbazine, mitomycin C, cisplatin and other platinum derivatives, such as carboplatin), antibiotics (such as bleomycin (proactinomycin), styraxin, dextrin, etc.). Erythromycin (formerly Doxorubicin), Doxorubicin, Idarubicin, styromycin, Mitomycin, Mitoxantrone, Procainum, Aminopicillin (AMC)), Diphtheria toxin and related molecules (e.g., diphtheria A chain and its active fragments and hybrid molecules), Ricin (e.g., ricin A or deglycosylated ricin A chain toxin), Cholera toxin, Shiga-like toxins (SLT-I, SLT-II, SLT-IIV), LT toxin, C3 toxin, Shiga toxin, Pertussis toxin, Tetanus toxin, Soybean Bowman-Birk protease inhibitor, Pseudomonas exotoxin, Alarin, Saponins, Modeccin, Gelatin, Abrus precatorius protein A chain, Modeccin A chain, α-Arcticin, Tung oil protein, Carnation toxin, Phytolacca acinosa protein (PAPI, PAPII and PAP-S), Bitter melon inhibitor, Jatropha curcas toxin (curcin), Croton toxin, Sapaonaria Inhibitors of officinalis, gelonin, mitogellin, restrietocin, phenolmycin, inomycin, and mixed toxins.

[0296] Other suitable conjugating molecules include ribonucleases (RNases), DNase I, antisense nucleic acids, repressive RNA molecules such as siRNA molecules, immunostimulatory nucleic acids, aptamers, ribozymes, triplet-forming molecules, and external guide sequences. Aptamers are small nucleic acids ranging from 15 to 50 bases in length that fold into defined secondary and tertiary structures, such as stem-loops or G-tetramers, and can bind small molecules, such as ATP (US Patent No. 5,631,146) and theophylline (US Patent No. 5,580,737), as well as large molecules, such as reverse transcriptase (US Patent No. 5,786,462) and thrombin (US Patent No. 5,543,293). Ribozymes are nucleic acid molecules capable of catalyzing chemical reactions intramolecularly or intermolecularly. Ribozymes typically cleave nucleic acid substrates through the recognition and binding of target substrates and subsequent cleavage. Triplex-forming nucleic acid molecules interact with double-stranded or single-stranded nucleic acids by forming triplets, where triplet DNA formation depends on Watson-Crick and Hoogsteen base pairing complexes. Triple-stranded molecules can bind to target regions with high affinity and specificity.

[0297] Functional nucleic acid molecules can act as effectors, inhibitors, regulators, and stimulants of the specific activities of target molecules, or they can have novel activities that are independent of any other molecule.

[0298] Therapeutic agents can be directly or indirectly linked to antibodies using any of the numerous available methods. For example, the therapeutic agent can be linked to the hinge region of a reduced antibody component via disulfide bond formation, the use of cross-linking agents such as N-succinyl 3-(2-pyridyl dithio)propionate (SPDP), or via the carbohydrate portion of the Fc region of the antibody (Yu et al. 1994 Int. J. Cancer 56:244; Upeslacis et al., “Modification of Antibodies by Chemical Methods,” in Monoclonal antibodies: principles and applications, Birche et al. (eds.), pages 187-230 (Wiley-Liss, Inc. 1995); Price, “Production and Characterization of Synthetic Peptide-Derived Antibodies,” in Monoclonal antibodies: Production, engineering and clinical application, Ritter et al. (eds.), pages 60-84 (Cambridge University Press 1995)).

[0299] Techniques for conjugating therapeutic agents to antibodies are well known (Amon et al., “Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy,” in Monoclonal Antibodies And Cancer Therapy; Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., “Antibodies For Drug Delivery,” in Controlled Drug Delivery (2nd Ed.); Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, “Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review,” in Monoclonal Antibodies'84: Biological And Clinical Applications, Pinchera et al. (eds.), pp. 475-506 (1985); “Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody in Cancer Therapy,” in Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985), and Thorpe et al., “The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates,” (1982) Immunol. Rev. 62:119-58).

[0300] The antibodies or their antigen-binding regions disclosed herein can be linked to another functional molecule, such as another antibody or ligand of a receptor, to produce bispecific or multispecific molecules that bind to at least two or more different binding sites or target molecules. Antibodies can be linked to one or more other binding molecules (e.g., another antibody, antibody fragment, peptide, or binding mimicry) via, for example, chemical coupling, genetic fusion, or nonvalent binding. In addition to first and second target epitopes, multispecific molecules may also include a third binding specificity.

[0301] Bispecific and multispecific molecules can be prepared using methods known in the art. For example, each binding unit of a highly specific molecule can be generated individually and then conjugated together. When the binding molecule is a protein or peptide, covalent coupling can be performed using a variety of coupling agents or cross-linking agents. Examples of cross-linking agents include protein A, carbodiimide, N-succinimide-S-acetyl-thioacetate (SATA), 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB), o-phenylenediamine (oPDM), N-succinimide-3-(2-pyridinedithio)propionate (SPDP), and sulfosuccinimide-4-(N-maleimidemethyl)cyclohexane-I-carboxylate (sulfon-SMCC) (Karpovsky et al. (1984) J.Exp.Med. 160:1686; Liu et al. (1985) Proc.Natl.Acad.Sci.USA 82:8648). When the binding molecule is an antibody, they can be conjugated via thiol bonding in the C-terminal hinge regions of the two heavy chains.

[0302] The antibodies or fragments thereof disclosed herein can be linked to portions of cells to which the antibody binds to form “consuming” antibodies. These antibodies are particularly useful in applications that require the depletion of NK cells.

[0303] The antibodies disclosed herein can also be attached to solid supports, which is particularly useful for immunoassays or purification of target antigens. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride, or polypropylene.

[0304] Antibodies can also bind to many different carriers. Therefore, this disclosure also provides compositions comprising an antibody and another active or inert substance. Well-known examples of carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylase, natural and modified cellulose, polyacrylamide, agarose, and magnetite. For the purposes of this disclosure, the nature of the carrier may be soluble or insoluble. Those skilled in the art will recognize other suitable carriers for binding monoclonal antibodies, or will be able to determine them using routine experiments.

[0305] In some respects, this disclosure relates to antibodies or antigen-binding fragments that specifically recognize or bind to head or tail domains, tail fragments, or head fragments of a DNABII protein or a fragment thereof. The DNABII protein or a fragment thereof may be an IHF or HU peptide.

[0306] Functional analysis using antibodies

[0307] The antibodies disclosed herein can be used to purify the disclosed peptides and identify bioequivalent peptides and / or polynucleotides. They can also be used to identify reagents that alter the function of the disclosed peptides. These antibodies include polyclonal antisera, monoclonal antibodies, and various reagents derived from these formulations, which are familiar to those skilled in the art and described above.

[0308] By adding such neutralizing antibodies to in vivo and in vitro assay systems, antibodies that neutralize the activity of proteins encoded by identified genes can also be used in vivo and in vitro to demonstrate their function. They can also be used as agents to modulate the activity of the peptides disclosed herein.

[0309] Various antibody preparations can also be used in analytical methods, such as ELISA or Western blotting, to demonstrate the expression of proteins encoded by identified genes in test cells in vitro or in vivo. Fragments of these proteins produced by protease degradation during metabolism can also be identified using appropriate polyclonal antiserum and samples from experimental samples.

[0310] The antibodies disclosed herein can be used alone or in combination with peptide- or protein-based vaccines or dendritic cell-based vaccines for vaccination or booster vaccination.

[0311] Diagnosis and treatment methods

[0312] This document provides a method for preventing, inhibiting, or competing for the binding of a DNABII peptide or protein to microbial DNA by contacting an effective amount of one or more reagents as described above (e.g., antibodies or antigen-binding fragments thereof disclosed herein, peptides, or CDRs), thereby preventing, inhibiting, or competing for the binding of a DNABII protein or peptide to microbial DNA. The DNABII peptide may be an IHF or HU peptide. In one aspect, the antibody or its antigen-binding fragment selectively binds to the head region of the DNABII peptide (including, but not limited to, the head region of IHF or HU, the head region of IHFA or IHFB, and / or the head chimeric peptide IhfA5-mIhfB4). NTHIIn one embodiment, this document provides an antibody or a fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable domain sequence and / or a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of SEQ ID NO:24 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of SEQ ID NO:25 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of SEQ ID NO:25. In another embodiment, the antibody or fragment thereof comprises, or substantially comprises, a heavy chain (HC) immunoglobulin variable domain sequence and / or a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, an amino acid sequence selected from SEQ ID NO: 1, 2 or 3 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, an amino acid sequence selected from SEQ ID NO: 7, 8 or 9 or an equivalent thereof, and the contact is performed in vivo or in vitro. In another embodiment, the contact is performed in vivo or in vitro.

[0313] In another aspect, the antibody or antigen-binding fragment thereof used in the methods disclosed herein comprises, or substantially comprises, a heavy chain (HC) immunoglobulin variable domain sequence and / or a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, a sequence selected from SEQ ID NO:13, 24 or 26 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, a sequence selected from SEQ ID NO:14, 25 or 27 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, a sequence selected from SEQ ID NO:14, 25 or 27 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, a sequence selected from SEQ ID NO:14, 25 or 27.

[0314] On the other hand, one or more of the DNABII peptides and / or microbial DNA and / or their antibodies or antigen-binding fragments and / or peptides or CDRs disclosed herein are detectably labeled, for example, with a radioactive isotope or a luminescent molecule that signals when in close contact with each other. Contact can be performed in vitro or in vivo. These methods can be combined with diagnostic methods to detect and / or monitor biofilm formation and / or disruption, for example, using one or more DNABII peptides and / or microbial DNA and / or their antibodies or antigen-binding fragments and / or peptides or CDRs as disclosed herein. On one hand, the diagnostic methods include using antibodies or antigen-binding fragments as disclosed herein that specifically bind to the tail region or fragment of the DNABII peptide (including, but not limited to, the tail region of IHF or HU, the tail region of IHFA or IHFB, and / or the tail chimeric peptides IhfA3-IhfB2). NTHI On the other hand, the antibody or antigen-binding fragment is detectably labeled. In one embodiment, an antibody or fragment thereof is provided herein comprising, or substantially composed of, a heavy chain (HC) immunoglobulin variable domain sequence and / or a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially constitutes, the amino acid sequence of SEQ ID NO:26 or its equivalent, and the LC immunoglobulin variable domain sequence comprises, or substantially constitutes, the amino acid sequence of SEQ ID NO:27 or its equivalent, and the LC immunoglobulin variable domain sequence comprises, or substantially constitutes, the amino acid sequence of SEQ ID NO:27. In another embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) immunoglobulin variable domain sequence and / or a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or is substantially composed of, an amino acid sequence selected from SEQ ID NO:4, 5 or 6 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or is substantially composed of, an amino acid sequence selected from SEQ ID NO:10, 11 or 12 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or is substantially composed of, an amino acid sequence selected from SEQ ID NO:10, 11 or 12 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or is substantially composed of, an amino acid sequence selected from SEQ ID NO:10, 11 or 12.

[0315] On the other hand, this article provides a method for disrupting microbial biofilms by contacting the biofilm with an effective amount of one or more reagents as described above (e.g., antibodies or their antigen-binding fragments, peptides, or CDRs). In one aspect, the antibody or its antigen-binding fragment selectively binds to the head region of a DNABII peptide (including, but not limited to, the head region of IHF or HU, the head region of IHFA or IHFB, and / or the head chimeric peptide IhfA5-mIhfB4). NTHIThe DNABII polypeptide can be an IHF or HU peptide. In one embodiment, this document provides an antibody or a fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable domain sequence and / or a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of SEQ ID NO:24 or its equivalent, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of SEQ ID NO:25 or its equivalent, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of SEQ ID NO:25. In another embodiment, the antibody or fragment thereof comprises, or substantially comprises, a heavy chain (HC) immunoglobulin variable domain sequence and / or a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, an amino acid sequence selected from SEQ ID NO: 1, 2 or 3 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, an amino acid sequence selected from SEQ ID NO: 7, 8 or 9 or an equivalent thereof, and the contact is performed in vivo or in vitro. In another embodiment, the contact is performed in vivo or in vitro.

[0316] In one aspect, the microbial biofilm is produced by microorganisms that export DNABII peptides. The DNABII peptide can be an IHF or HU peptide. In another aspect, one or more of the antibody, antibody fragment, DNABII peptide, and microbial DNA are detectably labeled, for example with a radioactive isotope or a luminescent molecular label that signals when they come into close contact with each other. Contact can be performed in vitro or in vivo. In one aspect, the reagent is one or more antibody and / or antigen-binding fragments that are the same as or different from each other. In some embodiments, such antibodies or antigen-binding fragments are administered alone or in combination with each other, or in combination with reagents other than antibodies or other pharmaceutically effective reagents, alone or in combination with a pharmaceutically acceptable carrier. These methods can be combined with diagnostic methods to detect and / or monitor biofilm formation and / or destruction. In one aspect, the diagnostic method includes using an antibody or antigen-binding fragment as disclosed herein that specifically binds, in one aspect, to a tail region or tail fragment of the DNABII peptide (including, but not limited to, tail regions of IHF or HU, tail regions of IHFA or IHFB, and / or tail chimeric peptides IhfA3-IhfB2). NTHI On the other hand, antibody or antigen-binding fragments are detectably labeled.

[0317] This document also provides a method for preventing the formation of biofilms on surfaces or for disrupting biofilms on surfaces, the method comprising, or substantially consisting of, the following steps: treating a susceptible biofilm or a biofilm-containing surface with an effective amount of one or more antibodies or antigen-binding fragments thereof as described herein, peptides or CDRs, wherein the antibody or antigen-binding fragment thereof binds to the head region of a DNABII peptide (including, but not limited to, the head region of IHF or HU, the head region of IHFA or IHFB, and / or the head chimeric peptide IhfA5-mIhfB4). NTHI The DNABII polypeptide can be an IHF or HU peptide. In one embodiment, this document provides an antibody or a fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable domain sequence and / or a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of SEQ ID NO:26 or its equivalent, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of SEQ ID NO:27 or its equivalent, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of SEQ ID NO:27. In another embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) immunoglobulin variable domain sequence and / or a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or is substantially composed of, an amino acid sequence selected from SEQ ID NO:4, 5 or 6 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or is substantially composed of, an amino acid sequence selected from SEQ ID NO:10, 11 or 12 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or is substantially composed of, an amino acid sequence selected from SEQ ID NO:10, 11 or 12 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or is substantially composed of, an amino acid sequence selected from SEQ ID NO:10, 11 or 12.

[0318] In one aspect, the antibody or antigen-binding fragment contains a detectable marker. These methods can be combined with diagnostic methods to detect and / or monitor biofilm formation and / or disruption. In one aspect, the diagnostic method includes using an antibody or antigen-binding fragment as disclosed herein, which specifically binds to the tail region or fragment of a DNABII peptide (including, but not limited to, the tail region of IHF or HU, the tail region of IHFA or IHFB, and / or the tail chimeric peptide IhfA3-IhfB2). NTHIIn another aspect, the antibody or antigen-binding fragment is detectably labeled. In one embodiment, an antibody or fragment thereof is provided herein comprising, or substantially composed of, a heavy chain (HC) immunoglobulin variable domain sequence and / or a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially composed of, the amino acid sequence of SEQ ID NO:26 or its equivalent, and the LC immunoglobulin variable domain sequence comprises, or substantially composed of, the amino acid sequence of SEQ ID NO:27 or its equivalent, and the LC immunoglobulin variable domain sequence comprises, or substantially composed of, the amino acid sequence of SEQ ID NO:27. In another embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) immunoglobulin variable domain sequence and / or a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or is substantially composed of, an amino acid sequence selected from SEQ ID NO:4, 5 or 6 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or is substantially composed of, an amino acid sequence selected from SEQ ID NO:10, 11 or 12 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or is substantially composed of, an amino acid sequence selected from SEQ ID NO:10, 11 or 12 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or is substantially composed of, an amino acid sequence selected from SEQ ID NO:10, 11 or 12.

[0319] This document further provides a method for detecting biomembranes in a subject, comprising, or substantially comprising, the following steps: administering to the subject an effective amount of one or more of the antibodies, fragments thereof, peptides, or CDRs disclosed herein. In one aspect, the diagnostic method includes using an antibody or antigen-binding fragment as disclosed herein, which in one aspect specifically binds to the tail region or fragment of a DNABII peptide (including, but not limited to, the tail region of IHF or HU, the tail region of IHFA or IHFB, and / or the tail chimeric peptide IhfA3-IhfB2). NTHIThe DNABII polypeptide may be an IHF or HU peptide. In another embodiment, the antibody or antigen-binding fragment is detectably labeled. In one embodiment, an antibody or fragment thereof is provided herein comprising, or substantially composed of, a heavy chain (HC) immunoglobulin variable domain sequence and / or a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially constitutes, the amino acid sequence of SEQ ID NO:26 or its equivalent, and the LC immunoglobulin variable domain sequence comprises, or substantially constitutes, the amino acid sequence of SEQ ID NO:27 or its equivalent, and the LC immunoglobulin variable domain sequence comprises, or substantially constitutes, the amino acid sequence of SEQ ID NO:27. In another embodiment, the antibody or fragment thereof comprises, or is substantially composed of, a heavy chain (HC) immunoglobulin variable domain sequence and / or a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or is substantially composed of, an amino acid sequence selected from SEQ ID NO:4, 5 or 6 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or is substantially composed of, an amino acid sequence selected from SEQ ID NO:10, 11 or 12 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or is substantially composed of, an amino acid sequence selected from SEQ ID NO:10, 11 or 12 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or is substantially composed of, an amino acid sequence selected from SEQ ID NO:10, 11 or 12.

[0320] This document provides a method for preventing or disrupting biofilms in a subject. The method includes, or substantially comprises, the following criteria: application to the subject of a head region of a DNA-binding peptide disclosed herein (including, but not limited to, the head region of IHF or HU, the head region of IHFA or IHFB, and / or the head-chimeric peptide IhfA5-mIhfB4). NTHI The method provides, in one aspect, a method for preventing or disrupting biofilms in a subject, comprising, or consisting of, the steps of: administering to the subject an effective amount of one or more antibodies, fragments thereof, peptides, or CDRs as disclosed herein, and / or an effective amount of one or more polynucleotides or carriers encoding said antibody, fragment thereof, peptide, or CDR. The DNABII peptide may be an IHF or HU peptide. In one aspect, said antibody or its antigen-binding fragment selectively binds to the head region of the DNABII peptide (including, but not limited to, the head region of IHF or HU, the head region of IHFA or IHFB, and / or the head chimeric peptide IhfA5-mIhfB4). NTHIIn one embodiment, this document provides an antibody or a fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable domain sequence and / or a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of SEQ ID NO:24 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of SEQ ID NO:25 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of SEQ ID NO:25. In another embodiment, the antibody or fragment thereof comprises, or substantially comprises, a heavy chain (HC) immunoglobulin variable domain sequence and / or a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, an amino acid sequence selected from SEQ ID NO: 1, 2, or 3, or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, an amino acid sequence selected from SEQ ID NO: 7, 8, or 9, or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, an amino acid sequence selected from SEQ ID NO: 7, 8, or 9, or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, an amino acid sequence. In yet another embodiment, contact is performed in vivo or in vitro. The antibody or antigen-binding fragment thereof may be detectably labeled. These methods may be combined with diagnostic methods to detect and / or monitor biofilm formation and / or disruption. On one hand, diagnostic methods include the use of antibodies or antigen-binding fragments as disclosed herein, which specifically bind to the tail region or fragment of a DNABII peptide (including, but not limited to, the tail region of IHF or HU, the tail region of IHFA or IHFB, and / or the tail chimeric peptide IhfA3-IhfB2). NTHI On the other hand, the antibody or antigen-binding fragment is detectably labeled.

[0321] This article provides a method for treating a condition characterized by the formation of a biofilm in a subject, the method comprising, or substantially comprising, the following steps: administering to the subject a head region of a DNA-binding peptide disclosed herein (including, but not limited to, the head region of IHF or HU, the head region of IHFA or IHFB, and / or the head chimeric peptide IhfA5-mIhfB4). NTHIThe present invention provides an antibody or fragment thereof. In one aspect, the present invention provides a method for preventing or treating a disease characterized by biofilm formation in a subject, which involves administering to the subject an effective amount of one or more of the antibodies, fragments thereof, peptides, or CDRs disclosed herein, and / or an effective amount of one or more polynucleotides or carriers encoding said antibody, fragment, peptide, or CDR. In another aspect, the present invention provides a method for inhibiting, preventing, or treating microbial infections that produce biofilms in a subject, the method comprising, or consisting of, the following steps: administering to the subject an effective amount of one or more antibodies, fragments thereof, peptides, or CDRs disclosed herein, and / or an effective amount of one or more polynucleotides or carriers encoding said antibody, fragment, peptide, or CDR. The DNABII peptide may be an IHF or HU peptide. In one aspect, the antibody or its antigen-binding fragment selectively binds to the head region of the DNABII peptide (including, but not limited to, the head region of IHF or HU, the head region of IHFA or IHFB, and / or the head chimeric peptide IhfA5-mIhfB4). NTHI In one embodiment, this document provides an antibody or a fragment thereof comprising, or substantially comprising, a heavy chain (HC) immunoglobulin variable domain sequence and / or a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of SEQ ID NO:24 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of SEQ ID NO:25 or an equivalent thereof, and the LC immunoglobulin variable domain sequence comprises, or substantially comprises, the amino acid sequence of SEQ ID NO:25. In another embodiment, the antibody or fragment thereof comprises, or substantially comprises, a heavy chain (HC) immunoglobulin variable domain sequence and / or a light chain (LC) immunoglobulin variable domain sequence, wherein the HC immunoglobulin variable domain sequence comprises, or substantially comprises, an amino acid sequence selected from SEQ ID NO: 1, 2 or 3 or an equivalent thereof, wherein the LC immunoglobulin variable domain sequence comprises, or substantially comprises, an amino acid sequence selected from SEQ ID NO: 7, 8 or 9 or an equivalent thereof, wherein the LC immunoglobulin variable domain sequence comprises, or substantially comprises, an amino acid sequence selected from SEQ ID NO: 7, 8 or 9. In yet another embodiment, the contact is performed in vivo or in vitro. These methods can be combined with diagnostic methods to detect and / or monitor the formation and / or disruption of biofilms. In one aspect, the diagnostic method includes using an antibody or antigen-binding fragment as disclosed herein, which specifically binds, in one aspect, to the tail region or tail fragment of a DNABII polypeptide (including, but not limited to, the tail region of IHF or HU, the tail region of IHFA or IHFB, and / or the tail chimeric peptide IhfA3-IhfB2). NTHI On the other hand, the antibody or antigen-binding fragment is detectably labeled.

[0322] In the above methods, the biofilm originates from bacteria that produce Gram-negative or Gram-positive biofilms. Non-limiting examples of conditions include: chronic non-healing wounds, including venous ulcers and diabetic foot ulcers; ear infections; sinus infections; urinary tract infections; gastrointestinal diseases; lung infections; respiratory tract infections; cystic fibrosis; chronic obstructive pulmonary disease; catheter-related infections; indwelling device-related infections; implant-related prosthesis infections; osteomyelitis; cellulitis; abscesses; and periodontal disease.

[0323] In some embodiments of the methods disclosed herein, administration of one or more of the antibody, its fragment, peptide, or CDR reduces one or more pro-inflammatory cytokines in the target. Non-limiting examples of pro-inflammatory cytokines include IL-1β, IL6, IL8, IL12p70, IL17A, interferon (IFN), and tumor necrosis factor (TNF). Additionally or alternatively, administration of an effective amount of one or more of the antibody, its fragment, peptide, or CDR increas...

Claims

1. An antibody or antigen-binding fragment thereof that specifically binds to the head region of a DNABII peptide, comprising: (a) a heavy chain immunoglobulin variable domain comprising: i. Heavy chain complementarity determining region 1, which consists of the sequence GFTFRTY; ii. heavy chain complementarity determining region 2, which consists of the sequence GSDRRH; iii. heavy chain complementarity determining region 3 consisting of the sequence VGPYDGYYGEFDY; and (b) a light chain immunoglobulin variable domain comprising: i. Light chain complementary determining region 1, which consists of the sequence QSLLDSDGKTF; ii. light chain complementarity determining region 2, which consists of the sequence LVS; and iii. Light chain complementarity determining region 3, which consists of the sequence WQGTHFPYT.

2. The antibody or antigen-binding fragment thereof of claim 1, wherein the heavy chain immunoglobulin variable domain sequence comprises an amino acid sequence that is at least 90% identical to aa 25 to aa 144 of SEQ ID NO: 1, and / or wherein the light chain immunoglobulin variable domain sequence comprises an amino acid sequence that is at least 90% identical to an amino acid sequence of aa 21 to aa 132 of SEQ ID NO:

7.

3. The antibody or antigen-binding fragment thereof of claim 1, wherein the heavy chain immunoglobulin variable domain sequence comprises an amino acid sequence that is at least 90% identical to aa 25 to aa 144 of SEQ ID NO: 1, and / or wherein the light chain immunoglobulin variable domain sequence comprises an amino acid sequence that is at least 90% identical to an amino acid sequence of aa 21 to aa 132 of SEQ ID NO:

8.

4. The antibody or antigen-binding fragment thereof of claim 1, wherein the heavy chain immunoglobulin variable domain sequence comprises an amino acid sequence that is at least 90% identical to aa 25 to aa 144 of SEQ ID NO: 1, and / or wherein the light chain immunoglobulin variable domain sequence comprises an amino acid sequence that is at least 90% identical to an amino acid sequence of aa 21 to aa 132 of SEQ ID NO:

9.

5. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody comprises (i) a heavy chain immunoglobulin sequence comprising an amino acid sequence of aa 25 to aa 144 of SEQ ID NO: 1; and (ii) a light chain immunoglobulin sequence comprising an amino acid sequence of aa 21 to aa 132 of SEQ ID NO:

8.

6. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, wherein the antibody further comprises a constant region selected from: an IgA constant region, an IgD constant region, an IgE constant region, an IgG constant region or an IgM constant region. The antibody or antigen-binding fragment thereof according to claim 6 , wherein the constant region is an IgG1 constant region.

8. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, wherein the antigen-binding fragment is selected from Fab, F(ab') 2 , Fab', scFv or Fv.

9. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, wherein the antibody or antigen-binding fragment thereof is modified by a method selected from PEGylation, polysialylation, HESylation or glycosylation.

10. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, wherein the antibody is a monoclonal antibody.

11. An isolated polynucleotide encoding the antibody or antigen-binding fragment thereof according to any one of claims 1 to 10.

12. The isolated polynucleotide of claim 11, wherein the isolated polynucleotide encoding the antibody or antigen-binding fragment thereof is operably linked to a promoter and / or enhancer element.

13. A vector comprising the isolated polynucleotide of claim 11 or 12.

14. A host cell comprising the isolated polynucleotide of claim 11 or 12 or the vector of claim 13.

15. A composition comprising a vector and one or more: the antibody or antigen-binding fragment thereof of any one of claims 1-10, the isolated polynucleotide of claim 11 or 12, the vector of claim 13, or the host cell of claim 14.

16. The composition of claim 15, wherein the carrier comprises a component having buffering capacity comprising alanine, glycine, arginine, betaine, histidine, glutamic acid, aspartic acid, cysteine, lysine, leucine, isoleucine, valine, methionine, phenylalanine, or aspartame; and wherein the carrier comprises a carbohydrate excipient selected from monosaccharides, disaccharides, polysaccharides, and / or sugar alcohols; wherein the monosaccharides are selected from fructose, maltose, galactose, glucose, D-mannose, and sorbitol; the disaccharides are selected from lactose, sucrose, trehalose, and cellobiose; the polysaccharides are selected from raffinose, melezitose, maltodextrin, dextran, and starch; and the sugar alcohols are selected from mannitol, xylitol, maltitol, lactitol, sorbitol, and inositol.

17. An in vitro method for producing the antibody or antigen-binding fragment thereof of any one of claims 1-10, the method comprising culturing a host cell comprising a polynucleotide encoding the antibody or antigen-binding fragment thereof under conditions where the antibody or antigen-binding fragment thereof is expressed.

18. The in vitro method according to claim 17, wherein the method further comprises isolating the antibody or antigen-binding fragment thereof.

19. An in vitro method for inhibiting or competing for the binding of a DNABII polypeptide or protein to a microbial DNA comprises contacting a DNABII polypeptide or protein with an antibody or its Fab of any one of claims 1 to 10, wherein the antibody or its Fab binds to the head region of a DNABII peptide.

20. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 10 in the preparation of a medicament for destroying biofilm, wherein the antibody or antigen-binding fragment thereof binds to the head region of the DNABII peptide.

21. The use of any one of the antibodies or their antigen-binding fragments described in claims 1-10 in the preparation of a medicament for preventing the formation of biofilm from the teeth outwardly or destroying biofilm on the teeth outwardly, wherein the antibody or its antigen-binding fragment binds to the head region of the DNABII peptide.

22. Use of the antibody or antigen binding fragment thereof as described in any one of claims 1-10 in the preparation of a medicament for preventing or destroying biofilm in a subject, wherein the antibody or antigen binding fragment thereof binds to the head region of the DNABII peptide.

23. The use of an antibody or its antigen-binding fragment as described in any one of claims 1-10 in the preparation of a medicament for suppressing, preventing or treating a microbial infection that produces a biofilm in a subject, wherein the antibody or its antigen-binding fragment is bound to the head region of the DNABII peptide.

24. Use of the antibody or its antigen binding fragment described in any one of claims 1-10 in the preparation of a medicament for treating a disease characterized by forming a biofilm in a subject, wherein the antibody or its antigen binding fragment binds to the head region of the DNABII peptide.

25. Use according to any one of claims 20 to 24, wherein the medicament is formulated for administration together with one or more antibiotics.

26. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 10 in the preparation of a medicament for detecting a biofilm in a subject, wherein detecting the biofilm in the subject comprises detecting binding of the antibody or antigen-binding fragment thereof to the biofilm.

27. A non-physiological surface coated with the antibody or antigen-binding fragment thereof according to any one of claims 1 to 10.

28. The non-physiological surface of claim 27, wherein the non-physiological surface is in an industrial environment.

29. A kit comprising one or more of the following components: the antibody or antigen-binding fragment thereof of any one of claims 1-10, the polynucleotide of claim 11 or 12, the vector of claim 13, the host cell of claim 14, or the composition of claim 15.

30. The kit of claim 29, wherein the kit further comprises instructions for use.

31. A monoclonal antibody or an antigen-binding fragment thereof that specifically binds to the head region of a DNABII peptide, wherein the antibody comprises: (i) a heavy chain immunoglobulin sequence comprising the amino acid sequence of SEQ ID NO: 1; and (ii) a light chain immunoglobulin sequence comprising the amino acid sequence of SEQ ID NO:

8.

32. A composition comprising: A monoclonal antibody or an antigen-binding fragment thereof that specifically binds to the head region of a DNABII peptide, wherein the antibody comprises: (i) a heavy chain immunoglobulin sequence comprising the amino acid sequence of SEQ ID NO: 1; and (ii) a light chain immunoglobulin sequence comprising the amino acid sequence of SEQ ID NO: 8; a buffer comprising histidine; and Trehalose.

33. Use of a composition comprising an antibody that specifically binds to the head region of a DNABII peptide in phosphate-buffered saline in the preparation of a medicament for treating pneumonia in a subject in need thereof, the antibody comprising: (i) a heavy chain immunoglobulin sequence comprising the amino acid sequence of SEQ ID NO: 1; and (ii) a light chain immunoglobulin sequence comprising the amino acid sequence of SEQ ID NO: 8, wherein the medicament is formulated for administration to the subject by intravenous infusion in an effective amount of a single dose, wherein the pneumonia is community-acquired pneumonia or hospital-acquired pneumonia.

34. A composition comprising (i) an antibody or antigen-binding fragment thereof as described in any one of claims 1-10 and 31, or an isolated polynucleotide encoding the antibody or antigen-binding fragment thereof as described in any one of claims 1-10 and 31, and (ii) one or more isolated polynucleotides encoding a DNABII peptide.

35. according to the described compositions of claim 34, wherein said DNABII peptide is selected from: the head region of integration host factor, the head region of histone sample protein, the head region of IHF subunit A, the head region of IHF subunit B and the head chimeric peptide.

36. The composition of claim 35, wherein the head chimeric peptide comprises the amino acid sequence of any one of SEQ ID NOs: 38-40.

37. according to the described compositions of claim 34, wherein said one or more separated polynucleotides encoding DNABII peptides encode two or more amino acid sequences in SEQ ID NO:38-40.

38. A composition according to any one of claims 34-37, wherein the isolated polynucleotide is RNA.

Citation Information

Patent Citations

  • Apparatus and process for electrolysis using a cation-permselective membrane and turbulence inducing means

    EP0002009A1

  • Method for generating variable domain sequences of heavy chain antibodies

    US20060211088A1

  • Adaptive Ambiance Lighting

    US20200041082A1

  • Osmotically powered agent dispensing device with filling means

    US3760984A

  • Photographic silver halide recording material with cellulose dicarboxylic acid semiester particles in outer layer

    US4603102A